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viii Abstract 
 
Chronic rheumatic mitral regurgitation (CRMR) is a commonly encountered 
lesion in the developing world, yet it remains an understudied disease in comparison 
to degenerative MR. There are several unresolved issues in CRMR ranging from 
limited data on the current demographic and clinical profile of the contemporary 
patient with CRMR, to the evaluation of this lesion with sophisticated techniques 
utilising strain (Ɛ), magnetic resonance imaging (MRI) and biomarkers. Furthermore, 
the role of medical therapy has been mainly restricted to studies pertaining to 
degenerative MR. Thus, in this thesis the aim was to address some of the 
aforementioned deficiencies in the field of CRMR. In the process of studying the 
atrioventricular functional parameters in CRMR, we established age and vendor-
specific (Philips QLAB 9) normative data for left atrial (LA) functional and volumetric 
parameters in a normal black population. 
Eighty four subjects with CRMR were studied at Chris Hani Baragwanath 
Hospital (CHBAH) and compared with a prior landmark study by Marcus et al 
conducted at this institution.  Mean age was 44.0±15.3 years, compared to 19 years 
in the study by Marcus et al.  Acute rheumatic fever (ARF) was rare compared to the 
previous study.  Hypertension and human immunodeficiency virus (HIV) were 
present in 52% and 26% respectively.  Echocardiography showed leaflet thickening 
and calcification, restricted motion and sub-valvular disease, as opposed to pliable 
leaflets with predominant prolapse and chordal rupture in the study by Marcus et al. 
One hundred and twenty normal black subjects from 18 and 70 years of age 
were studied.  Maximum LA volume indexed (LAVi) was 19.7±5.9 mL/m2.  LA pump 
function increased with age (r=0.2, p=0.02), and the conduit function decreased with 
 xx 
 
age (r=-0.3, p< 0.001). LA Ɛ in the reservoir phase was 39.0±8.3%. LA Ɛ in the 
reservoir phase declined with age (p<0.001). Two studies were conducted using 
speckle tracking in 77 patients with CRMR. The first study found that 86% had 
decreased LA peak reservoir Ɛ and 58% had depressed left ventricular (LV) peak 
systolic Ɛ. In the second study, right ventricle (RV) peak systolic Ɛ was lower in the 
MR group compared to controls (-16.8±4.5% vs -19.2±3.4%, p=0.003). LV peak 
systolic Ɛ was an independent predictor of RV peak systolic Ɛ (r=0.46, p<0.004). 
CRMR is a disease characterised by eccentric jets due to distorted leaflet 
architecture.  Thus, the echocardiographic proximal isovelocity surface area (PISA) 
method, to assess MR severity, is suboptimal.  In CRMR there may be involvement 
of the LV by the rheumatic process especially in the postero basal region.  To study 
these issues, 22 patients without comorbidities underwent MRI.  On comparison of 
MR severity assessment by echocardiography (using an integrated approach) and 
MRI, there was concordance between the two techniques in all but seven patients. 
Six patients were reclassified as severe MR after MRI and one patient was re-
categorised as moderate MR.  Only four patients had fibrosis on late gadolinium 
enhancement.  No particular regional involvement was noted. We also studied 
markers of collagen degradation and synthesis in CRMR and their relation with MRI 
parameters.  Matrix metalloproteinase-1 was increased compared to controls (log 
MMP-1 3.5±0.68 vs 2.7±0.9, p=0.02), implying increased collagen degradation rather 
than synthesis in CRMR.  This supports the paucity of fibrosis found on MRI. 
Effects of combination medical therapy in heart failure (HF) secondary to 
severe CRMR in 31 patients was studied.  On optimal therapy no HF-related 
admissions or deaths were noted.  There was improvement in LA peak systolic 
strain. LV and RV functional indices remained unchanged on maximal therapy. 
 xxi 
 
In conclusion, the contemporary CRMR patients are older, have comorbidities 
and less ARF.  Upper limits of maximum LAVi are lower in the black population 
compared to Caucasians, and age needs to be considered when interpreting 
abnormalities of LA function.  LA dysfunction was noted with or without involvement 
of the LV, therefore perhaps in CRMR, LA dysfunction precedes LV dysfunction.  RV 
peak systolic Ɛ was useful for assessment of subclinical RV dysfunction in CRMR, 
therefore quantitative measurement of RV systolic function should not rely solely on 
conventional indices.  Cardiac MRI was a useful adjunctive tool for MR severity 
assessment in 32% of CRMR patients when echocardiography alone was 
insufficient. CRMR is characterised by predominant collagen degradation and is 
associated with low prevalence of fibrosis.  Finally, there may be a role for 
combination anti-remodelling therapy in HF secondary to MR.  Finally, we have 
provided normal reference ranges for LA volume and strain parameters that would 
serve as platform for future studies in this population.   Our findings pertaining to 
imaging, biomarkers and role of combination anti-remodelling therapy in CRMR may 
aid in the clinical assessment and management of patients with CRMR, and serve as 
a base for further research in these fields. 
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1.1 Introduction 
  
Chronic rheumatic heart disease (RHD) is common in the developing world 
(World Health organization (WHO) 2001).  WHO statistics show that about 15 million 
people suffer from RHD worldwide and which is associated with 250 000 deaths 
annually (WHO 2001).  Across Africa RHD accounts for 6.6-34% of cardiovascular 
(CVS) disease-related hospital admissions or echocardiographic examinations 
(Sliwa and Mocumbi 2010b).  From surveys of school-going children the prevalence 
of chronic RHD varies from 2.7/1000 in Nairobi to 14.3/1000 in Kinshasa (Essop and 
Nkomo 2005).  The prevalence of RHD in Sub‐Saharan Africa is estimated at 
5.7/1000 (Nkomo 2007).   From data derived from older surveys from the 1970s, 
predominantly from school children, the estimated prevalence of RHD in sub-
Saharan Africa was high at 5.1/1000 (Nkomo 2007).  From older literature, McClaren 
et al. in 1975, reported an incidence of 6.9/1000 among school children in Soweto 
(McClaren et al.1975). More recently, Engel et al. reported an incidence of 20.2/1000 
cases among scholars in the Bonteheuwel and Langa communities of Cape Town, 
with the prevalence being higher in poorer communities (Engel et al. 2015).  
Recently Sliwa et al. reported a high incidence of 23.5/100 000 of RHD among adults 
at Chris Hani Baragwanath Hospital (CHBAH) and chronic rheumatic mitral 
regurgitation (CRMR) was noted to be the most common lesion (59%) (Sliwa et al. 
2010a).  A declining incidence (64 cases per year in 1993, to 3 per year in 2010) in 
ARF in the paediatric population of Baragwanath Hospital has been reported (Cilliers 
2014).  The recent global heart disease registry (REMEDY study) reported 
contemporary data on presentation, complication and treatment of RHD but the 
incidence or prevalence of RHD in South Africa was not clearly addressed (Zuhlke et 
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al. 2015).  However, 25.8% (86/3343) participants were from upper middle income 
countries (SA/ Namibia) (Zuhlke et al. 2015.  In the present study we specifically 
analysed a subgroup of RHD patients, specifically those with isolated CRMR, as it is 
one of the most commonly encountered valvular lesions in the adult patient with 
RHD at CHBAH (Sliwa et al. 2010a).  Even though it is a commonly encountered 
lesion and an important cause of mitral regurgitation (MR) in the developing world, it 
remains an understudied disease compared to MR of degenerative aetiology (Mohan 
J and Mohan S 2012, Essop and Peters 2005).  Additionally, it is uncertain whether 
current guidelines derived mainly from literature pertaining to degenerative MR can 
be applied to rheumatic MR (Mohan J and Mohan S 2012).  While the body of 
knowledge expands in the field of degenerative MR, rheumatic MR constantly lags 
behind, although this disease afflicts a large proportion of the world population (Haub 
and Kaneda 2012).  Thus, in this thesis we will attempt to address some of the 
aforementioned deficiencies in the field of CRMR. 
From the limited studies done in the past, CRMR tended to be a lesion of the 
young, who presented with acute, fulminant carditis and no comorbidities (Clur 2006, 
Marcus et al. 1994).  In contrast, currently a decline in ARF and increase in number 
of new cases of RHD (predominantly CRMR) among the adult population; alongside 
the emergence of diseases such as HIV and hypertension among the predominantly 
older black population has been reported (Sliwa et al. 2010a, Sliwa et al. 2008).  
There is a paucity of literature which has systematically documented the change in 
the demographic and clinical characteristics of contemporary patients with CRMR 
and the impact of these emerging comorbidities in this patient group.  Thus, one of 
my aims was to document the prevalence of these comorbidities in the current cohort 
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of patients with CRMR at CHBAH and compare and contrast our finding with an 
earlier cohort of patients reported by Marcus et al. from the same institution as ours. 
The timing of surgical intervention for MR is critically influenced by imaging 
criteria.  There is limited data regarding imaging in the developing world for CRMR. 
The most commonly used modality to assess MR is two-dimensional (2D) rest 
echocardiography.  Cardiac magnetic resonance imaging (CMR) and newer 2D 
strain imaging techniques constitute important emerging imaging modalities (Van De 
Heyning et al. 2012).  Current valvular heart disease guidelines recommend surgery 
based on left ventricular (LV) ejection fraction, dimensions or presence of symptoms 
(Nishimura et al 2014, Lancelloti et al 2013, Zoghbi et al. 2003).  The former, 
volume-based parameters have limited value for assessment of contractile LV 
function (Marciniak et al. 2007).  Strain imaging using speckle tracking 
echocardiography has emerged as a valuable tool for myocardial and left atrial (LA) 
function assessment and for prognostication in various disease states at a 
subclinical stage (Hoit et al. 2014, Fine et al. 2014, Dandel et al. 2009).  In 
degenerative MR LV global longitudinal strain (GLS), LA volume of ≥60mL/m2 and 
depressed peak global LA strain are important predictors of postoperative outcomes, 
five-year survival and worse prognoses (Yang L et al. 2015, Le Torneau et al. 2010, 
Lancellotti et al. 2008).  Recently, Le Torneau et al. emphasised the importance of 
biventricular function impairment on postoperative outcomes in degenerative MR (Le 
Torneau et al. 2013).  Right ventricular peak systolic strain (RV PSS) has been 
shown to be an important parameter for evaluation of subclinical RV dysfunction and 
is of prognostic significance in various disease states such as MR and low-flow, low-
gradient aortic stenosis (Dahou et al. 2016, Fine et al. 2014, Le Torneau et al. 2013).  
Limited studies in CRMR prompted us to initially establish normative data for LA 
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volumetric and strain parameters in a black population, to study the extent of 
abnormality in these parameters in CRMR. A previous study pertaining to the LV 
functional parameters in a normal black population, allowed me to study the LV 
parameters in patients with CRMR (Maharaj et al. 2013). Further, we studied RV 
function in CRMR and healthy controls. 
Chronic MR is associated with progressive left ventricular (LV) dysfunction and, 
eventually death if left untreated (Enriquez-Sarano et al. 2005).  This disease has a 
long silent period before symptoms manifest. During this latent period LV function 
progressively deteriorates, and results in poor outcomes for patients even if surgery 
is performed (Bonow et al. 2012, Gaasch and Meyer 2008).  Little data exists with 
regard to imaging, biomarkers and medical therapy for CRMR in the context of the 
developing world.  Accurate delineation of the severity of MR with multimodality 
imaging and risk stratification with the aid of biomarkers could prove to be valuable 
non-invasive tools in accurate timing of surgery (Banerjee et al. 2014, Bergler-Klein J 
et al. 2014, Van De Heyning and Magne 2012, Lee and Marwick 2007).  Early 
referral for mitral valve surgery has been shown to improve long term clinical 
outcomes.  Given the general insufficient availability of adequate cardiothoracic 
surgical services, effective medical therapy for chronic MR would be ideal.  This 
may, at the very least, serve as a bridge to surgery.  
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1.2 Demographics of chronic rheumatic mitral regurgitation: current and past 
observations at Chris Hani Baragwanath Academic Hospital 
 
Previous studies have documented the high prevalence of rheumatic fever and 
RHD in the population of Soweto and have provided a detailed description of the 
echocardiographic findings in these patients (Sliwa et al. 2010a, Marcus et al. 1994). 
In developed countries, degenerative disease is the major cause of chronic MR and 
when surgery is indicated, repair of the valve is the preferred therapy (Enriquez-
Sarano et al. 2009).  In geographically low and middle income areas, chronic MR is 
still due predominantly to rheumatic disease and when severe, mitral valve 
replacement is often required (Essop et al. 2005).  While the demographic profile 
and echocardiographic features of degenerative MR have been well documented, 
there remains uncertainty regarding rheumatic MR ranging from diagnostic 
echocardiographic criteria to optimal management (Essop and Peters 2014, 
Enriquez-Sarano et al. 2009, Essop and Nkomo 2005).  
CRMR is a frequently encountered lesion in which the mitral valve is not 
inherently stenotic and must be distinguished from a mixed lesion which is 
characterised by varying degrees of mitral stenosis (Sliwa et al. 2010a, Marcus et al. 
1994).  Rheumatic valvular regurgitation was predominantly a disease of the young, 
as documented in earlier literature and stenotic lesions tended to occur in older 
patients (Essop and Peters 2014, Sliwa et al. 2010a, Marcus et al. 1994).  In clinical 
practice we have observed that in recent years the demographic profile of patients   
presenting with CRMR appear to have changed.  The two major factors contributing 
to this may be related to the decline in rheumatic fever, likely secondary to 
improvement in socioeconomic status and access to penicillin, with a concomitant 
emergence in diseases associated with a western lifestyle (Stewart et al. 2008).  A 
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third potential confounding variable is the pandemic of HIV which adds to the 
comorbidity of patients with CRMR in this era (Essop and Peters 2014).  We 
hypothesised that these changes may have a significant impact on the clinical 
presentation, assessment and management of patients with CRMR.  Thus, we 
embarked on this study to systematically document the clinical and 
echocardiographic features of the current patients with moderate or severe CRMR 
and compare them to the study by Marcus et al. done at CHBAH thirty years ago.  A 
second objective was to compare the clinical presentation and echocardiographic 
assessment of CRMR in patients with and without comorbidities.  This topic will be 
addressed in Chapter 2 of this thesis. 
Additionally, due to the prognostic role of the LA in MR, we studied the LA and 
myocardial deformation parameters in CRMR after establishing age-related 
normative data on LA volumetric and deformation parameters in a black population.  
 
1.3 Left atrial volumetric and strain parameters  
1.3.1 Left atrial function assessment using traditional parameters 
LA size and volume are altered in many disease states and are important 
predictors of morbidity and mortality in many CVS diseases such as hypertension, 
valvular heart disease, diabetes and sleep apnoea (Hoit 2014, Seward and Hebl 
2014, Cameli et al. 2012, Leung et al. 2008).  Additionally, LA volume is 
independently associated with adverse CVS outcomes such as atrial fibrillation, 
acute coronary events, HF and stroke (Tsang et al. 2012). 
The LA has multiple functions. It is a contractile chamber that also acts as a 
reservoir, conduit and volume sensor (Bonow et al. 2012).  The LA acts as a 
reservoir to receive blood from the pulmonary veins during ventricular systole (Viera 
 8 
 
et al. 2014, Tsang et al. 2012).  During the ventricular early diastolic phase, it acts as 
a conduit and transfers blood passively into the LV and during end-diastole it 
contracts and pumps the blood actively into the LV (Viera et al. 2014, Tsang et al. 
2012).  All the aforementioned phases are influenced by compliance of the LA 
chamber and thus by LA relaxation and contraction (Viera et al. 2014).  The anatomy 
and pathophysiology of the LA is complex, its multifaceted profile cannot be 
effectively defined by a single anatomical, functional or clinical feature (Seward and 
Hebl 2014).  Thus, optimal quantification of its function is difficult (Seward and Hebl 
2014, Cameli et al. 2009). 
The traditional parameters of LA function assessment such as LA size, volume 
and functional parameters and Doppler flow assessment across the mitral valve and 
pulmonary veins have proved useful and are readily available to most imagers (Viera 
et al. 2014).  However, they are limited by factors such as poor echocardiographic 
windows, foreshortening, errors in volumetric measurement using biplane Simpson’s 
method and no reference gold standard of LA function measurement (Viera et al. 
2014).  Recently, three dimensional LA volumetric assessment showed promise, but 
it too is limited by problems of gain settings and extensive variability between 
observers (Viera et al. 2014). 
 
1.3.2 Overview of basic concepts in strain imaging 
 
Knowledge in the field of myocardial deformation imaging has advanced rapidly 
with various techniques utilising velocity imaging, displacement imaging and 
deformation imaging (strain and strain-rate imaging) (Shah and Solomon 2012, 
Gorcsan et al. 2011). Strain is less load-dependent compared to the traditional 
parameters such as EF (Shah and Solomon 2012, Dandel et al. 2009). 
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Strain measures myocardial deformation and is expressed as a percentage 
(Shah and Solomon 2012, Gorcsan and Tanaka 2011, Dandel et al. 2009).  The 
concept of Lagrangian strain not only takes into account the initial and final length of 
an object before and after deformation, but also during the process of deformation 
(Dandel et al. 2009).  It can be stated using the following formula: Ɛ= L – L0 /L0 and 
was initially used to measure LV deformation but now it can be applied to the LA; 
where Ɛ = strain, L = baseline length and L = final length after myocardial 
deformation (Shah and Solomon 2012, Dandel et al. 2009).  By convention, 
thickening and shortening of a given myocardial segment related to its initial length is 
described by positive and negative strain values, respectively (Dandel et al. 2009). 
As the myocardium contracts, shortening and thickening of the wall occurs and thus 
one can measure the radial thickening or positive radial strain, circumferential 
shortening or negative circumferential strain as well as longitudinal shortening, or 
negative longitudinal strain during ventricular systole (Figure 1.1 and 1.2) (Shah and 
Solomon 2012, Dandel et al. 2009). 
Different echocardiographic techniques can be used to measure myocardial 
strain (Marwick 2006).  These include M-mode techniques, tissue Doppler and 
speckle tracking methods.  There are inherent challenges with each of the 
aforementioned modalities.  The main limitations of tissue derived strain include 
signal noise, underestimation, angle dependence, through–plane motion and 
respiratory drift.  These technical limitations can be minimised by careful image 
acquisition.  Further, this technique has been validated with sonomicrometry and 
correlation with magnetic resonance imaging (MRI) has been confirmed.  To 
overcome the aforementioned limitations, the speckle tracking technique emerged 
(Dandel et al. 2009, Marwick 2006).  Speckles are natural acoustic markers (20 to 40 
 10 
 
pixels in size), distributed throughout the myocardium (Dandel et al. 2009).  The 
movement of the speckles represents motion of the tissue.  Speckles can be tracked 
from frame to frame in the 2D ultrasonic image with the aid of specialised software. 
Thus, 2D strain and strain-rate can be calculated by tracking the motion of these 
speckles.  The major limitation of this technique is the necessity of high image quality 
and adequate frame rate.  Additionally, strain values derived from speckle tracking 
echocardiography (STE) have low inter-observer variability (Dandel et al. 2009).  The 
overall limitation of all the aforementioned techniques is a lack of consensus 
regarding normal reference values for strain due to considerable inter-vendor 
measurement variability (Lang et al. 2015). 
 Strain imaging in contrast to traditional parameters of LA, LV and RV 
functions such as volume and ejection fraction is able to detect subclinical disease in 
these chambers in pathologic states such as MR, aortic regurgitation and stenosis, 
hypertension, diabetes, ischaemic heart disease, chemotherapy induced cardiac 
dysfunction and cardiomyopathies (Moustafa et al 2016, Dandel et al. 2009).  
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Figure 1.1 Apical 4C view depicting LV peak longitudinal strain. 
 
 
Figure 1.2 Apical 4C view depicting RV free wall peak longitudinal strain. 
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1.3.3 Left atrial speckle tracking echocardiography 
 
The physiology of the LA can be depicted in the LA strain curves derived by 
speckle tracking echocardiography (Figure 1.3) (Viera et al. 2014).  The reservoir 
phase, which corresponds to isovolumetric contraction, ejection, and isovolumic 
relaxation of the LV, results in stretching of the LA as it receives blood from the 
pulmonary veins (Viera et al. 2014).  This results in an increased LA longitudinal 
strain (Ɛ), ultimately reaching a positive peak at end of ventricular systole, as the LA 
filling ends (Viera et al. 2014).  The descent of the mitral annulus as the LV contracts 
in systole also influences this phase (Viera et al. 2014). During the conduit phase as 
the LA empties its contents passively into the LV in early diastole the LA Ɛ plateaus 
(LA diastasis) (Viera et al. 2014).  Finally, as the LA contracts and actively pushes 
blood into LV the LA wall shortens resulting in decrease in LA Ɛ (Viera et al. 2014). 
Speckle tracking echocardiography has been found to be a feasible and 
reproducible technique in the evaluation of longitudinal LA strain (Ɛ) thus providing 
an additional new parameter for LA function assessment (Kowallick et al. 2014, 
Pinton et al. 2009).  This may enable earlier identification of subclinical LA 
dysfunction which has additional prognostic implications in various disease states 
(Hoit et al. 2014). 
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Figure 1.3 Apical 2C view of the LA depicting reservoir, conduit and contractile 
phases. 
 
1.3.4 LA volumetric and strain parameters in a normal black population - Do 
data exist? 
 
Recent data from the EchoNoRMAL study has highlighted the possibility that 
echocardiographic measurements of LA size may differ among various ethnic 
populations with black Africans having lower LA diameters than Caucasians (Aune et 
al. 2015).  For example; in a 50-year old African men the average LA size was 4.0 
cm compared to 4.5 cm in a Caucasian male of the same age. Reference values for 
LA parameters in the recent chamber guidelines have been derived largely from 
studies done in Caucasians (Lang et al. 2015).  Additionally, there is still no 
consensus on normal values pertaining to LA Ɛ, as there are limited multi-ethnic 
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studies on different vendor platforms.  There are no studies which have documented 
normative data on LA volumes indexed to body surface area in black Africans.  This 
is required to ensure that application of current cut-off values for LA parameters 
defined in guidelines can be accurately applied to this population. Further, there is no 
current evidence that ethnicity may affect Ɛ values of the LA since this has not been 
studied previously.  Thus, we sought to establish normal reference ranges of LA 
volumetric parameters and peak positive LA Ɛ (ƐR, LA reservoir function) and peak 
negative LA Ɛ (ƐCT, LA contractile function) in a black African population.  This aspect 
of the study will be addressed in Chapter 3 of the thesis.  Further, the impact of 
healthy aging has not been studied in a normal black population in relation to the LA 
size and function. 
 
1.3.5 Effects of age on LA volumetric and strain parameters 
 
As the number of older individuals increase in our population it becomes 
relevant to develop reference values for various cardiovascular parameters to 
accurately risk-stratify these individuals.  This would help to correctly distinguish 
normal aging from pathological states.  In healthy humans, aging is associated with 
progressive cardiac structural and functional alterations.  Aging is associated with LV 
diastolic dysfunction secondary to increase in LV wall thickness and HF with 
resultant LA enlargement and functional abnormalities such as atrial fibrillation 
(Lakata and Levy 2003, Gerstenblith et al. 1997).  Further, aging per se causes 
intrinsic LA dysfunction (Casaclang-Verzosa et al. 2008).  Due to these changes, the 
need for age-related reference values for CVS risk stratification becomes imperative 
(Lakata and Levy 2003, Gerstenblith et al. 1997). 
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Age-related changes in the LA have been studied extensively in white 
populations using traditional parameters such as LA size, volumes, and more 
recently, 2D strain (Boyd et al. 2011, Aurigemma et al. 2009, Thomas et al. 2002, 
Spencer et al. 2001).  The data from the aforementioned studies have been 
discrepant with reference to LA volumetric parameters. Thomas et al. attributed the 
lack of change in volumes in their study to normal healthy aging whereas others 
have demonstrated increase in LA volumes and size with normal aging ((Aurigemma 
et al. 2009, Casaclang-Verzosa 2008, Spencer et al. 2001). The limited data 
regarding LA Ɛ have shown a decline in LA peak systolic Ɛ with aging (Boyd et al. 
2011). 
There are no age-related reference values for LA volumes or strain in Africans. 
Thus, we sought to determine the effects of healthy aging on LA function in a black 
population with the aid of both traditional and newer echocardiographic techniques of 
2D strain and this will be elaborated further in Chapter 4.  Establishing the normative 
data was crucial for us to study atrioventricular mechanics in CRMR. 
 
1.4 Atrioventricular mechanics in chronic rheumatic mitral regurgitation 
 
The consequence of the chronic volume overload of MR on the LA and the LV 
results in chamber dilatation of these chambers (Bonow et al. 2102).  The LV 
develops eccentric hypertrophy as a result of neuro-hormonal activation resulting in 
a compensated state (Bonow et al. 2012, Gaasch and Meyer 2008).  During this 
period the patient remains asymptomatic at the expense of the compensatory 
mechanisms (Bonow et al. 2012).  However, there are certain deleterious effects, 
such as toxic effects of noradrenalin, resulting in cell loss secondary to myocyte 
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necrosis and apoptosis (Tsutsui et al. 1994).  Additionally, LV dilatation results from 
myocardial slippage secondary to loss of interstitial collagen (Bonow et al. 2012, 
Tsutsui et al. 1994).  Ultimately, LV dysfunction supervenes and the transition to a 
decompensated ventricle and HF occurs (Bonow et al. 2012, Tsutsui et al. 1994). 
Similarly, the LA dilates secondary to neuro-hormonal activation.  Volume 
overload is a stressor that results in numerous adaptive and maladaptive changes 
(Casaclang-Verzosa et al. 2008, Cohn et al. 2000).  On a microscopic level these 
comprise increased myocyte hypertrophy and growth, necrosis, apoptosis and 
increase extracellular matrix production with interstitial fibrosis (Casaclang-Verzosa 
et al. 2008, Cohn et al. 2000).  There are also changes at the cellular ionic channel 
level and in energy generation and consumption (Casaclang-Verzosa et al. 2008, 
Cohn et al. 2000).  Finally, activation of the fetal gene programme results in an 
increase in atrial hormone expression (Casaclang-Verzosa et al. 2008, Cohn et al. 
2000).  All of these processes eventually culminate in LA remodelling with resultant 
structural and functional alterations including changes in LA size, compliance and 
atrial fibrillation (Casaclang-Verzosa et al. 2008, Cohn et al. 2000).  The LA 
eventually decompensates and fails, as it becomes fibrotic and noncompliant and 
reaches the descending limb of the Frank-Starling curve.  Additionally, in rheumatic 
MR the LA may be directly involved by the rheumatic process and result in a giant, 
fibrotic, calcified and noncompliant LA as a result of ongoing inflammation (Shriki et 
al. 2011, Edwards et al. 2006, Roberts and Vermani 1978, Plaschkes et al. 1971). 
Imaging has been used to study the compensated and transition states of the LV and 
the LA.  In degenerative MR there is an initial increase in LV peak global strain due 
to volume overload with later decline as LV decompensation occurs (Klein 2013, 
Witkowski et al. 2012).  Strain is able to detect subclinical changes in the LV in the 
 17 
 
asymptomatic phase before decline in EF and thus may be a more sensitive marker 
for follow-up of LV function (Gunjan et al. 2012, Yurdakal et al. 2011, Lee and 
Marwick 2007).  In rheumatic MR, LV dysfunction may be a result of not just volume 
overload but also due to intrinsic myocardial involvement by the rheumatic process 
(Choi et al. 2006, Barlow 1987, Stollerman et al.1975). There are limited data 
pertaining to the LV deformation parameters in CRMR.  In a study of patients with 
rheumatic MR, LV longitudinal strain was found to be diminished (Gunjan et al. 
2012).  We thus studied LV deformation with strain imaging in a black population 
with rheumatic MR. 
Several studies have evaluated the three LA mechanical phases in MR by non-
invasive tools using 2D echocardiography and strain imaging (Borg et al. 2009, Ren 
et al. 2014, Yurdakul et al. 2014, Debonnaire et al. 2013, Mustafa et al. 2011, 
Aksakal et al. 2012).  Discrepant findings were noted in the aforementioned studies. 
LA reservoir function was depressed in most studies Debonnaire et al. 2013, Aksakal 
et al. 2012, Mustafa et al. 2011) while conduit function was increased in others 
(Mustafa et al.2011, Borg et al. 2009).  Results regarding booster function show 
conflicting results between studies (Ren et al.2014, Askakal et al. 2012, Mustafa et 
al.2011, Borg et al. 2000).  Ren et al, Yurdakul et al. and Borg et al. reported 
preserved booster function based on volumetric parameters, whereas Mustafa et al. 
and Askakal et al. reported decline in booster function.  The possible reasons for the 
discrepant observations may be due to a variable combination of MR severity, 
aetiology, LA and LV compliance as well as their intrinsic characteristics.  
Few studies have evaluated LA mechanics in MR of rheumatic origin.  A study of 
rheumatic MR showed a decrease in reservoir and booster function in these patients 
but preserved conduit function on volumetric analysis (Askakal et al. 2012).  Further, 
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their study showed a decrease in longitudinal strain in all three LA mechanical 
phases (Askakal et al. 2012).  Therefore, strain imaging may prove useful for 
detection of subclinical LA dysfunction in MR, before a change in the more 
traditionally used marker of adverse outcome such as LA volume; and thus aids in 
earlier risk stratification for surgery. 
The current guidelines, largely derived from literature around degenerative MR, 
recommend surgical intervention based on LV dimensions and EF (Nishimura et al. 
2014).  An enlarged LA has been known to be associated with adverse outcome in 
MR (Le Torneau et al. 2010, Borg et al. 2009).  Recent valvular heart disease 
guidelines recommend new onset atrial fibrillation as an indication for surgery 
(Nishimura et al. 2014).  However, LA size or volume does not feature prominently, 
although they are likely earlier markers of LA dysfunction.  Further, the current 
guidelines do not as yet include strain cut-off values for the LA or LV as indications 
for surgery. 
In a normal individual LA and LV chambers interact synergistically to maintain 
adequate cardiac output and this interaction becomes of utmost importance in 
disease states where LV dysfunction is present as the atrial contribution to total 
stroke volume (SV) becomes significant (Todaro et al. 2012).  This intimate 
physiologic interaction in systole and diastole between these chambers results from 
their close anatomic connection (Silbiger et al. 2012).  LA and LV longitudinal fibres 
insert into the common mitral annulus and hence the descent of the annulus during 
LV systolic contraction, allows filling of the LA during LA diastole.  The contraction of 
the LA fibres during LA systole contributes to LV filling at end-diastole (Silbiger et al. 
2012).  It would seem more insightful to study both chambers simultaneously with 
strain imaging due to interdependence of each chamber in systole and diastole on 
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each other and to determine the dysfunction of LA and LV in MR.  We therefore, 
sought to study LA and LV mechanics in moderate or severe CRMR with the aid of 
traditional volumetric parameters and newer echocardiographic techniques of 2D 
strain.  We further hypothesised that LA dysfunction may precede LV dysfunction in 
CRMR due to both the fact that its thinner wall would make it more susceptible to 
haemodynamic stress and that it may be directly involved in the rheumatic process. 
The above-mentioned aspects will be discussed in detail in Chapter 5 of the thesis. 
In addition to the intimate anatomic relationship between the LV and the LA, 
there exists a strong interdependence between the RV and LV since both share a 
common septum.  We therefore decided to study the RV function in CRMR and 
explore LV-RV interaction in this disease.  The reason for this will be elaborated 
further in the following section. 
 
1.5 Right ventricular functional assessment in chronic rheumatic mitral 
regurgitation 
 
RV function is an important prognostic determinant in various cardiovascular 
and pulmonary diseases, including MR (Hyllen et al. 2014, Fine et al. 2014, Burgess 
et al. 2002, D’Alonzo et al.1991).  The RV has been poorly studied compared to the 
LV, which has established normative data for dimensions, volumes, mass and 
function (Hyllen et al. 2014, Rudski et al. 2010).  The complex geometry of the RV 
presents challenges to its accurate structural and functional assessment, and there 
is limited data on RV function in MR (Hyllen et al. 2014, Rudski et al. 2010).  The 
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prognostic value of RV functional assessment and its utility in guiding indications for 
surgery in MR do not feature in the standard guidelines (Nishimura et al. 2014). 
Multiple methods exist for assessment of RV systolic function. These include 
tricuspid annular plane systolic excursion (TAPSE), tissue Doppler derived Sˈ and 
RV fractional area change (FAC).  One or more of these parameters can be used to 
assess RV function (Lang et al. 2015).  These parameters have several limitations. 
TAPSE is unable to measure global RV function, is influenced by tricuspid 
regurgitation and image quality (Finel et al. 2014, Rudski et al. 2010).  Sˈ only 
measures the longitudinal function of the RV. Sˈ is also dependent on image quality, 
the volume of tissue sampled, and myocardial tissue motion - all potentially resulting 
in measurement variability (Fine et al. 2014, Rudski et al. 2010).  Additionally, RV 
FAC is reliant on good image quality (Lang et al. 2015). 
Thus RV strain imaging is increasingly being used, as it enables assessment of 
global RV function and detection of subclinical disease, in a reproducible manner 
(Fine et al. 2014, Rudski et al. 2010).  RV strain analysis by speckle tracking 
echocardiography has been shown to be useful for the assessment and 
management of congenital heart disease, valvular heart disease, and various 
interventional procedures such as cardiac resynchronisation therapy and balloon 
mitral valvuloplasty (Todaro et al. 2015, Forsha et al. 2014, Kumar et al. 2014). 
There is however a paucity of data regarding RV functional and strain parameters in 
CRMR. 
The RV and the LV have an interdependent relationship.  This relationship 
stems from the anatomic continuity between the superficial fibres of the RV and LV 
(Ho et al. 2006).  This anatomic relationship between the RV and LV represents the 
physiological basis for RV free wall traction caused by contraction of the LV (Haddad 
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et al. 2008).  Assessment of RV function provides incremental information for the 
decision making process regarding surgical intervention in MR (Hyllen et al. 2014). 
Thus, we felt it useful to study the RV using traditional and newer strain imaging 
techniques, in patients with CRMR. Further, we explored the RV and LV interaction 
in CRMR using strain imaging, given that biventricular functional impairment is a 
predictor of both CV and overall survival postoperatively (Le Torneau et al. 2013a,b). 
CRMR results in pulmonary hypertension (PHT) and secondary RV remodelling.  
The RV function is usually maintained until the latter stages of its function when LV 
dysfunction occurs.  Neuro-hormonal factors from the LV abnormality and secondary 
PHT may also influence development of RV dysfunction.  Further, the RV akin to the 
LV myocardium may be directly involved by the rheumatic process (Barlow 1987, 
Roberts and Vermani 1978, Stollerman et al.1975).  These concepts shall be 
discussed further in Chapter 6 of this thesis. 
Multimodality imaging and biomarkers are increasingly being used in MR for 
accurate quantification of valve lesion severity, especially in cases incompletely 
evaluated by echocardiography alone (Banerjee et al. 2014, Bergler-Klein et al. 
2014, Rajani et al. 2014, Leong et al. 2013, Van De Heyning et al. 2012, Lee and 
Marwick 2007).  Increasingly, cardiac MRI is being utilised in MR for: assessment of 
regurgitant fraction (RF) using phase contrast mapping and evaluation of cardiac 
chamber volumes; and prognostication and surgical risk stratification based on the 
presence or absence of LV fibrosis on late gadolinium enhancement (LGE) and T1 
mapping (Kammerlander et al. 2016, Uretsky et al. 2015, Edwards et al. 2014, Van 
De Heyning et al. 2014).  We therefore investigated the role of echocardiography, 
cardiac MRI and biomarkers of collagen turnover in CRMR in the thesis and these 
aspects are elaborated below.  
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1.6 Role of cardiac magnetic resonance imaging in evaluation of LV function 
and assessment of mitral regurgitation severity 
 
CMR is advantageous over conventional echocardiography in assessment of 
valve lesions (Kar and Sharma 2015).  It has higher spatial and temporal resolution 
and is less operator dependent (Kar and Sharma 2015).  There is no dependence on 
body habitus (Kar and Sharma 2015).  Quantification of LV volumes is much more 
accurate (Kar and Sharma 2015).  Furthermore, it can be used as a surrogate for LV 
fibrosis (Kammerlander et al. 2016, Doltra et al. 2013, Di carli et al. 2012).  The main 
limitations of MRI are related to cost, lengthy study time, and lack of compatibility 
with magnetic devices (Kar and Sharma 2015). 
 
1.6.1 Role of CMR in evaluation of cardiac volumes and function 
 
CMR is regarded as a gold standard for the quantification of LV volumes and 
function (Myerson 2012).  In this regard it is highly accurate and reproducible.  Unlike 
echocardiography it measures volumes in three dimensional planes.  Semi-
automated algorithms make the measurements of volume and function more reliable 
and reproducible compared to echocardiography, where measurements are largely 
operator-dependant and thus prone to variations (Kar and Sharma 2015) (Figure 
1.4).  However, CMR requires the correct placement of the basal ventricular image 
slice and careful contour placement while post-processing, to accurately differentiate 
atrial and ventricular chambers (Myerson 2012).  Erroneous inclusion or exclusion of 
the basal slice, incorrect contour placement and chamber delineation can result in 
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significant errors in volume calculation.  The prognostic role of increased LV volumes 
and dimensions in MR is well recognised (Nishimura et al. 2014, Gaasch and Meyer 
2008). Thus, accurate quantification of volumes by CMR makes it a useful tool for 
ventricular function assessment and especially, serial follow-up of MR as it has a 
long asymptomatic period (Bonow et al. 2012, Myerson 2012). 
 
 
Figure 1.4 a) Measurement of LV end-diastolic and end-systolic volumes on 
cardiac MRI. b) Measurement of aortic flow using phase contrast Imaging. 
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1.6.2 CMR for quantification of mitral regurgitation 
 
CMR is a useful adjunctive tool to echocardiography in assessment of valve 
lesions (Kar and Sharma 2015, Myerson 2012).  In MR its main use is for accurate 
quantification of regurgitation severity and assessment of ventricular volume and 
function (Myerson 2012).  Additionally, it can provide anatomical information 
pertaining to leaflet morphology and function equivalent to trans-oesophageal echo. 
The effective regurgitant orifice area can be directly planimetered in some patients 
with less complex mitral valve morphology.  Cine imaging is useful for directly 
visualising valve anatomy and motion and hence provides information regarding 
mechanism of regurgitation.  Additionally, the direct visualisation of flow allows one 
to assess location, direction of jet as well as measurement of jet width and vena 
contracta. CMR, in contrast to echocardiography has the ability to directly quantify 
flow and velocity using through–plane phase contrast velocity mapping (Figure 1.4).  
This technique unlike echocardiography or invasive catheterisation does not require 
complex equations to calculate regurgitant volumes (RegV) and fractions.  MR 
severity can be easily assessed by quantifying RF using the following simple 
formulae: (regurgitant volume/forward volume × 100%) (Edwards et al. 2014, 
Myerson 2012).  The difference between LV, SV and the aortic forward stroke 
volume is used to derive the RegV.  A regurgitant fraction greater than 40% is 
regarded as significant regurgitation.  Quantification of flow by CMR has shown 
accuracy when compared to in vitro studies and has a good correlation with in vivo 
measurements.  CMR has a few limitations when assessing valve lesions which 
include the need to acquire images over several cardiac cycles resulting in 
suboptimal visualisation of small objects such as vegetations.  The thin nature of 
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valve leaflets makes them prone to partial volume effects resulting in poor 
visualisation and inaccurate effective regurgitant orifice area (EROA) assessment 
may result from misalignment of imaging plane at the true mitral leaflet tips. 
However, CMR still remains advantageous over echocardiography in MR 
assessment, whereas, a single CMR scan is able to provide pertinent information 
regarding valve anatomy, function, severity of regurgitation, LV volumes and 
function; and the presence of myocardial scarring. 
Recently, CMR has been used as an adjunctive non-invasive imaging modality 
to characterise the severity of degenerative MR (Kar and Sharma 2015, Uretsky et 
al. 2015, Van De Heyning et al. 2013).  Discordance was noted between the two 
techniques (CMR and echocardiography) in one study, with MRI classifying a 
significant 30% of the lesion as moderate that were assessed as severe by 
echocardiography (Uretsky et al. 2015).  The results from prior smaller studies have 
shown equivalence or superiority of MRI in assessing MR severity (Van De Heyning 
et al.2013, Sukpraphute 2012, Uretsky et al. 2010, Cawley and Otto et al. 2009, 
Hellgren et al. 2008, Gelfand et al. 2006).  No studies have examined whether 
similar discrepancies in the assessment of MR severity applies to rheumatic MR, 
where the MR jets are predominantly eccentric and the proximal isovelocity surface 
area (PISA) method is thus not always reliable in assessment of MR severity 
(Enriquez-Sarano et al.1993).  Therefore, we studied a subgroup of patients with 
CRMR using both echocardiography and MRI. 
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1.7 CMR for detection of fibrosis 
 
CMR technology has enabled us to characterise tissue in various cardiac 
pathologies (Doltra et al. 2013, Di Carli et al. 2012).  LGE is a widely used technique 
for detection and quantification of fibrosis in myocardial tissue.  Extracellular volume 
(ECV) expansion may have prognostic value in predicting mortality and other 
composite end-point (Wong et al. 2012).  Gadolinium is an extracellular agent (Doltra 
et al 2013, Di Carli et al. 2012).  The extracellular space expands as a result of an 
infiltrative disease process, fibrosis or oedema, and this resultant increase in the 
ECV allows gadolinium to accumulate in the extracellular space.  The gadolinium 
washes out slowly and is seen as an area of enhanced myocardium on delayed T1-
weighted imaging compared to normal myocardium (Di Carli et al. 2012).  Therefore, 
diseases that result in diffuse fibrosis of the myocardium may be missed by this 
technique as there a lack of a normal reference myocardial region.  To overcome this 
limitation, contrast-enhanced T1 mapping has been developed to detect diffuse 
fibrosis (Jellis et al. 2010).  Additionally, T1 mapping has proven to be a useful 
technique for assessment of both macroscopic and microscopic fibrosis 
(Kammerlander et al. 2016).  
In chronic degenerative MR detection of fibrosis by LGE may help risk-stratify 
patients for earlier surgery before irreversible myocardial damage supervenes (Van 
De Heyning et al. 2014, Edwards et al. 2014).  The prevalence of fibrosis has not 
been studied in CRMR; previous studies have noted involvement of the posterobasal 
region of the LV by the rheumatic process (Barlow 1987).  Sepulveda et al. and Choi 
et al. reported diffuse, mesocardial and heterogeneous enhancement of myocardium 
by LGE in ARF and patchy delayed enhancement of the LV in chronic rheumatic in a 
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case report, respectively (Sepulveda et al. 2013, Choi et al. 2006).  Therefore, based 
on the above-mentioned observations and findings we speculated that there may be 
LV fibrosis in CRMR and this may have a similar relevance as in degenerative MR.  
 
1.8 Biomarkers of collagen turnover in mitral regurgitation 
 
It is well known that increased morbidity and mortality is associated with 
myocardial remodelling and chamber dilation irrespective of aetiology (Bonow et al. 
2012).  The LV geometry and structural integrity of myocardial cells is maintained by 
myocardial fibrillar collagen matrix (Bonow et al. 2012, Li et al. 2000, Spinale et al. 
2000).  The two most abundant collagen precursors in the heart include procollagen I 
and III (Lopez et al. 2010).  Circulating biomarkers of collagen metabolism are 
generally divided into two broad groups; these include biomarkers of collagen 
degradation and biomarkers of collagen synthesis (Lopez et al. 2010).  Alteration in 
collagen matrix occurs in various cardiac diseases (Bonow et al. 2012, Li et al. 2000, 
Spinale et al. 2000).  LV remodelling results from alterations in collagen volume and 
collagen organization due to a complex interplay between matrix metalloproteinase 
(MMP) activation and tissue inhibitors of metalloproteinase (TIMP) expression (Mann 
and Taegtmeyer 2001).  Fibrosis is characterised by decreased collagen breakdown 
and increased collagen synthesis (Bonow et al. 2012).  MMPs are endogenous 
enzymes involved in the degradation of collagen (Bonow et al. 2012, Lopez et al. 
2010, Li et al. 2000, Spinale et al. 2000).  Their action is inhibited by TIMPs.  MMP 
activity is controlled by endogenous physiological inhibitors and substrate interaction 
(Bonow et al. 2012, Lopez et al. 2010, Li et al. 2000, Spinale et al. 2000).  They are 
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also regulated at pre- and post - transcriptional levels (Li et al. 2000, Spinale et al. 
2000).  Therefore, the progression of the fibrotic process in the myocardium is 
determined by the interplay of MMPs, the tissue inhibitors of MMPs (TIMPs) and 
their regulators (Bonow et al. 2012, Lopez et al. 2010, Li et al. 2000, Spinale et al. 
2000).  Increased MMP activity leads to excessive degradation of extracellular matrix 
(ECM) and lead to slippage of myocyte bundles and/or individual myocytes within the 
LV wall resulting in LV remodelling, dilation and dysfunction (Mann and Taegtmeyer 
2001).  The MMPs rise in the HF state and contribute to the matrix remodelling 
process (Bonow et al. 2012, Lopez et al. 2010).  The MMPs increase in HF of any 
aetiology (Bonow et al. 2012, Li et al. 2000).  The following MMPs increase more 
than others in heart failure: MMP-9, 3, 13 and 14 (Bonow et al. 2012, Li et al. 2000, 
Spinale et al. 2000). 
Chronic MR results in volume overload which in turn activates a series of 
downstream pro-fibrotic pathways (Chemaly et al. 2013).  The exact pathophysiology 
of fibrosis in MR still remains poorly understood (Van De Heyning et al. 2014).  
Histopathology studies have shown the presence of extensive interstitial fibrosis in 
the hearts of patients with severe MR; sometimes even greater than that in pressure 
overloaded states such as severe aortic stenosis and hypertensive heart disease 
(Fuster et al. 1977).  In contrast more recent work in animals, report increased 
fibrosis in pressure loaded ventricles as opposed to volume loaded ventricles 
(Chemaly et al. 2013).  This is explained on the basis of increased oxygen supply- 
demand ratio in the pressure loaded ventricle resulting in ischaemia and fibrosis, as 
well as reduced activation of pro-fibrotic pathways in reactive fibrosis (Chemaly et al. 
2013). 
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The increase in wall stress in chronic MR has also been implicated in 
ventricular fibrosis as a result of neuro-hormonal activation (Edwards et al. 2014).  
Yet other studies have attributed lack of fibrosis in volume overload states to 
activation of alternative pathways such as the Kallikrein-kinin system resulting in an 
increase in enzymes such as matrix metalloproteinase (MMP).  This activation 
results in collagen degradation rather than synthesis as the primary abnormality in 
MR (Wei et al. 2012, Janicki et al. 2005).  A study on CRMR and biomarkers found 
increased MMP-1 activity in patients with chronic MR (Banerjee et al. 2014).  
Novel biomarkers, in the context of rheumatic valve disease, are procollagen 
type1C-peptide (PIP) and procollagen III N-Terminal propeptide (PIIINP) (Banerjee 
et al. 2014).  Type-I collagen, which is ubiquitous in valve and other tissues, is initially 
synthesized as procollagen I (Bonow et al. 2012, Lopez et al. 2010).  This protein 
undergoes cleavage of amino-terminal and carboxy-terminal ends, to produce the 
triple helical monomers (Bonow et al. 2012, Lopez et al. 2010).  PIP is released into 
the blood stream during collagen synthesis (Bonow et al. 2012, Lopez et al. 2010). 
PIP has been shown to increase in hypertensive heart disease, HF, and hypertrophic 
cardiomyopathy (Lopez et al.2010, Morillas et al. 2013, Ho et al. 2010).  Procollagen 
III undergoes similar metabolism by collagen proteinases and the propeptide PIIINP 
is released into the blood stream.  In ischaemic heart disease and idiopathic dilated 
cardiomyopathy, an association has found between PIIINP concentrations and 
myocardial collagen type II content (Lopez et al. 2010).  Banerjee et al. reported an 
increase in activity of PIP and PIIINP in CRMR (Banerjee et al. 2014).  Therefore, we 
studied biomarkers of collagen synthesis (PIP and PIIINP) and breakdown (MMP-I 
and TIMP-I) in CRMR. 
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In summary, a paucity of data exists in CRMR on:  
1) Presence of myocardial fibrosis by LGE and biomarkers of collagen turnover on 
MRI and; 
2) A comparison of CMR and echocardiographic techniques for assessment of 
rheumatic MR severity. These findings are presented in Chapter 7 of the thesis. 
The aforementioned biomarkers may be used as non-invasive tools for the diagnosis 
of asymptomatic valve disease, therapeutic targets for anti-remodelling therapy and 
follow-up of patients with valvular heart disease such as MR (Banerjee et al. 2014, 
Lopez et al. 2010, Khan et al.2006, Mann and Taegtmeyer 2001, Spinale et al. 
2000).  Anti-remodelling therapy in hypertension and HF with angiotensin-receptor 
blockers (ARB) and aldosterone-receptor antagonists have been shown to decrease 
levels of PIP and PIIINP (Lopez et al. 2010).  Therefore, anti-remodelling therapy 
may be used in MR to halt cardiac remodelling and thus prevent progression to HF. 
These findings are presented in Chapter 7 of the thesis. 
 
1.9 Anti-remodelling therapy for heart failure secondary to chronic rheumatic 
mitral regurgitation 
 
In chronic MR the persistent volume overload results in activation of 
compensatory mechanisms which include activation of SNS-RAAS, the Frank-
Starling mechanism and eccentric hypertrophy (Bonow et al. 2012, Tsutsui et al. 
1994).  Over the long-term, these compensatory mechanisms are deleterious and 
culminate in myocardial dysfunction and failure (Bonow et al. 2012, Tsutsui et al. 
1994).  These pathways have provided the rationale for benefit of medical therapy in 
MR.  Most of above-mentioned trials were small studies involving vasodilators such 
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as ACEI and beta-blockers in degenerative MR and have been inconclusive (Ahmed 
et al. 2012, Carabello 2008, Evangelista 2007).  
Beta-blockade has demonstrated efficacy in reducing mortality in patients with 
cardiac failure due to non-valvular causes (Yancy et al. 2013).  In canine models with 
chronic experimental MR chronic beta-blocker therapy improves LV function (Tsutsui 
et al. 1994).  A pilot study involving patients with moderate to severe MR on beta-
blocker therapy (metoprolol) was conducted over a 2-week period.  CMR was used 
to follow-up this cohort.  No reduction in RegV was demonstrated, however, LV work 
was reduced by beta-blocker therapy (Stewart et al. 2008).  A larger study was 
therefore proposed to assess the effect of beta-blockers on LV function and 
symptoms due to MR (Stewart et al. 2008).  A subsequent trial was published, 
involving patients with moderate to severe, degenerative MR on beta-blocker 
therapy, (metoprolol) over a 2-year follow-up.  LV function was assessed using CMR. 
Improvements were found in LVEF and LV early diastolic filling rate.  No change in 
LV end-diastolic volume (EDV) or LV end-systolic volume (ESV) was noted (Ahmed 
et al. 2012).  
In addition to beta-blockers, the introduction of ACEIs or ARBs and 
spironolactone have resulted in further dramatic declines in mortality due to systolic 
HF due to non-valvular causes (Yancy et al. 2013).  Limited data exist on their use in 
valvular heart disease. 
ACEIs have been used in the treatment of systolic HF with significant 
reductions in morbidity and mortality (Yancy et al. 2013).  In the context of MR, 
benazepril was used in dogs with moderate to severe MR and showed improved 
survival (Kittelson et al. 2009).  Wisenbaugh et al. studied the effects of captopril in 
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thirty-two patients with severe isolated MR over a 6-month period, and found no 
difference in LV diameters or EF when compared to placebo (Wisenbaugh et al. 
1994b).  In a trial on humans assessing a combined population of patients with 
moderate to severe aortic regurgitation and MR, a significant reduction in regurgitant 
fraction, LV end-systolic and EDVs and LV mass, was noted when quinapril was 
used (Schön et al. 1994). 
ARBs seem to produce a similar beneficial effect. In a, small study on the use 
of losartan for the treatment of MR, a modest but variable improvement in the 
severity of MR was noted.  Specifically, the RegV and the effective regurgitant orifice 
decreased and the effect was durable for one month (Dujardin et al. 2001).  Another 
trial assessing moderate degenerative and rheumatic MR also found a beneficial 
effect with losartan over a 6-week period with regards to MR severity, LA size, and 
LV function (Sekuri et al. 2008).  
Spironolactone has been evaluated in the context of systolic HF resulting in 
favourable LV remodelling and a decline in morbidity and mortality through 
aldosterone antagonism (Yancy et al. 2013, Soberman and Weber 2000).  The 
mortality reduction in HF was attributed to a decrease in sudden death and 
progression of HF (sudden death has not been reduced by any other agent used in 
systolic HF) (Soberman and Weber 2000).  No human trials with spironolactone in 
MR have been noted in the literature.  In dogs however, a study investigating 
spironolactone in moderate to severe MR resulted in a significant reduction (55%) in 
a composite end-point of cardiac-related death, euthanasia, or severe worsening of 
MR (Bernay et al. 2010). 
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Studies have not evaluated the effects of combination therapy (ACEI/ARB, 
beta-blockers, aldosterone-receptor antagonist) in HF secondary to MR.  There is 
proven reduction of mortality and morbidity with combination anti-remodelling 
therapy in HF resulting from ischaemia and cardiomyopathies (Yancy et al. 2013, 
Merlo et al. 2011).  Therefore, we hypothesised that a similar benefit may be derived 
in HF secondary to rheumatic MR.  Our patients’ clinical profiles differ significantly 
from those of the western world.  Timeous surgical intervention is hampered by late 
presentation to a tertiary care centre as a result of misdiagnosis at a primary health 
care level, as well as a general lack of cardiothoracic services.  A substantial 
proportion of these patients are thus admitted in HF and are treated with medical 
therapy.  We studied the effect of combination anti-remodelling therapy in terms of 
clinical outcome; and traditional as well as newer echocardiographic parameters 
such as 2D strain in a subset of patients with CRMR.  Combined anti-remodelling 
therapy would potentially offer an alternative option to these patients who are at high 
risk for need for surgery or are not inclined to undergo surgical intervention.  Further, 
the benefit of anti-remodelling therapy may extend to asymptomatic patients with 
significant MR to stabilise the disease process and thus delay the time to surgery or 
perhaps even obviate the need for surgical intervention.  The finding of this study are 
presented in Chapter 8 of this thesis. 
In summary, CRMR is a commonly occurring, unique disease associated with 
significant morbidity and mortality.  In this thesis I, have studied the demographic 
and clinical profiles of an evolving disease because the population with rheumatic 
MR ages and ARF recedes in a peri-urban hospital.  We also established age-
related normative data in a black population regarding LA volumetric and strain 
parameters. This allowed me to study the atrio-ventricular mechanics in CRMR. RV 
 34 
 
plays an important prognostic role in MR and therefore part of this thesis focused on 
the study of RV function in CRMR.  Older literature has alluded to rheumatic MR not 
only being a disease of the mitral valve, but also the myocardium, however this 
concept has not been extensively explored by modern imaging and biomarkers.  
Therefore, we studied CRMR with not only conventional echocardiography, but with 
cardiac MRI also which entailed two main aspects - quantification of CRMR severity 
and prevalence of LV fibrosis by LGE.  We further evaluated the role of biomarkers 
in CRMR and their relation to imaging parameters.  There have been a few studies 
that aimed to provide answers regarding the use of medical therapy in degenerative 
MR but patients with CRMR were under represented and thus the role of 
combination anti-remodelling therapy in CRMR was explored. 
 
1.10 Study aims 
 
The aims of this study were: 
a) To examine our contemporary patient population with moderate or severe 
rheumatic mitral regurgitation specifically to detect the changing demographic 
and echocardiographic profile at Chris Hani Baragwanath Academic Hospital 
(Chapter 2). 
b) To establish normal reference ranges of left atrial volumetric parameters and 
peak positive LA Ɛ (ƐR, left atrial reservoir function) and peak negative left 
atrial Ɛ (ƐCT, left atrial contractile function) in a black African population 
(Chapter 3). 
 35 
 
c) To determine the effects of healthy aging on left atrial function in a black 
population with the aid of both traditional and newer echocardiographic 
techniques of two-dimensional strain (Chapter 4). 
d)  To study the left atrial and left ventricular mechanics in moderate or severe 
chronic rheumatic mitral regurgitation with the aid of traditional volumetric 
parameters and newer echocardiographic techniques of 2D strain (Chapter 5). 
e) To study right ventricle function using traditional and the newer two-
dimensional strain imaging techniques in chronic rheumatic mitral 
regurgitation (Chapter 6). 
f) To study the echocardiographic and cardiac magnetic resonance 
characteristics of patients with chronic rheumatic mitral regurgitation and their 
association with biomarkers (Chapter 7). 
g) To study the effect of anti-remodelling therapy in chronic rheumatic mitral 
regurgitation, in terms of clinical outcome and echocardiographic parameters 
(Chapter 8). 
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Chapter 2 
 
 
The changing spectrum of chronic rheumatic  
mitral regurgitation in Soweto, South Africa 
 
 
 
 
 
 
 
 
       
 
 
 37 
 
2.1 Abstract 
 
2.1.1 Background 
Previous studies have documented the high prevalence of rheumatic heart 
disease in the population of Soweto and have provided a detailed description of the 
echocardiographic findings.  We sought to determine whether the clinical and 
echocardiographic characteristics of rheumatic mitral regurgitation (MR) had 
changed in a more contemporary population.   
 
2.1.2 Methods and Results 
This cross-sectional study included 84 subjects with moderate or severe 
rheumatic MR.  It comprised 84% females with a mean age of 44±15.3 years.  Acute 
rheumatic fever (ARF) was documented in only one patient.  Hypertension and HIV 
were present in 52% and 26% respectively.  Echocardiography showed leaflet 
thickening in 41%, calcification in 25% and restricted motion and sub-valvular 
disease in 34% of the study population.  Carpentier IIIa leaflet dysfunction occurred 
in 80%.  Leaflet prolapse was seen in 20%.  Patients older than 30 years had 
hypertension (69% vs 9% p<0.01) and HIV (32% vs 9% p=0.03) more commonly.  
These findings are in marked contrast to previous literature, in which younger 
patients (mean=19 years), commonly presented with rheumatic carditis, and had no 
comorbidities.  In that study, leaflets were pliable, with 84% having isolated leaflet 
prolapse, and no commissural fusion.  Elongated (92%) and ruptured (25%) chordae 
predominated.   
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2.1.3 Conclusion 
Contemporary patients with rheumatic MR are older, have less ARF and 
greater associated comorbidities.  Further, the echocardiographic features have 
evolved to greater leaflet thickening, calcification and reduced motion with little 
prolapse.  These findings may have significant implications for the management of 
rheumatic disease in the modern era and serve to inform strategies for future 
management. 
 
2.2 Introduction 
 
The epidemiology of mitral regurgitation (MR) shows striking regional variation 
(Essop and Nkomo 2005, Enriquez-Sarano and Sundt 2010).  In developed 
countries, degenerative disease is the major cause of MR and when surgery is 
indicated, repair of the valve is the preferred therapy (Enriquez-Sarano and Sundt 
2010).  In geographically low and middle income areas MR is still predominantly due 
to rheumatic disease and when severe, mitral valve replacement is often required 
(Essop and Nkomo 2005).  While the demographic profile and echocardiographic 
features of degenerative MR have been well documented, there remains uncertainty 
regarding rheumatic MR ranging from diagnostic echocardiographic criteria to 
optimal management (Essop and Nkomo 2005, Enriquez-Sarano and Sundt 2010, 
Adams et al. 2010).  This uncertainty is compounded by several factors including: 
the declining incidence of acute rheumatic fever (ARF), the rising incidence of 
comorbidities such as human immunodeficiency virus (HIV) infection and chronic 
lifestyle diseases associated with increasing urbanisation (Essop and Peters 2014, 
Stewart et al. 2008).  In a landmark study of 700 patients with rheumatic valvular 
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disease from CHBAH, published approximately 30 years ago, Marcus et al. provided 
detailed echocardiographic and surgical data.  The demographic profile and 
echocardiographic features of patients with rheumatic MR within that cohort were 
characterised by a disease afflicting predominantly young individuals with a high 
burden of concomitant acute rheumatic carditis.  We therefore chose to examine our 
contemporary patient population with severe rheumatic MR specifically to detect the 
changing demographic and echocardiographic profile in a hospital serving the large 
community of Soweto in South Africa. 
 
2.3 Methods 
 
We conducted a prospective cross-sectional study at the Chris Hani 
Baragwanath Academic Hospital (CHBAH).  Patients were enrolled from January 
2014 and October 2014 from the valvular heart disease clinic.  This study formed 
part of an ongoing study of rheumatic mitral regurgitation.  All patients were 
screened and those deemed to have moderate or severe rheumatic MR were 
referred for possible inclusion in the study.  Ninety-one patients with presumed 
rheumatic MR underwent clinical evaluation, resting electrocardiogram and detailed 
echocardiographic assessment according to a pre-determined protocol. 
Patients aged 14 years or older with echocardiographic features of moderate or 
severe rheumatic MR were included.  Patients were excluded if they had significant 
aortic valve disease, concurrent mitral stenosis (MS) with a valve area of less than 
2.0 cm2 (as assessed by planimetry), documented ischaemic heart disease, pre-
existing non-valvular cardiomyopathy, prior cardiac surgery, congenital or pericardial 
disease, pregnancy, severe systemic disorders such as renal failure, uncontrolled 
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hypertension (systolic blood pressure >140mmHg and diastolic blood pressure 
>90mmHg) on medication or severe anaemia (Haemoglobin <10g/dl).  Seven 
patients were excluded because of anaemia, renal dysfunction, mild MR, and MR of 
non-rheumatic etiology.  The final study group included 84 patients.  We performed 
sub-group analysis of patients younger than 30 years and those greater than 30 
years (based on the mean age of the patients in the study by Marcus et al of patients 
with isolated CRMR of 19±11 years with 89% of patients being less than 30 years of 
age). Additionally, clinical and echocardiographic characteristics of patients with and 
without hypertension were compared and contrasted. The study was approved by 
the University of the Witwatersrand Ethics Committee (M140114). 
After obtaining voluntary consent, all patients underwent a detailed clinical 
evaluation, 12 lead electrocardiogram followed by transthoracic echocardiography.  
The assessment of previous heart failure (HF) was made based on a combination of 
the patient’s prior history, as well as available clinical records. Acute or recurrent 
rheumatic carditis was diagnosed using the modified Jones and the World Health 
Organization criteria (Dajani et al. 1992, WHO 2001).  The HIV status was available 
for all patients from prior medical records. 
Transthoracic echocardiography was performed on all patients in the left lateral 
position using a S5-1 transducer on a Philips iE33 system (Amsterdam, the 
Netherlands).  Images were obtained according to a standardised protocol. Data was 
transferred and analysed off-line using the Xcelera workstation (Philips). 
All linear chamber measurements were performed according to the American 
Society of Echocardiography (ASE) chamber guidelines (Lang et al. 2015). Left atrial 
(LA) volume was measured using the biplane area length method (apical 4 and 2 
chamber for LA), and was indexed to body surface area (BSA).  Left ventricular (LV) 
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end-diastolic- volume (EDV), end-systolic volume (ESV) and ejection fraction (EF) 
were assessed using the Simpson’s method (Lang et al. 2015).  LV mass was 
calculated according to ASE recommendations and was indexed to BSA (appendix). 
LV diastolic function measurements were performed in accordance with the ASE 
guidelines on diastolic function and included pulse-wave Doppler at the mitral tips 
and tissue Doppler of both medial and lateral mitral annuli (Nagueh et al. 2009).  
Measurements relating to the right ventricle were based on the ASE guidelines on 
the RV (Rudski et al. 2010). 
MR severity was assessed using qualitative, semi-quantitative and quantitative 
methods as per ASE and ESC valvular regurgitation guidelines (Lancelloti et al. 
2013, Zoghbi et al. 2003) (appendix).  In equivocal cases the echocardiographic data 
was integrated with the clinical evaluation by an experienced cardiologist to 
distinguish moderate from severe MR. 
MR was considered of rheumatic aetiology when the morphology of the valve 
satisfied the proposed World Heart Federation (WHF) criteria for the diagnosis of 
chronic RHD (Reményi et al. 2012) (appendix).  The Carpentier classification was 
used to assess leaflet motion (Chauvaud et al. 2001).  The extent of morphological 
abnormality of the valve was determined using the Wilkins score (Wilkins et al. 
1998).  The Wilkins score was used to characterise the mitral valve due to the 
absence of an alternate scoring system.  Although it was originally designed for 
prediction of success for balloon mitral valvotomy in MS, its systematic classification 
of structural changes to the mitral valve was considered useful to characterise the 
morphology of chronic rheumatic valve disease, and thus was utilised in this study.  
The Wilkins score is divided into four components:  
1) leaflet thickening,  
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2) leaflet mobility,  
3) leaflet calcification,  
4) sub-valvular apparatus involvement.  
The individual components are then graded from 0 (absent) to 4 (severe) depending 
on the extent of involvement ranging from none to severe (Wilkins et al. 1998). 
Statistical analysis was performed with Statistica version 12.5 series 0414 for 
Windows.  Continuous variables are expressed as means ± standard deviations 
(SDs) or medians (IQRs).  Student’s t test or Mann-Whitney U test were used to 
compare continuous variables.  Categorical variables were evaluated by the chi-
square and Fisher’s exact test when necessary.  A p value of < 0.05 was recognised 
as statistically significant. 
 
2.4 Results 
 
The baseline characteristics of the study patients are listed in Table 2.1.  All 
patients were black South Africans, predominantly from Soweto.  MR was moderate 
in 59 (68%) and severe in 25 (32%) of patients.  The mean patient age was 44±15.3 
years with 84% female patients.  Two-thirds of patients were NYHA II or III, with 26% 
having been hospitalised for HF in the preceding year.  One patient presented with 
features of acute rheumatic carditis two years prior to this study.  No patients had 
recurrent rheumatic carditis despite 6% being on penicillin for secondary prophylaxis 
for ARF.  Four (5%) patients presented with atrial fibrillation (AF). 
Hypertension was the most important comorbidity present in 52% of patients.  
Concomitant HIV infection occurred in 26% of patients and 19% were on highly 
active antiretroviral therapy.  Eighty-five percent (85%) of patients were on varying 
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combinations of medical therapy for either hypertension or HF and AF with 15% not 
on any drug therapy.  None of the eight patients who underwent coronary 
angiography during their surgical workup had occlusive coronary artery disease.  
The mean LVEF was 58±12.7% with 43% of patients having a LVEF <60%.  The 
EDV and ESV were 93.8±31.4 mL/m2 and 39.7±22.3 mL/m2, respectively.  
Pulmonary hypertension was present in 38 (45%) subjects with none having 
contributing pulmonary abnormality.  Concomitant organic rheumatic tricuspid valve 
(TV) disease was present in 29% of patients with the mean tricuspid annulus 
diameter of 38±7.2 mm.  Of the 64% of patients presenting with tricuspid 
regurgitation (TR), 31% had moderate or severe disease (Table 2.1).  
 
Table 2.1 Baseline clinical and echocardiographic characteristics* 
Characteristics n=84   
Age (years)  44±15.3   
Gender %    
   Females 84   
Clinical    
   SBP, mmHg 124.1±11.4   
   DBP, mmHg 77.2±8.8   
   HR, beats/min 78.2±12.7   
   BMI, kg/m2 27.1±6.1   
   BSA. m2 1.7±0.2    
NYHA functional class %    
   I/II/III/IV 34/42/24/0   
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Comorbidities %    
   Hypertension 52   
   Diabetes mellitus type 2 3    
   HIV 26   
Medication %    
   HAART 19   
   Diuretics 71   
   Spironolactone 21   
   ACE inhibitors 40   
   Beta Receptor Antagonists 25   
   Calcium Channel Antagonists 29   
   Aspirin 12   
   Warfarin 5   
   Digoxin 5   
   Amiodarone 1    
Left ventricle    
   LV EDD, mm 55.3±9.5   
   LVESD, mm 41.4±10.3   
   IVSD, mm 8.9±3.5   
   PWD, mm 8.6± 1.6   
   EDV indexed, mL/m2 † 93.8±31.4   
   ESV Indexed, mL/m2 † 39.7±22.3   
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   LV mass, g 175.7±64.2   
   LV mass indexed, g /m2 † 77.9±22.5   
   LVEF % 58.8±12.8   
   Average E/E’, cm/s 18±10.0   
   Dec time, cm/s 214.2±63.3   
   E’, cm/s 8.6±3.3   
   E/A ratio 1.5±0.7   
Left atrium    
   LA indexed, mL/m2 † 69.5±50.7   
Right ventricle    
   RV S’, cm/s 12.8±11.0   
   PASP, mmHg 36.2±18.9   
   TR (none/mild/mod or sev) % 36/33/31   
* Data are presented as mean± SD or %. † Values are indexed to BSA.   
ACE – Angiotensin converting enzyme. BSA – Body surface area. BMI – Body mass 
index. DBP - Diastolic blood pressure. Dec. time – Deceleration time. EDV – End-
diastolic volume. EROA – Effective regurgitant orifice area. ESV – End-systolic 
volume. HAART – Highly active antiretroviral therapy. HIV – Human 
immunodeficiency virus.  HR- Heart rate. IVSD – Interventricular septal diameter. LA 
– Left atrium.   LV – Left ventricle. LV EDD – Left ventricular end-diastolic diameter. 
LVEF – Left ventricular ejection fraction. LVESD – Left ventricular end- systolic 
diameter.  NYHA – New York Heart Association.  PASP - Pulmonary artery systolic 
pressure.  PWD – Posterior wall diameter. RV – Right ventricle. SBP - systolic blood 
pressure. 
 
The mean mitral annulus diameter was 43±8.5 mm with 71 (84.5%) having an 
annulus greater than 35 mm.  A Wilkins score of 4-8 was present in 26%, and 8-12 
present in 74% of patients with chronic rheumatic MR.  Sub-valvular apparatus 
thickening contributed the most to the total score (34.4%), followed by leaflet 
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calcification (27%) (Figure 2.1).  Figure 2.2 depicts the overall distribution of subjects 
in each component of the Wilkins score.  Chordae were not elongated and 
echocardiographic features suggestive of calcification within the leaflets were found 
in all subjects.  Significant commissural fusion was present in 30% of cases. 
Eighty percent of (80%) cases were classified as having restrictive-Carpentier 
type IIIa leaflet dysfunction while the remaining 20% had a mixed lesion which was a 
combination of type II (excessive leaflet motion) and type IIIa dysfunction.  All 
patients had greater degrees of restriction of the posterior mitral leaflet (PML) except 
in three cases where the anterior mitral leaflet (AML) was restricted to a greater 
degree than the PML.   A posteriorly-directed eccentric MR jet was present in 96% of 
cases except for three subjects that had anteriorly directed jets secondary to 
posterior mitral leaflet prolapse (Figure 2.3).  
 
 
Figure 2.1 Distribution of valve abnormality according to the Wilkins score 
components. 
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Patients younger and older than 30 years of age were compared (Table 2.2).   
Twenty-six percent (26%) were younger than 30 years of age.  There was no 
significant difference in the proportion of individuals having moderate or severe MR 
(p>0.05).  The remodelling parameters of the LV, LVEF and LA volume were similar 
in both groups (p>0.05).  Older patients were more likely to have comorbidities 
including hypertension (69% vs 9%, p<0.01) and HIV (32% vs 9%, p=0.03), and a 
greater degree of impairment of early diastolic relaxation (E' = 11.4±3.3 vs 7.6±2.3, 
p<0.01).  The comparative analysis of the morphology of the mitral valve revealed no 
significant differences in the overall Wilkins score between the two groups (8.31±1.2 
vs 8.1±1.0, p=0.33).  No statistically significant difference was noted in the degree of 
calcification of the leaflets, mobility, sub-valvular apparatus thickening and 
commissural abnormality (p>0.05).  Compared to normotensive patients with MR, 
patients with hypertension were older (51.7±11.1 vs 35.1±14.2 years, p<0.01).  The 
majority were in NYHA functional class II or III (71% vs 44%, p=0.03), with a greater 
prevalence of moderate MR, accompanied by a greater degree of impairment of 
early relaxation in diastole (Table 2.2).  Normotensive MR patients had a greater 
prevalence of dilatation of the left ventricle and severe MR with larger LA volume 
(Table 2.3).  There were no significant differences with regard to the morphology of 
the mitral valve apparatus or Carpentier classification of leaflet dysfunction between 
the two groups (p>0.05). 
A greater proportion of patients with HIV had severe MR compared to HIV 
negative patients (50% vs 23%, p=0.015).  However, no significant differences were 
observed in the echocardiographic parameters relating to dilatation of the LV, LVEF, 
LV diastolic function or LA volumes (p>0.05).  Similarly, no significant differences 
were noted in any morphological parameters or Wilkins score between the two 
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groups (8.4±1.2 vs 8.0±0.9, p=0.14).  All HIV positive patients had type IIIa 
(restrictive) leaflet dysfunction, compared to HIV negative individuals in whom 15% 
had mixed lesions (p=0.05).  Concomitant organic morphological TV disease was 
more common than in HIV negative patients (50% vs 21%, p=0.02).  A similar 
degree of TR (p>0.05) was present in both groups.  There was no difference in the 
pulmonary artery systolic pressure between the HIV positive and HIV negative 
groups (37.2±15.4 mmHg vs 35.2±18.7 mmHg, p=0.64).  The degree of RV dilatation 
(33.5±9.0 mm vs 31.4±5.8 mm, p=0.22) and RV function (11.9±2.9 cm/s vs 
13.4±13.2 cm/s, p=0.61) were not statistically different in between the HIV positive 
and HIV negative groups. 
A comparison of clinical characteristics and mitral valve morphology of our 
cohort with Marcus et al. is depicted in Table 2.4. 
 
 
Figure 2.2 Distribution of patient morbidity according to components of the 
Wilkins score.  
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Figure 2.3 a) Parasternal long-axis view depicting an eccentric anteriorly 
directed mitral regurgitation jet secondary to restricted posterior mitral 
leaflet motion. b) Parasternal long-axis view depicting a contemporary 
patient with established rheumatic heart disease: thickened shortened 
chordae, restricted posterior mitral leaflet. 
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Table 2.2 Clinical and echocardiographic characteristics according to age.* 
 
 
Variable Age<30 (n=22) Age>30 (n=62) P Value 
Clinical 
Age (Years) 23.3±3.6                  51.2±10.1                      <0.001 
Systolic blood pressure 121.9±11.2 124.9±11.3 0.29 
Diastolic blood pressure 77.8±6.83 76.6±9.6 0.60 
Body mass index (kg/m2) 23.84±4.78 28.2±6.23 0.19 
Body surface area (m2) 1.62±0.16 1.72±0.18 0.04 
NYHA functional class (I/II and III) 14/8 21/41 0.01 
Sex (F/M) (%) 18/4 (81/19) 53/9 (85/15) 0.68 
Echocardiographic 
Moderate mitral regurgitation (%) 13 (59) 46 (74)  
Severe mitral regurgitation (%) 9 (41) 16 (26) 0.18 
LV end-diastolic diameter (mm) 53.7±9.06 55.7±9.7 <0.0001 
LV end-systolic diameter (mm) 38.7±9.31 42.3±10.5 0.15 
Interventricular septum diameter 
(mm) 
9.8±5.9 8.6±2.3 0.21 
Posterior wall diameter (mm) 7.9±1.1 8.9±1.6 0.01 
LV EDV indexed (ml/m2)† 90.8±22.9 94.8±33.9 0.61 
LV ESV indexed (ml/m2)† 35.5±16.9 42.4±24.7 0.23 
LV Mass indexed (g/m2)† 102.2±44.2 105.7±38.5 0.72 
Relative wall thickness 0.30±0.1 0.33±0.1 0.24 
LV ejection fraction (%) 61.4±12.7 57.1±12.7 0.26 
Ejection fraction ≥ 60%  18 30  
Ejection fraction < 60% 4 32 0.006 
Average E' (cm/s) 11.4±3.3 7.6±2.3 <0.01 
E/E' lateral (cm/s) 13.2±8.2 17.2±9.3 0.04 
E/A ratio 1.7±0.34 1.4±0.7 0.05 
S' Lateral (cm/s) 8.9±3.3 6.63±1.7 <0.0001 
LA volume indexed (ml/m2)†¶  45 (37.1-148.5) 53 (41.2-74.5) 0.53 
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*Data are presented as mean ± SD, ¶ median (interquartile range) or percentage. † 
Values are indexed to body surface area. LA – Left atrium. LV – Left ventricle. NYHA 
– New York Heart Association.  
 
Table 2.3 Clinical and echocardiographic features according to the presence or 
absence of hypertension.* 
 
 
Hypertension         
  n=45 
No Hypertension  
n=39 
p value 
 
Age 
 
51.7±11.1 
 
35.1±14.2 
 
<0.0001 
Gender    
   Female % 86 82 0.62 
Clinical parameters    
   SBP, mmHg 127.9±8.4 119.5±12.8 0.0008 
   DBP, mmHg 79.2±8.5 74.2±8.8 0.01 
   BMI, kg/m2 28.6±6.1 25.0±5.8 0.01 
   BSA, m2             1.7±0.2 1.7±0.2 0.21 
   NYHA (I/II and III) 29/71 56/44 0.03 
Left ventricle    
   LV EDD, mm 52.4±8.4 58.3±9.8 0.004 
   LVESD, mm 39.7±9.5 43.2±10.9 0.12 
   IVSD, mm 9.0±2.3 8.9±4.6 0.97 
   PWD, mm 9.1±1.6 8.1±1.3 0.0009 
   EDV indexed, mL/m2   † 87.7±29.9 100.9±32.0 0.05 
   ESV Indexed, mL/m2     † 35.9±17.7 46.1±27.4 0.046 
   LV mass indexed, g /m2 † 100.1±39.4 110.4±40.2 0.24 
   RWT 0.4±0.1 0.3±0.1 0.0001 
   LVEF % 58.4±12.6 58.1±13.1 0.91 
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   EF ≥ 60%  24 24  
   EF < 60% 20 16 0.61 
   Average E/E’, cm/s 19.2±10.9 17.7±8.9  
   E’, cm/s 7.4±2.5 9.9±3.4 0.006 
   E/A ratio 1.3±0.6 1.6±0.6 0.008 
Left atrium    
   LA volume indexed mL/m2     † 57.6±24.1 83.37±67.7 0.42 
Right Ventricle    
   RV S’, cm/s 14.6±15.6 11.2±2.5 0.18 
   PASP, mmHg 33.7±19.2 37.9±16.1 0.28 
   TR (none/mild/mod to sev) % 38/36/26 33/31/36 0.46 
MR severity    
   Moderate mitral regurgitation % 82 56  
   Severe mitral regurgitation % 18 44 0.009 
* Data are presented as mean± SD or %. † Values are indexed to BSA.  
BSA – Body surface area. BMI – Body mass index. DBP - Diastolic blood pressure. 
EDV – End-diastolic volume. ESV – End-systolic volume. IVSD – Interventricular 
septal diameter. LA – Left atrium.  LV – Left ventricle. LV EDD – Left ventricular end-
diastolic diameter. LVEF – Left ventricular ejection fraction. LVESD – Left ventricular 
end-systolic diameter. NYHA – New York Heart Association. RWT- relative wall 
thickness PASP - Pulmonary artery systolic pressure. PWD – Posterior wall 
diameter. RV – Right ventricle. SBP - systolic blood pressure. 
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Table 2.4 Comparison of Marcus et al study with the current cohort of patients 
with isolated rheumatic mitral regurgitation. 
Variables Marcus et al 
(n=219) 
Meel et al 
(n=84) 
P value 
Clinical  
Age (years) 19±11 44±15.3 <0.001 
Females (%) Not specified 84%  
Race Black Africans Black Africans  
NYHA functional class III (100%) III (24%) 0.001 
Acute Rheumatic fever (%) 14 1.2 <0.001 
Co-morbidities (%) 0 78 <0.001 
Mitral valve morphology (%)  
Dilated annulus 95 84.5 0.001 
Leaflet thickness and 
pliability 
     
        Thin, pliable 95 5 <0.001 
        Thickened, non-pliable 59 41 0.0049 
Leaflet prolapse 84 20 <0.001 
Leaflet calcification (rigid) 5 27 <0.001 
Elongated chordae 92 0 <0.001 
Ruptured chordae 25 0 <0.001 
Commissural fusion 0 30 <0.001 
NYHA – New York Heart Association. 
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2.5 Discussion 
 
The pertinent findings in this contemporary cohort of patients with moderate to 
severe rheumatic MR include:  
(1) A significant increase in the mean age of patients compared to previous studies,  
(2) Infrequent occurrence of ARF, 
(3) A high incidence of comorbid disease including hypertension and HIV; and,  
(4) Advanced morphological changes in the mitral valve including leaflets and sub-
valvular apparatus on echocardiography. 
These findings are in marked contrast to the detailed evaluation published by 
Marcus et al. from the same hospital but almost three decades earlier (Marcus et al. 
1994). In that study, from the total cohort of 737 patients, 219 had pure MR, 275 
pure mitral stenosis and 220 mixed lesions.  Further, in Marcus’s study, patients with 
pure MR had thin leaflets, elongated chordae, dilated annuli and anterior leaflet 
prolapse – findings that were corroborated at the time of surgery (Marcus et al.1994).  
Pure MR was largely a function of active rheumatic carditis and age – most patients 
were younger than 20 years of age with clinical carditis documented in 14% and 
surgical features of acute rheumatic carditis in 47% of the entire MR cohort (Marcus 
et al. 1994).  In contrast, we found only one patient with active carditis.  The mean 
age of our cohort was 44±15.3 years and echocardiography revealed no leaflet 
prolapse and instead marked leaflet thickening, calcification and retraction 
accompanied sometimes by abnormality of the chordal structures.  
These features are compatible with the proposal that Marcus and ourselves 
have advanced in which fulminant carditis is thought to lead to pure severe MR and 
milder or recurrent carditis progressing to pure mitral stenosis or mixed mitral valve 
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disease (Essop and Nkomo 2005, Essop and Peters 2014, Marcus et al. 1994). 
Rheumatic MR of patients in the current era results in the predominance of 
Carpentier type IIIa leaflet dysfunction with Wilkins scores that are similar to patients 
with MS.  We postulate that less fusion of the commissures, predominance of 
posterior leaflet thickening and immobility, accompanied by sub-valvular 
abnormalities, predispose patients to develop predominantly regurgitant lesions.  
The reason some patients develop pure MS is unknown (Essop and Peters 2014). 
Differences in the interaction of host immunity, initial or recurrent streptococcal 
infections and chronic exposure of the valve leaflets to abnormalities of 
haemodynamic flow may account for these difference in morphology and dictate 
which lesion may predominate. 
The current data confirm that there has been a dramatic decline in the 
incidence of rheumatic carditis in the population of Soweto although the reasons for 
this are not entirely clear.  The striking trend toward a substantial decline in ARF has 
also been documented in the paediatric section of Baragwanath Hospital with a 
reduction from 64 cases per year in 1993 to 3 per year in 2010 (Cilliers 2014).  This 
decline was attributed to improved socioeconomic status and better access to health 
care (Cilliers 2014).  Thirty years ago McClaren et al.reported a RHD incidence of 
6.9/1000 among school children in Soweto (by auscultation) (Cilliers 2014). 
Recently, Engel et al. reported a RHD incidence of 20.2/1000 cases among scholars 
in the Bonteheuwel and Langa communities of Cape Town (by echocardiography), 
with the prevalence being higher in poorer communities (Engel et al. 2015).  The 
incidence of adults presenting with RHD was reported as high (23.5/100000) at 
Baragwanath Hospital (Cilliers 2014).  The data from other areas of the country are 
scarce; the REMEDY study did not formally report on the incidence or prevalence of 
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RHD.  However, 25.8% (863/3343) participants were from upper middle income 
countries (Zuhlke et al. 2015).  
Concomitant with the decline in rheumatic fever, diseases associated with 
western lifestyle and urbanisation have emerged.  A considerable number of patients 
with rheumatic MR currently have comorbidities of hypertension (52%) and HIV 
(26%).  These findings differ considerably from previous studies conducted in our 
institution.  These comorbidities mandate a careful assessment of the patient’s 
clinical presentation since symptoms may not be solely attributed to the MR. It was 
not the intention of the study to study the impact of blood pressure on MR severity. 
However, elevated blood pressure may overestimate the echocardiographic severity 
of MR and should be controlled for, and LV dysfunction may be attributed to 
concomitant HIV infection in addition to volume overload due to MR. 
The morphological abnormalities of the mitral apparatus (thickened and 
shortened sub-valvular apparatus) and the nature of leaflet dysfunction (Carpentier 
IIIa) described in the current population has diagnostic implications.  MR jets that are 
eccentric may require careful off-axis imaging to accurately delineate the full extent 
of the colour jet.  Further, an integrated evaluation of MR severity is mandatory due 
to the limitations of quantitative Doppler in some instances of eccentric jets.  
The selection of patients for mitral valve repair maybe more challenging and 
requires detailed insight into the morphology of the entire valve apparatus.  A 
strategy of exclusively inserting an undersized ring to correct annular dilatation is 
inadequate in the current context of rheumatic MR.  The former strategy was often 
successful historically in repairing rheumatic MR, since most patients had type II 
leaflet dysfunction (prolapse), accompanied by annular dilatation (Wisenbauagh et 
al. 1994a). 
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An important observation of my study was the high frequency of concurrent TV 
leaflet abnormality and tricuspid annular dilatation.  These abnormalities were not 
reported by Marcus et al. and no data on surgical repair was given.  Our findings 
suggest that once rheumatic MR is identified careful assessment of the morphology 
and function of TV is mandatory when selecting patients who will undergo mitral 
valve surgery.  This strategy may reduce the likelihood of the late consequences of 
unrepaired TR in rheumatic patients which has been previously highlighted (Antunes 
and Barlow 2007).  Late TR causes increased morbidity and mortality despite the 
presence of successful mitral valve surgery and in addition a second operation to 
correct the residual TR carries increased mortality (Antunes and Barlow 2007). 
There are several limitations to this study.  The initial diagnosis of HF was 
made outside of our clinic with no uniform criteria applied.  None of the patients had 
surgery, so surgical confirmation of the echocardiographic abnormality was not 
possible.  Finally, the population studied may not truly reflect the nature of the 
disease in rural younger populations, where a greater prevalence of acute rheumatic 
carditis may be found.  
In conclusion the modern cohort of patients with rheumatic mitral regurgitation 
are older, have less acute rheumatic fever and greater associated comorbidities.  
The echocardiographic features have evolved to greater leaflet thickening, 
calcification and reduced motion with little prolapse.  These findings may have 
significant implications for the current management of rheumatic mitral valve disease 
and contribute to better understanding of the evolution from acute to chronic RHD. 
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Left atrial volume and strain parameters using  
echocardiography in a black population 
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3.1 Abstract 
 
3.1.1 Background 
 Left atrial (LA) volume is an important predictor of morbidity and mortality in 
cardiovascular disease. LA strain is a feasible technique for assessing LA function. 
The EchoNoRMAL study recently highlighted the possibility that ethnic-based 
differences may exist in LA size.  There is a paucity of data regarding LA parameters 
in an African population.  We sought to establish normative values for LA volumetric 
and strain parameters in a black population. 
 
3.1.2 Methods and Results  
This cross-sectional study comprised 120 individuals from 18 to 70 years of 
age.  LA volumes were measured by biplane Simpson’s method and strain 
parameters were measured using Philips QLAB 9 (Amsterdam, the Netherlands) 
speckle tracking software.  The mean age was 38.7±12.8 years (50% male). 
Maximum LA volume indexed (LAVi), pre-atrial LAVi and minimum LAVi were 
19.7±5.9 mL/m2, 12.2±4.4 mL/m2, and 7.7±3.2 mL/m2, respectively.  Females had a 
higher LAVi compared to males (20.9±6.3 vs 18.6±5.3 mL/m2, p=0.04).  Peak global 
longitudinal strain in the reservoir phase (ԐR) was 39.0±8.3% and the peak LA strain 
in the contractile phase (ԐCT) was -2.7±2.5%.  No gender differences were noted in 
ƐR. BSA, age, and weight were the main determinants of ƐR on multivariate linear 
regression analysis. 
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3.1.3 Conclusion 
The data reported in this study establish the normal reference values for phasic 
LA volumes and strain in a normal black population and serve as a platform for 
future studies. 
 
3.2 Introduction 
The left atrium (LA) has multiple functions.  It is a contractile chamber that also 
acts as a reservoir, conduit, and volume sensor (Bonow et al. 2012).  The anatomy 
and pathophysiology of the LA is complex, and thus, optimal quantification of its 
function is difficult (Seward et al. 2014, Cameli et al. 2009).  Bearing in mind these 
challenges, LA size and volume are altered in many disease states and are 
important predictors of morbidity and mortality in many cardiovascular disease states 
(Vieira et al. 2014, Cameli et al. 2012).  Speckle-tracking echocardiography has 
shown to be a feasible and reproducible technique in the evaluation of longitudinal 
LA strain (Ɛ), thus providing an additional parameter of LA function (Kowalick et al. 
2014, Vianna-Pinton et al. 2009).  This may enable earlier identification of subclinical 
LA dysfunction, which has additional prognostic implications in various disease 
states (Hoit 2014).  However, interpretation of the abnormality does require normal 
data on vendor-specific software to differentiate normality from pathology. Recent 
data from the EchoNoRMAL study has highlighted the possibility that 
echocardiographic measurements of LA size may differ among various ethnic 
populations, with black Africans having decreased LA diameters than whites (Aune 
et al. 2015).  There are no studies that have documented normative data on LA 
volume indexed (LAVi) to body surface area (BSA) in black Africans.  This is 
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required to ensure that current levels of abnormality defined in guidelines can be 
accurately applied to this population.  Further, there is no current evidence that 
ethnicity may affect strain values of the LA since this has not been studied 
previously.  Thus, we sought to establish normal reference ranges of LA volumetric 
parameters and peak positive LA Ɛ (ƐR, LA reservoir function) and peak negative LA 
Ɛ (ƐCT, LA contractile function) in a black African population. 
 
3.3 Methods 
 
3.3.1 Study group 
This prospective cross-sectional study was part of an ongoing study being 
conducted at Chris Hani Baragwanath Academic Hospital to provide normal 
echocardiographic reference ranges in subjects of African descent.  Subjects were 
recruited from unrelated staff at Baragwanath Hospital and volunteers who 
presented themselves to the echocardiography laboratory following an 
advertisement about this study.  A total of 190 subjects were screened.  
The inclusion criteria were:  
1) Absence of symptoms, 
2) Normal blood pressure (≤140/90 mm Hg), 
3) Absence of diabetes and cardiovascular disease,  
4) Absence of chronic medication,  
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5) Presence of sinus rhythm (heart rate between 50-85 beats/min).  
The exclusion criteria were:  
1) Abnormal 12-lead electrocardiograms (ECG), 
2) Abnormal screening echocardiograms, 
3) Suboptimal image quality.  
The final sample comprised 120 individuals (60 females) aged 18 to 70 years. 
The study was approved by the University of the Witwatersrand Ethics Committee 
(M140114) and was in accordance with the principles outlined in the Declaration of 
Helsinki.  The participants’ baseline clinical characteristics were recorded, and the 
participants subsequently underwent comprehensive echocardiography. 
 
3.3.2 Echocardiographic evaluation 
Transthoracic echocardiography was performed on all patients in the left lateral 
position by experienced sonographers using an S5-1 transducer on a Philips iE33 
system (Amsterdam, The Netherlands).  The images were obtained according to a 
standardised protocol.  The data were transferred and analysed off-line using the 
Xcelera workstation (Philips). 
 
3.3.3 Two-dimensional and Doppler quantification 
All linear chamber measurements were performed according to the American 
Society of Echocardiography chamber guidelines (Lang et al. 2015).  The biplane 
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Simpson’s method was used for calculation of LA volumes.  LA volume was 
planimetered in the four-chamber and two-chamber views by tracing the endocardial 
border (pulmonary vein confluence and LA appendage were excluded).  Maximum 
LA volume (LAmax) was obtained at left ventricular (LV) end-systole, from the 2-
dimensional (2D) frame, just before the mitral valve opened (Vianna-Pinton et al. 
2009, Kowalick et al. 2014).  Pre-atrial volume (Vpre-A) was obtained from the 
diastolic frame, just before the mitral valve reopened as the result of atrial 
contraction (Vianna-Pinton et al. 2009).  LA minimum volume (LAmin) was assessed 
at LV end-diastole, from the smallest volume seen after LA contraction (Vianna-
Pinton et al. 2009, Kowalick et al. 2014). 
LA phasic function assessment was done using the following formulae: 
1) Reservoir function: LA emptying fraction total = (LAmax - LAmin)/LAmax) × 
100%; expansion index = (LAmax - LAmin)/ LAmin) × 100% 
2) Conduit function: Passive emptying volume = (LAmax - Vpre-A); passive LA 
emptying fraction = (LAmax - Vpre-A/LAmax) x 100%; and conduit volume = LV 
(stroke volume - (LAmax - LAmin) 
3) Booster pump function: LA active emptying fraction = (LApre-A – LAmin)/LApre-
A) × 100%; LA active emptying volume = (Vpre-A - LAmin) (Vianna-Pinton et al. 
2009, Kowalick et al. 2014, Hoit 2014). 
All the LA volumetric parameters were indexed to BSA (Kowalick et al. 2014) 
(appendix). Measurements relating to LV diastolic function were performed in 
accordance with the ASE guidelines on diastolic function and included pulsed-wave 
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Doppler at the mitral tips and tissue Doppler of both medial and lateral mitral annuli 
(Nagueh et al. 2009). 
 
3.3.4 Speckle-tracking echocardiography 
Apical 4- and 2-chamber views were obtained using 2D grayscale 
echocardiography for speckle-tracking analysis (Cameli et al. 2012, Cameli et al. 
2009).  This was performed during end-expiratory breath-hold and stable ECG 
recording (Cameli et al. 2012, Cameli et al. 2009, Vianna-Pinton et al. 2009).  An 
adequate grayscale image that allowed separation of myocardial tissue and 
surrounding structures was obtained (Cameli et al. 2012).  Three consecutive 
cardiac cycles were recorded and averaged.  The frame rate was set between 60 
and 80 frames/second.  Philips QLAB version 9.0 software allowed off-line semi-
automated analysis of speckle-based strain.  The endocardial surface of the LA was 
traced manually in both 4- and 2-chamber views by a 3-point-and-click approach. 
The system then automatically generates an epicardial surface tracing (Figure 3.1). 
The region of interest was thus created, and this was then manually adjusted as 
needed to allow for adequate speckle tracking. 
The software divides the region of interest into seven segments in the 2-
chamber and the 4-chamber views.  It then generates the longitudinal Ɛ curves for 
each segment and a mean curve of all segments (Cameli et al. 2012).  From these 
strain curves the peak left atrial strain in the reservoir phase (ƐR) and contractile 
phase were calculated (Viera et al. 2014).  The QRS onset was used as the first 
reference frame. 
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Figure 3.1 Two-chamber view depicting peak systolic strain in the reservoir 
phase and peak negative strain in the contractile phase in a normal subject. 
 
3.3.5 Statistical analysis 
Statistical analysis was performed with Statistica version 12.5, series 0414 for 
Windows.  Continuous variables were expressed as means ± standard deviations 
(SDs) or medians (interquartile ranges).  Univariate and multivariate linear 
regression analyses were used to identify possible independent determinants of LA 
ƐR,, and maximum LAVi. Multivariate models to predict LA ƐR and for maximum LAVi 
were selected in a multiple linear regression analysis. Univariate variables with 
Pearson’s correlation coefficient ≥0.8 were not included in the multivariate models.  
Additionally, only clinically and statistically significant variables (P <0.05) were 
selected for inclusion in multivariate linear regression analysis.  The aforementioned 
models were further analysed using the forward and backward multiple linear 
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regression methods.  The assumptions were verified by performing residual analysis 
and advanced Durbin-Watson statistics. 
The intra-observer and inter-observer variabilities were assessed for peak 
positive LA ԐR, peak negative LA ƐCT, maximum LAVi, and minimum LAVi. 
Measurements were done in 20 randomly selected subjects.  To assess inter-
observer variability two independent observers measured the LA volumetric and 
strain parameters, whilst intra-observer variability was calculated from the analysis 
by the same observer after one month of the first measurement. Inter-observer and 
intra-observer reproducibility was assessed by calculating coefficients of variation 
(CV).  The CV was calculated as the standard deviation of the differences divided by 
the mean.  The T- test for dependent variables was used to compare the mean and 
SD of the values derived for strain and volumes and to calculate the significance 
value.  A p value<0.05 was considered statistically significant. 
 
3.4 Results 
 
3.4.1 Baseline characteristics and echocardiographic findings 
Of the 120 individuals, 60 were male with a mean age of 38.7±12.8 years 
(Table 1). Females had a higher body mass index (BMI) compared to males 
(29.8±6.1 kg/m2 vs 25.9±4.5 kg/m2, p<0.001) but a lower BSA (1.78±0.17 m2 vs 
1.86±0.19 m2, p=0.007). There was no difference in weight between the sexes 
(75.8±15.6 kg vs 75.8±14.1 kg, p=0.9) but males were taller (1.7±0.07 m 
vs1.58±0.06 m, p<0.001). 
 67 
 
3.4.2 LA volumetric parameters for the total sample 
The mean maximum LAVi, minimum LAVi, and pre-A LAVi were 19.7±5.9 
mL/m2, 7.7±3.2 mL/m2, and 12.2±4.4 mL/m2 respectively (Table 3.2).  The maximum 
LAVi was higher among females than males (20.9±6.3 vs 18.6±5.3 mL/m2, p=0.04). 
 
Table 3.1 Baseline clinical and echocardiographic characteristics.* 
Variable  Total 
(n=120) 
Age, years 38.7±12.8 
Sex, F:M ratio 60:60 
Body mass index, kg/m2 27.9±5.8 
Body surface area, m2 1.8±0.2 
Systolic blood pressure, mmHg 121.9±11.0 
Diastolic blood pressure, mmHg 76.3±9.3 
Heart rate, bpm 77.2±12.6 
End-diastolic diameter, mm 42.7±4.9 
End-systolic diameter, mm 27.1±4.6 
Interventricular septum end-diastolic diameter, mm 9.3±1.8 
LV posterior wall diameter, mm 9.0±1.6 
End-diastolic volume index, mL/m2 49.5±13.6 
End-systolic volume index, mL/m2 18.5±5.9 
Ejection fraction, % 62.5±8.1 
Relative wall thickness, ratio 0.42 ± 0.1 
LV mass index, g/m2 66.1±18.0 
E wave, cm/s 78.5±17.6 
A wave, cm/s 58.9±15.5 
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Deceleration time, ms 140.5±53.4 
E/A, ratio 1.4±0.4 
E´ medial, cm/s 9.3±2.8 
E´ lateral, cm/s 14.1±3.5 
E/E` med, ratio 9.1±2.7 
E/ E´lat, ratio 5.8±1.5 
Average E/E´, ratio 7.4±0.83 
S´ med, cm/s 7.4±1.5 
S´ lat, cm/s 8.7±2.6 
*Data reported as mean ± standard deviation, unless otherwise 
stated. F:M - female to male. LV - left ventricular. 
 
3.4.3 Determinants of maximum LAVi 
On univariate analysis, the main clinical determinants of maximum LAVi were 
sex (p=0.03), BMI (p=0.009), systolic blood pressure (p=0.03), and heart rate 
(p=0.0002).  On multivariate regression analysis the main predictors of maximum 
LAVi were male sex, heart rate, and systolic blood pressure after adjustment for age 
(Table 3.3). 
 
3.4.4 LA strain indices 
The mean peak positive LA strain and peak negative LA strain for all subjects 
were 39.0±8.4% and -2.7±2.5%, respectively (Table 3.2).  No gender differences in 
ƐR were noted (p=0.81). 
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3.4.4 Factors determining LA reservoir strain 
On univariate analysis clinical parameters such as age (p<0.001), BSA 
(p=0.002), BMI (p=0.02), weight (p=0.003), and systolic blood pressure (p=0.04) 
were determinants of ƐR.  However, sex was not associated with ƐR. On multivariate 
linear regression analysis, age, weight, and BSA were independently associated with 
ƐR after adjustment for sex and systolic blood pressure (Table 3.4). 
 
3.4.5 Reproducibility of LA volumetric and strain parameters 
The intra-observer coefficient of variation for maximum LA volume was 3% with 
a mean difference of 0.23±0.61 (p=0.10).  The inter-observer variability for maximum 
LA volume was 0.9% with a mean difference of 2.7±2.6 (p=0.0001).  The intra-
observer coefficient of variation for ƐR was 4.8% with a mean difference (of 3.2±0.67 
(p=0.3) and for ƐCT was 4.6% with a mean difference of 1.43±0.31 (p=0.3).  The 
inter-observer variability coefficient was 9% for both ƐR (p=0.6) and ƐCT (p=0.6) with a 
mean difference of 3.2±0.35 and 1.2±0.13, respectively.  
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Table 3.2 Left atrial volumetric and strain parameters.* 
Variable Total (n=120) 
LA volumes  
Max-LAVi, mL/m2 19.7±5.9 
Min-LAVi, mL/m2 7.7±3.2 
Pre-A LAVi, mL/m2                             12.2±4.4 
LA reservoir function  
LA total EV, mL/m2 12.2±4.8 
LAEF total, % 59.9±13.5 
LA exp index, %† 152.7 (109.5-228.8) 
LA conduit function  
LA PEVi, mL/m2†      6.8 (4.7-9.0) 
Conduit vol, mL/m2† 17.8 (12.1-24.5) 
LA PEF, %† 36.8 (28-47) 
LA pump function  
LA AEVi, mL/m2 4.6±2.6 
LAEF Booster, % 37.7±13.9 
LA strain  
ƐR, % 39.0±8.3 
ƐCT, % -2.7±2.5 
*Data reported as mean ± standard deviation or †median with interquartile ranges. 
LA - Left atrial; LA AEVi - Left atrial active emptying volume index; LAEF - Left atrial 
emptying fraction; LA exp index - Left atrial expansion index; Max-LAVi - Maximum 
left atrial volume index; Min- LAVi, - Minimum left atrial volume index; PEF - Passive 
emptying fraction; PEV - Passive emptying volume; Pre - A LAVi - Pre-atrial 
contraction left atrial volume index; ƐR - Peak left atrial strain in the reservoir phase; 
ƐCT - Peak left atrial strain in the contractile phase. 
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Table 3.3 Multivariate linear regression analysis for maximum LAVi 
Variables β coefficient ± 
SE 
p value 
Model 1 r=0.42 (p<0.0001) 
Age, years 0.01±0.03 0.6 
Male sex -2.7±0.8 0.003 
Heart rate, bpm -0.11±0.01 0.001 
Systolic blood pressure,  
mmHg 
0.05±0.02 0.03 
Model 2 r=0.32 (p<0.025) 
Age, years 
Male sex 
Weight, kg 
0.006±0.04 
-0.82±1.36 
0.03±0.03 
0.87 
0.54 
0.29 
Height, m -12.4±7.8 0.11 
Systolic blood pressure,  
mmHg 
0.07±0.03 0.02 
LAVI - left atrial volume index; SE - standard error. 
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Table 3.4 Multivariate Linear Regression Analysis for Left Atrial strain in the 
Reservoir Phase (ƐR). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
SE - standard error. 
 
 
 
 
 
 
 
 
 
 
Variables                                            β coefficient ± SE p value 
Model 1 r=0.47 (p<0.0001) 
Age, years -0.18±0.05 0.001 
Male sex -0.9±1.4 0.50 
Systolic blood pressure,  
mmHg 
-0.04±0.04 0.28 
Body surface area, m2 -9.6±2.5 0.01 
Model 2 r=0.42 (p<0.0001) 
Age, years -0.19±0.05 0.001 
Male sex 0.14±1.41 0.91 
Systolic blood pressure,  
mmHg 
-0.05±0.04 0.23                          
Weight, kg -0.09±0.04 0.04                         
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3.5 Discussion 
 
3.5.1 Main findings 
This study provides normative data for LA volumetric parameters and LA strain 
in a black African population.  Females had a higher LAVi compared to males. No 
difference in peak LA strain was noted between the sexes. Additionally, BSA, weight, 
and age were important determinants of LA strain. 
An increased LAVi is an important marker of chronic pressure overload and is a 
key measure utilised in clinical practice for the assessment of LV diastolic 
dysfunction (Nagueh et al. 2009).  The recent EchoNoRMAL study indicated that 
measurements of LA volume may vary considerably among normal individuals in 
different ethnic populations, implying that certain populations may have lower 
reference limits for LAVi (Aune et al.2015).  In this study, we found that LAVi 
(19.5±5.9 mL/m2) in a sub-Saharan African population is within normal defined 
ranges, albeit on the lower range of defined normality (Figure 3.2) (Lang et al. 2015, 
Kou et al. 2014, Pritchett et al. 2003 Thomas et al. 2002, Tsang et al. 2002, Wang et 
al.1984).  This is consistent with the findings that ethnicity does influence LAVi 
measurements, but the mechanism by which this occurs is not understood.  Further, 
when adjusted for 2 standard deviations, the upper limit of this range is 31.3 mL/m2, 
which is lower than the value of 34 mL/m2 utilised in the ASE chamber guidelines 
(Lang et al. 2015).  This implies that consideration of these lower limits should occur 
when assessing black African patients whose parameters fall within this range of 
supposed normality.  Future studies are required to determine whether this lower 
level will translate into clinical significance in various disease states. 
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Figure 3.2 Range graph depicting maximum left atrial volume in different 
studies. The y-axis reflects maximum left atrial volumes in mL/m2 (mean± 
standard deviation).  
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In our study, females had a higher maximum LAVi compared to males.  This 
differs from previous studies in which no difference in maximum LA volume indexed 
to BSA between sexes was noted (Nikitin et al. 2003, Pritchett et al. 2003, Wang et 
al. 1984).  In this study, females had a higher BMI but a lower BSA compared to 
males.  For a similar weight, females tended to be shorter and this may explain the 
higher BMI.  A higher maximum LAVi in females in this study may be explained by a 
greater BMI (Caputo et al. 2013, Aurigemma et al. 2009, Leung et al. 2008). 
Additionally, height may influence LA volumes.  Patel et al. showed that prevalence 
of LA enlargement may be underestimated or overestimated when LA volume is 
indexed to BSA depending on the individual’s obesity status (Patel et al. 2009). 
Further, in their study it was noted that LA volume indexed to height was not 
influenced by the level of obesity (Patel et al. 2009).  Thus, these anthropometric 
measurements may need to be taken into account individually instead of simply 
indexing to BSA or BMI.  Our results contrast with older studies of patients with 
cardiovascular disease in which LA size was influenced mainly by BSA and BMI 
rather than height (Aurigemma et al. 2009).  Aurigemma et al. found weight to be 
more strongly related to LA size than height (Aurigemma et al. 2009).  Due to 
discrepant findings, the significance of age, sex, and anthropometric parameters as 
determinants of maximum LAVi remains inconclusive. 
There is a lack of data on measurement of strain with Philips QLAB 9 software. 
Only regional strain data are available from a study done on similar software from 
the same vendor (Philips QLAB 8.1 software) (Xia et al. 2013).  The use of global 
parameters of LA strain is likely to be more feasible and perhaps more reproducible 
than regional LA strain analysis in terms of quantitative data and, thus, this study is 
important to provide some normative values using this vendor’s software.  The 
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average values of peak LA strain in the reservoir phase obtained in various studies 
using GE EchoPAC software are similar to our study (Morris et al. 2015, Sun et al. 
2013, Saraiva et al. 2010, Cameli et al. 2009, Kim et al. 2009).  However, no direct 
comparison can be assumed due to current vendor differences in the generation of 
parameters using speckle tracking.  Hence, our study provides reference data for 
comparison with pathology when using Philips QLAB 9 Software and may offer a 
useful reference when studying serial evaluation of LA strain in disease states.  Our 
finding of a trend of peak LA strain decreasing with age is similar to findings in 
studies using other vendors (Sun et al. 2013, Saraiva et al. 2010, Kim et al. 2009). 
The decline in LA strain had a moderate correlation with aging and implies that, to 
utilise this parameter to study disease, one must consider the normal age-related 
decline in peak LA strain. 
The impact of biologic variables such as gender, BSA, and BMI on LA peak 
systolic strain in normal populations has not been extensively studied. In this study 
as BMI, BSA, and weight increased, LA longitudinal strain decreased.  BMI has been 
found to have an inverse correlation with LA strain, and we found a similar 
correlation in my study (Caputo et al. 2013, Saraiva et al. 2010).  It may be 
associated with the pro-inflammatory milieu in overweight subjects causing alteration 
in LV, and subsequently LA, longitudinal strain (Caputo et al. 2013).  Sex has been 
shown to be a factor in determining normal echocardiographic parameters such as 
right ventricular strain (Chia et al. 2014).  However, we found no association 
between sex and peak LA systolic strain in this population.  Finally, it must be 
highlighted that potential differences in peak global LA reservoir strain may be 
anticipated among different ethnic groups since variations in LA volumes do occur. 
However, this has not been systematically studied, and comparisons between 
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normative data from existing studies is hampered primarily by variations in speckle-
tracking software by vendor; and possibly even in different versions of the same 
software. 
Minimal data pertaining to peak negative LA strain in the contractile phase 
exist.  This parameter is a surrogate of LA contraction and would offer important 
insight into the role of LA contractile function in many disease states in which, a 
compensatory mechanism for increasing abnormal early relaxation of the LV, 
necessitates increasing atrial booster function to preserve adequate late LV diastolic 
filling.  Declining LA booster function may be a contributing factor to clinical 
decompensation in disease states in addition to LV decompensation and perhaps 
even independently of LV abnormality.  Thus, determining normal values and 
variation with sex and anthropometric measurements on current available vendor 
software is important to permit further research utilising this parameter in disease 
states.  Currently, there are discrepant data available from a few studies, and this is 
likely due to different vendors, populations, and techniques being used to measure 
peak negative strain (Sun et al. 2013, Saravia et al.2010, Kim et al. 2009).  The true 
clinical application of this parameter requires further research. 
 
3.5.2 Study limitations  
The study had several limitations: 
1) The minority of subjects were older than 60 years of age.  
2) LA strain measurement lacks a criterion standard - strain values vary with different 
software packages. 
3) The quantitative values defined for LA strain are vendor-specific.  
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4) The exercise capacity of the study subjects was not assessed to unmask 
subclinical diastolic dysfunction and symptoms. 
 
3.6 Conclusion 
 
LAVi measured in a black African population has a reference range that is 
comparable with guidelines but, importantly, the upper limits of the normal range are 
lower than guideline definitions.  The interpretation of normality requires 
consideration of sex and anthropometric differences.  Measurement of LA strain is 
feasible and reproducible in this population, and we have provided reference values 
for this population using QLAB software. 
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Chapter 4 
 
 
Effects of age on left atrial volume and strain parameters  
using echocardiography in a normal black African population 
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4.1 Abstract 
 
4.1.1 Background  
Recent reports have projected an increase in the aging population worldwide. 
In South Africa where the majority of the population is black, the average life 
expectancy is on the rise from 52 years in 2005 to 61 years in 2014.  Data pertaining 
to the aging population from the low and middle income countries is scarce.  Normal 
aging amongst other physiological alterations is known to affect cardiovascular 
structure and function.  There are studies in white populations that have evaluated 
the effects of aging on left atrial (LA) function.  No age-related studies pertaining to 
the LA exist in a black African population.  
 
4.1.2 Objectives   
To determine the effects of aging on LA function in a black population. 
 
4.1.3 Methods 
This was a prospective cross-sectional study and comprised 120 individuals 
aged between 18-70 years.  The subjects were classified into four age groups: 18-
29, 30-39, 40-49, and 50-70 years.  LA volumes were measured by biplane 
Simpson’s method, and Philips QLAB 9 (Amsterdam, The Netherlands) speckle-
tracking software was used to measure strain parameters (LA peak strain in the 
reservoir and contractile phase). 
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4.1.4 Results 
The mean age was 38.7 ± 12.8 years (50% men).  There was no statistically 
significant difference in maximum and minimum LA volumes between the four age 
groups (P>.05).  LA pump function increased with age (r = .2, P = .02), and the 
conduit function decreased with age (r = -0.3, P < .001).  There was a significant 
decrease in the ƐR (P < .0001) with advancing age. Older age was associated with a 
decrease in diastolic function (r = .4, P < .001).  On multivariate linear regression 
analysis the main predictors of maximum LA volume indexed (LAVi) were male sex, 
heart rate, E/E´ lateral, and LV mass indexed after adjustment for age. Age was not 
a significant determinant of ƐR when S´ lateral and E´ medial were added to the 
model after adjusting for sex and systolic blood pressure. 
 
4.1.5 Conclusions  
LA maximum and minimum volumes do not change with age.  However, the 
conduit function decreases with age and the booster function shows a compensatory 
increase with age as the diastolic function declines with age.  ƐR may be a more 
sensitive marker for assessing LA function than maximum LAVi. 
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4.2 Introduction 
The average life expectancy of South Africans, 80% of whom are blacks, is 
increasing (Statistics South Africa 2014).  Since 2005, life expectancy increased by 
8.5 years due to a decline in AIDS related deaths, decreased infant mortality and an 
improvement in the general health of the populous.  Concurrently, the proportion of 
older black people is increasing. Normal aging results in changes in cardiac structure 
and physiology (Lakatta and Levy 2003, Gerstenblith et al.1977).  For these reasons, 
age-related reference values in older black individuals are imperative for 
cardiovascular risk stratification (Lakatta and Levy 2003, Gerstenblith et al.1977).  
The LA has been described as a gauge of diastolic burden, and disturbances in 
its function can result in impairment of overall cardiac performance (D’Andrea et al. 
2013, Nikitin et al. 2003).  Age-related changes in the LA have been studied 
extensively in white populations using traditional parameters such as LA size, 
volumes, and, more recently, 2D strain (Boyd et al. 2011, Aurigemma et al. 2009, 
Thomas et al. 2002, Spencer et al. 2001).  In the Echo-Normal study, the upper 
reference values for LA diameter were highest for Europeans and American Blacks 
and lowest for South Asians and Africans (Aune et al. 2015).  The change in the 
upper reference values of LA diameter with increasing age was statistically 
significant for European, African, and African American men.  
Importantly, no age-related reference values for LA volumes or strain exist in 
black Africans.  Additionally, aging populations in the developing world differ from 
those in developed nations, with respect to limited access to health care, limited 
social support systems, poverty, rapid urbanisation and adoption of more sedentary 
lifestyles (Chatterjee et al. 2014).  The interplay of these factors coupled with 
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differences in the ethnicity may cause the two populations to age differently. We 
suspect that there may be differences in LA structure and function between blacks 
and Caucasians with normal aging.  Thus, we sought to determine the effects of 
aging on LA function in a black population with the aid of both traditional and newer 
echocardiographic techniques of 2D strain.  We further hypothesised that LA 
volumetric and strain parameters would demonstrate changes with age in a black 
population.  
 
4.3 Methods 
 
4.3.1 Study population 
From January 2014 to June 2015, 190 normal subjects were screened at our 
echocardiographic laboratory at Chris Hani Baragwanath Academic Hospital.  This 
cross-sectional sub-study formed part of ongoing research being conducted at our 
institution to provide normal echocardiographic reference ranges in people of African 
descent. 
The study population was recruited from unrelated staff at Baragwanath Hospital and 
volunteers who presented themselves to the echocardiographic laboratory following 
an advertisement about this study.  The volunteers were excluded if the image 
quality was poor or had abnormal 12 - lead electrocardiograms (presence of 
arrhythmias, chamber enlargement, conduction system abnormalities and evidence 
of prior infarcts) or screening echocardiogram was abnormal (mitral valve prolapse, 
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greater than trivial valvular regurgitation, left ventricular hypertrophy and wall motion 
abnormalities). The subjects were included if they:  
1) were asymptomatic,  
2) lacked comorbidities (diabetes, cardiovascular disease), 
3) were not on chronic medication,  
4) were in sinus rhythm.  
The final sample comprised 120 individuals (60 women) aged 18 to 70 years. 
The subjects were classified into four age groups: 18-29, 30-39, 40-49, and 50-70 
years.  A tolerance of 5 years was allowed for age matching in each subgroup.  All 
the participants gave written informed consent and the study was approved by the 
local Ethics committee (M140114).  A detailed history, clinical examination, 
electrocardiography and comprehensive echocardiographic exam of the participants 
were performed.  
 
4.3.2 Echocardiographic examination 
Transthoracic echocardiography was performed by an experienced 
sonographer on a Philips iE33 system (Amsterdam, The Netherlands) using S5-1 
transducer. All the echocardiographic measurements were obtained using a 
standardised protocol, from the standard left parasternal and apical views.  An off-
line workstation (Xcelera- Philips) was used for data transfer and subsequent 
analysis.  
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4.3.3 Two-dimensional and Doppler quantification 
Previously described in chapter 3. 
 
4.3.4 2-D Strain imaging 
Previously described in chapter 3.  The LA stiffness index was calculated non-
invasively as the ratio of E/Eˈ lateral and ƐR (Boyd et al. 2011, Kurt et al. 2009).
 
 
4.3.5 Statistical analysis 
Statistical analysis was performed with Statistica, version 12.5, series 0414 for 
Windows.  Continuous variables are expressed as means ± standard deviations 
(SDs) or medians (interquartile ranges).  Continuous variables according to age 
categories were compared using one-way ANOVA analysis of variance or Kruskal-
Wallis test when the distribution was non-normal.  Post-hoc comparisons were 
performed with the Scheffé test.    
Univariate and multivariate linear regression analyses were used to identify 
possible independent determinants of LA ƐR, and maximum LAVi. Multivariate 
models to predict LA ƐR and maximum LAVi were selected in a multiple linear 
regression analysis.  Univariate variables with Pearson’s correlation coefficient ≥0.8 
were not included in the multivariate models.  Additionally, only clinically and 
statistically significant variables (P <0.05) were selected for inclusion in multivariate 
linear regression analysis.  The aforementioned models were further analysed using 
the forward and backward multiple linear regression methods.  The assumptions 
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were verified by performing residual analysis and advanced Durbin-Watson 
statistics. 
The intra-observer and inter-observer variabilities were assessed for peak 
positive LA ԐR, peak negative LA ƐCT, maximum LAVi, and minimum LAVi. 
Measurements were done in 20 randomly selected subjects.  To assess inter-
observer variability two independent observers measured the LA volumetric and 
strain parameters, whilst intra-observer variability was calculated from the analysis 
by the same observer after one month of the first measurement.  Inter-observer and 
intra-observer reproducibility was assessed by calculating coefficients of variation 
(CV).  The CV was calculated as the standard deviation of the differences divided by 
the mean.  The T- test for dependent variables was used to compare the mean and 
SD of the values derived for strain and volumes.  A p value<0.05 was considered 
statistically significant. 
 
4.4 Results 
 
4.4.1 Baseline characteristics and echocardiographic findings  
Of the 120 individuals, 60 were men and the mean age of the group was 
38.7±12.8 years.  Comparisons between the four preselected age groups (Table 4.1) 
revealed that while all parameters remained within normal defined ranges, there 
were age related differences.  An increment in LV wall thickness (p< 0.001), the A 
wave (p<0.001) and E/Eˈ (p< 0.001) was noted with aging while a concomitant 
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decrement in LV volumes (p=0.001) and E wave (p<0.001) was observed.  No 
significant changes in LV ejection fraction (p=0.7) and LV mass occurred (p=0.4). 
 
4.4.2 LA volumetric parameters for the total sample  
The normative data are presented in Table 4.2.  No significant differences were 
noted between the four age categories in the maximum and minimum LAVi with 
aging (P = 0.1, P = 0.2).  Furthermore, even though there was a trend of increasing   
LAmax with older age it did not reach statistical significance (P = 0.08) (Figure 4.1).  
No differences were noted in the maximum and minimum LAVi with aging (p=0.1, 
p=0.2)).  Further, no correlation was observed between maximum LA volume and 
age (p=0.08) (Figure 4.1).  Analysis of the parameters relating to the various phases 
of LA function revealed there was no change in reservoir function parameters with 
age (p>0.05).  The conduit function parameters decreased with age while 
parameters indicative of booster function displayed either a significant increase with 
age (LA active emptying volume index, p=0.001) or a trend suggestive of increasing 
function as measured by LA active emptying fraction (Table 4.2, Figure 4.2).  
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Table 4.1 Baseline clinical and echocardiographic characteristics according to 
age.* 
Variable Total  
(18-70) 
n=120 
Group 1  
(18-29) 
n=34 
Group 2  
(30-39) 
n=30 
Group 3  
(40-49) 
n=27 
Group 4  
(50-70) 
n=29 
p value 
(ANOVA) 
Age (y) 38.7±12.8 23.5±3.1 34.5±2.8 43.2±2.7 56.4±6.42 0<.0001 
Sex (F:M) 60:60 16:8 13:17 15:12 16:13 0.73 
BMI (kg/m2) 27.9±5.8 25.9±5.8a,c 26.2±4.1b 31.1 ±5.9 29.2 ± 5.6 0.0003 
BSA (m2) 1.8±0.2 1.8±0.2a 1.8±0.2 1.9±0.2 1.8±0.2 0.040 
SBP (mmHg) 122±11.0 119.7±10.5 118.9±11.1 126.1±9.9 123.8±11.3 0.04 
DBP (mmHg) 76±9.3 72.3±9a 76.4±8.7 81.1±7.3 76.5±10.2 0.003 
HR  77.2±12.6 78±14 79±13 77±11 75±13 0.468 
LV EDD (mm) 42.7±4.9 44±4.3 43.2±5.2 43±5 41±5.3 0.207 
LV ESD (mm) 27.1±4.6 27.3±5.4 28±4 27±4.4 26±5 0.20 
IV EDD (mm) 9.3±1.8 9.0±2.0a,c 9.0±2.0 10±1.4 10±2.3 0.005 
LV PWD(mm) 9.0±1.6 8.0±2.0c 9.0±1.3 9.3±1.3 10.0±2.0 0.0017 
EDV index 
(mL/m2) 
49.5±13.6 53.0±13.0c 54.0±15.0d 50.0±12.3 41.0±11.4 0.0010 
ESV index 
(mL/m2) 
18.5±5.9 20.0±5.0c 20.0±6.0d 19.0±6.3e 15.0±5.0 0.0007 
LV EF (%) 62.5±8.1 63.1±6.0 63±6.2 61.0±13.0 63.0±7.1 0.731 
RWT (ratio) 0.42±0.10 0.37±0.06a,c 0.41±0.07 0.44±0.08 0.5±0.12 0.0002 
LV mass 
index (g/m2) 
66.1±18.0 62.2±18.1 67.8±19.3 65.9±17.0 69.0±18.0 0.474 
E wave (cm/s) 78.5±17.6 88.0±17.0c 76±14.0 82.3±19.0e 68.0±15.0 0.0001 
A wave (cm/s) 58.9 ± 15.5 53 ± 16.4c 54.2±11.4d 63 ± 15.2 67.0±15.0 0.0003 
DT (m/s) 140.5±53.4 145.0±73.0 129.0±41.0 134.2±45.0 153.4±44.3 0.278 
E/A (ratio) 1.4±0.4 1.6±0.5a,c 1.4±0.3d 1.4±0.3e 1.0±0.3 0<.0001 
Eˈ medial 
(cm/s) 
9.3±2.8 12.0±2.0a,c 10.3±3.0f,d 8.1±2.1 7.0±2.0 0<.0001 
Eˈ lateral 
(cm/s) 
14.1±3.5 17.1±3.0a,c 15.0±3.0d 13.0±3.0 11.1±3.0 0<.0001 
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E/Eˈ medial 
(ratio) 
9.1±2.7 8.0±2.0a,c 8.0±2.2f,d 11.0±3.0 10.3±3.0 0<.0001 
E/Eˈlateral 
(ratio) 
5.8±1.5 5.3±2.0a 5.4±1.3f 7.0±2.0 6.2±1.3 0.0010 
Average 
E/E´(ratio) 
7.4±1.83 6.5±1.4ac 6.6±1.4f,d 8.5±1.8 8.2±1.7 0<.0001 
Sˈmedial 
(cm/s) 
7.4±1.5 8.0±1.2 8.1±2.0d 7.3±1.4 7.0 ±1.3 0.005 
Sˈlateral 
(cm/s) 
8.7±2.6 9.0±3.0 9.2±3.0 9.0±3.0 8.0±2.0 0.20 
*Data reported as mean ± standard deviation or †median (IQR). 
aGroup 1 vs. Group 3 p<0.05, bGroup 2 vs. Group 3 p<0.05, cGroup 1 vs. Group 4 p<0.05, 
dGroup 2 vs. Group 4 p<0.05, eGroup 3 vs. Group 4 p<0.05, fGroup 2 vs. Group 3 p<0.05. BMI 
- Body mass index. BSA - Body surface area. DBP - Diastolic blood pressure. DT - 
Deceleration time. EDD - End-diastolic diameter. EDV - End-diastolic volume. EF - Ejection 
fraction. ESD - End-systolic diameter. ESV - End-systolic volume. F:M - female:male ratio. HR 
- Heart rate (beats per minute). IV - Interventricular septum. LV - Left ventricular. PWD - 
posterior wall diameter. RWT - Relative wall thickness. SBP - Systolic blood pressure. 
 
 
Figure 4.1 Correlation between left atrial volume and age (r= 0.14, p=0.08). 
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Table 4.2 Left atrial volumetric and strain parameters with age.* 
Variable Total 
(120) 
Group 1 
(18-29) 
n=34 
Group 2 
(30-39) 
n=30 
Group 3 
(40-49) 
n=27 
Group 4 
(50-70) 
n=29 
p value 
(ANOVA) 
LA volumes 
Max-LAVi 
(mL/m2) 
 
19.7±5.9 
 
18.4±5.5 
 
19.1±4.7 
 
22.0±7.0 
 
20.2±6.2 
 
0.10 
Min-LAVi 
(mL/m2) 
7.7±3.2 7.3±3.2 7.1±2.6 7.8±3.2 8.5±3.6 0.27 
Pre-A LAVi 
(mL/m2)                             
12.2 ±4.4 10.9±4.5c 11.1±3.6d 12.4±4.4 14.6±4.3 0.003 
 
LA reservoir function 
LA total EV 
(mL/m2) 
12.2 ± 4.8 11.1±4.2 12.1±4.3 14.2±5.8 11.6±4.6 0.08 
LAEF total 
(%) 
59.9±13.5 57.3±13.3 61.9±12.
4 
63.2±14.
1 
57.9±13.
8 
0.25 
LA exp index 
(%)† 
152.7 
(109.5-
228.8) 
139 
(111.5-
218.1) 
178.7 
(115.4-
234) 
172.3 
(231-
114.9) 
129.7 
(92.4-
242) 
 
0.16 
LA conduit function  
LA PEVi 
(mL/m2)†      
6.8 (4.7-9.0) 6.9 (4.7-
9.0) 
7.4 (6.0-
10.2)d 
8.6 (5.2-
11)e 
4.2(3.1-
6.1) 
0.0008 
Conduit vol 
(mL/m2)† 
17.8 (12.1-
24.5) 
19.9 (15.7-
28.1) 
20.9 
(13.9-
26.6) 
14.6 
(11.1-
23.2) 
15.4 
(10.5-
18.9) 
0.01 
LA PEF (%)† 36.8 (28-47) 38.7 (31.6-
51)c 
39.1 
(31.4-
51)d 
40.2 
(33.6-
56)e 
26 (17.3-
35) 
0.0001 
LA pump function 
LA AEVi 
(mL/m2) 
4.6±2.6 3.7±2.4c 4.0±2.3d 4.6±2.7 6.1±2.6 0.001 
LAEF 
Booster (%) 
37.7±13.9 32.6±10.6 37.8± 
12.5 
39.7± 
15.4 
41.4± 
15.8 
0.07 
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LA strain       
ƐR (%) 39.0±8.3 40.7±7.9
c 42.8±8.5d 39.4±7.7e 33.2±5.5 <0.0001 
ƐCT (%) -2.7±2.5 -3.2±3.0 -2.9±2.5 -2.6±2.2 -1.9±2.1 0.27 
Left atrial stiffness index 
E/Eˈ lateral 
/ƐR 
0.2±0.05 0.1± 
0.03a,c 
0.1±0.04b
,d 
0.2±0.06 0.2±0.05          
<0.001 
*Data reported as mean ± standard deviation or †median (IQR). 
aGroup 1 vs. Group 3 p<0.05, bGroup 2 vs. Group 3 p<0.05, cGroup 1 vs. Group 4 
p<0.05, dGroup 2 vs. Group 4 p< 0.05, eGroup 3 vs.  group 4 p<0.05, fGroup 2 vs. 
Group 3 p< 0.05. LA AEVi - Left atrial active emptying volume index; LAEF - Left 
atrial emptying fraction; LA exp index - Left atrial expansion index; Max-LAVi - 
Maximum left atrial volume index; Min- LAVi - Minimum left atrial volume index; PEF 
- Passive emptying fraction; PEV - Passive emptying volume; Pre-A LAVi - Pre- atrial 
contraction left atrial volume index; ƐR - Peak left atrial strain in the reservoir phase; 
ƐCT -Peak left atrial strain in the contractile phase. 
 
 
Figure 4.2 Correlation between left atrial emptying fraction and age (r=0.2, 
p=0.02).  
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4.4.3 Determinants of maximum LAVi 
On univariate analysis the main determinants of maximum LAVi were sex 
(p=0.03), body mass index (p=0.009), systolic blood pressure (p=0.03), heart rate 
(p=0.0002), end-diastolic volume index (p=0.001), end-systolic volume index 
(p=0.002), E wave (p=0.01), A wave (p=0.02), E/Eˈ medial (p=0.008), Sˈ lateral 
(p=0.004), E/Eˈ lateral (p<0.001), average E/Eˈ (p<0.001), minimum LAVi (p<0.001), 
LA emptying fraction total (p=0.03), pre-A LAVi (p<0.001), and LV mass indexed 
(LVMi) (p=0.015).  Age was not a determinant of maximum LAVi (p=0.2). 
On multivariate linear regression analysis, the main predictors of maximum 
LAVi were male sex, heart rate, E/Eˈ lateral, and LVMi after adjustment for age 
(Table 4.3).  
 
Table 4.3 Multivariate linear regression analysis for maximum left atrial volume 
indexed 
Variables β coefficient± 
standard error 
Partial 
coefficient 
R2 p value 
Model 1  r=0.54, p< 0.0001 
Age (y) -0.04±0.04 -0.09 0.11 0.32 
Men -3.2±1.16 -0.25 0.15 0.006 
Heart rate (beats/min) -0.13±0.04 -0.27 0.09 0.003 
E/Eˈ lateral (ratio) 1.5±0.39 0.35 0.14 0.0001 
LVMi (g/m2) 0.08±0.03 0.26 0.08 0.004 
LVMi - left ventricular mass index 
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4.4.4 LA strain indices  
Normative data are presented in Table 4.2.  There was a significant decrease in 
the LA ƐR (p<0.0001) with increased age (Figures 4.3 and 4.4).  No significant 
difference was noted in the LA ƐCT between the age groups (p=0.27).  The LA 
stiffness index increased with age (p<0.001) (Table 4.2). 
 
 
Figure 4.3 Correlation between left atrial peak global longitudinal strain (%) 
and age (r=-0.36, p<0.001). 
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Figure 4.4 Two-chamber view depicting peak left atrial systolic strain in a 21 
year-old male (A) compared to a 51-year-old male (B). 
 
4.4.5 Factors determining LA strain  
On univariate analysis factors such as age (p<0.001), body surface area 
(p=0.002), systolic blood pressure (p=0.04), LV mass (p=0.01), E wave (p< 0.001), 
E/A ratio  (p=0.04), Eˈ medial (p<0.001), Eˈ lateral (p<0.001), E/Eˈ medial (p=0.002), 
Sˈ medial (p<0.001), Sˈ lateral (p<0.001), average E/Eˈ (p=0.006), LA emptying 
fraction total (p<0.001), pre-A LAVi (p=0.005), minimum LAVi (p<0.001), LA 
expansion index (p<0.001), passive emptying volume (p=0.003), and passive 
emptying fraction (p<0.001) were determinants of LA ƐR . On multivariate linear 
regression analysis, age, E/Eˈ medial, Eˈ medial, and reservoir phase indices (LA 
expansion index and LA emptying fraction total) were independently associated with 
LA ƐR after adjustment for sex and systolic blood pressure (Table 4.4).  Age was no 
longer a significant determinant when Sˈ lateral and Eˈ medial were added to the 
model after adjusting for sex and systolic blood pressure (Table 4.4).  
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Table 4.4 Multivariate linear regression analysis for left atrial strain in the 
reservoir phase (ƐR) 
Variables β coefficient ± 
standard error 
Partial 
coefficient 
R2 p value 
Model 1 r=0.57, p< 0.0001 
Age (y) -0.16±0.05 -0.28 0.19 0.003 
Men -0.6±1.34 -0.05 0.08 0.64 
Systolic blood 
pressure (mmHg) 
-0.02±0.04 -0.04 0.14 0.61 
Left atrial emptying 
fraction total (%) 
0.23±0.04 0.4 0.03 <0.0001 
E/Eˈ medial (ratio) -0.72±0.27 -0.2 0.25 0.01 
Model 2 r=0.57,  p<0.0001 
Age (y) -0.16±0.05 -0.27 0.19 0.003 
Men -0.83±1.33 -0.06 0.08 0.53 
Systolic blood 
pressure (mmHg) 
-0.04±0.04 -0.10 0.12 0.26 
Left atrial expansion 
index (%) 
0.02±0.004 0.46 0.03 <0.0001 
E/Eˈ medial (ratio) -0.72±0.27 -0.24 0.25 0.009 
Model 3   r=0.5, p<0.0001 
Age (y) -0.09±0.07 -0.12 0.45 0.16 
Systolic blood 
pressure (mmHg) 
-0.01±0.04 
0.02 
- 0.14 0.071 
Men -0.79±1.37 
0.06 
- 0.05 0.56 
Sˈ lateral (cm/s) 0.94±0.28 
 
0.30 0.13 0.001 
Eˈ medial (cm/s)                                0.70±0.33 0.2 0.49 0.03 
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4.4.6 Reproducibility of LA volumetric and strain parameters 
The intra-observer coefficient of variation for maximum LA volume was 3% with 
a mean difference of 0.23±0.61 (p=0.10). The inter-observer variability for maximum 
LA volume was 0.9% with a mean difference of 2.7±2.6 (p=0.0001). The intra-
observer coefficient of variation for LA ƐR was 4.8% with a mean difference of 
3.2±0.67 (p=0.3) and for LA ƐCT was 4.6% with mean difference of 1.43±0.31 
(p=0.3). The inter-observer variability coefficient was 9% for both LA ƐR (p=0.6) and 
ƐCT (p=0.6) with a mean difference of 3.2±0.35 and 1.2±0.13, respectively. 
 
4.5 Discussion 
 
This study provides normative age-related data for LA volumetric parameters 
and LA strain in a black African population.  Normal aging is associated with key 
physiological changes such as rising systolic blood pressure and declining LV 
diastolic function with abnormal relaxation and increased LA stiffness.  Volumetric 
analysis of LA function reveals that global measures of LA function remain normal 
but conduit function declines with increasing booster function with advancing age. 
Further, normal aging is associated with an absolute decline in global LA reservoir 
strain. 
A key factor that may influence LA volumetric measurements is aging. 
Maximum LAVi did not change with aging in our study.  Additionally, age was not an 
independent predictor of maximum LAVi in our study.  There are discrepant findings 
from a number of studies relating to the effect of aging on LA volume (Aune et al. 
2015, Lang et al. 2015, D’Andrea et al. 2013, Aurigemma et al. 2009, Okamatsu et 
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al. 2009, Pritchett et al. 2003, Spencer et al. 2001).  This may be attributed to 
varying sample sizes, racial differences, and different methods and vendors used for 
assessing maximum LA volumes.  However, the impact of aging on LA volumetric 
measurements that are surrogates of conduit and booster function appears to be 
more consistent.  Our findings suggest that with aging, a decrement in conduit 
volumes occurs while an increase in booster function volumes occurs 
simultaneously, which is consistent with other studies (Nikitin et al. 2003, Spencer et 
al. 2001).  This may be explained by an age-associated decrease in early relaxation, 
thus resulting in relative decrease in the conduit function and greater reliance on 
booster function for LV filling (Nikitin et al. 2003, Spencer et al. 2001).  The evidence 
for a decline in early relaxation was based on the declining Eˈ on tissue Doppler 
imaging and E wave on pulsed-wave Doppler in this study.  Further, the increase in 
age-related filling pressures can be attributed to the greater relative increase in the E 
velocity compared to Eˈ velocity with aging. However, the aforementioned 
parameters still fall within the normal reference ranges defined in guidelines (Nagueh 
et al. 2009).   
The major factors determining LA ƐR are the initial and final length of the 
longitudinal fibres.  Initial length is determined by atrial contraction and LA minimum 
volume (Barbier et al.1999).  The final length is determined by atrial relaxation, the 
atrial longitudinal compliance in response to the volume of blood entering the atrium 
from the pulmonary veins during ventricular systole, and the descent of the mitral 
annulus during systole (Sˈ) (Todaro et al. 2012, Boyd et al. 2011, Barbier et al. 
1999).  The latter may be affected by factors governing LV systolic function and end-
systolic volume (Barbier et al. 1999). 
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The age-related decline in LA ƐR in our study conforms to earlier studies by 
Sun et al. and Saraiva et al. (Sun et al. 2013, Saraiva et al. 2010).  In this study, 
factors that may determine initial length, namely LA minimum volume and LA ƐCT — 
a surrogate of LA contraction, do not differ among age groups.  The effect of aging 
on factors determining final length, are more intriguing.  There are no validated 
echocardiographic parameters that can be used as a surrogate of atrial relaxation 
(Kurt et al. 2009).  In this study, LA stiffness increased significantly with aging.  The 
Sˈ decreased with age despite a lack of age dependent change in maximum LA 
volume.  This may infer that with aging in normal individuals, the decrement we 
observed in peak reservoir strain most likely occurs due to abnormalities determining 
final length rather than initial length.  The Sˈ at both annuli decreases with age while 
atrial stiffness increases in this study.  While age may be a predictor of LA ƐR it 
appears that Sˈ and indices of diastolic function such as Eˈ are more consistent 
predictors.  The link between decreasing efficient early relaxation and LA strain is 
difficult to elucidate in normal individuals with normal LA pressures.  The decreased 
LA compliance due to increased pressures would hamper atrial longitudinal function 
resulting in decreased atrial strain with age.  One postulate may be that the same 
process predisposing to diminishing abnormal early relaxation, may also affect the 
LA reservoir function, for example, fibrosis of the sub-endocardium and atria with 
aging or sub-endocardial ischaemia (Boyd et al. 2011).  The latter may be associated 
with decreased longitudinal shortening of the LV during systole, thus causing 
decreased mitral annular motion and, consequently, diminished atrial longitudinal 
strain during the reservoir phase.  
A final observation from our data is a lack of correlation between volumetric 
indices, and LA strain with aging.  As outlined earlier, with aging there is greater 
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reliance on booster function for LV filling.  However, the LA ƐCT does not increase 
concomitantly.  Similarly, LA volume maximum and LA volume minimum do not 
change with aging implying that volumetric filling during the reservoir phase is 
maintained despite peak reservoir strain decreasing with age.  The above must imply 
that strain decreases absolutely or relatively to LA volume and is a more sensitive 
marker of atrial dysfunction with aging (Boyd et al. 2011).  The effect of radial 
compliance or contraction on LA volume was not studied and may represent a 
compensatory means of maintaining the observed changes in LA volume with age 
despite the relative or absolute decrement in atrial longitudinal strain. 
 
4.5.1 Study Limitations 
This study had several limitations:  
1) A minority of subjects were over age 60;  
2) LA strain measurement lacks a criterion standard — strain values vary with 
different software packages;  
3) Exercise capacity of the study subjects was not assessed to unmask subclinical 
diastolic dysfunction and symptoms. 
 
4.6 Conclusion 
 
LA contractility increases with age as the conduit function decreases. These 
changes reflect the compensatory mechanisms associated with the age-related 
normal decline in LV diastolic function.  There is no change in maximum and 
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minimum LAVi with healthy aging.  There is an age-related decline in LA ƐR before 
maximum LAVi.  This suggests that LA ƐR may be a more sensitive marker for 
assessing LA function.  The aforementioned age-related normative data may serve 
as a guide for future studies in black African populations.  
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Chapter 5 
 
 
Atrioventricular function assessment in chronic rheumatic  
mitral regurgitation: looking beyond the left ventricle. 
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5.1 Abstract 
 
5.1.2 Background 
Chronic MR has historically been shown to affect the LV function primarily.  The 
impact on morbidity and mortality of increased LA volume in MR has recently been 
highlighted and yet LA does not feature prominently in the current guidelines 
compared to the LV.  Additionally, LA dysfunction may exist in the absence of LV 
dysfunction and absence of symptoms; and thus have implications in terms of earlier 
surgical referral of this patient subgroup.  Further, the two chambers function as a 
unit and thus must be studied as such because the functional abnormality of one 
impacts the other, especially in diseased states such as MR.  Thus, we aimed to 
study the atrio-ventricular mechanics in CRMR with particular emphasis on the LA, 
as it may primarily be afflicted by the rheumatic process. 
 
5.1.3 Methods 
This cross-sectional study comprised 77 patients with isolated moderate or 
severe CRMR, and 40 controls.  All underwent echocardiographic exam on a Philips 
iE33 system.  The standard LA and LV measurements were performed in 
accordance with the current ASE guidelines.  LA function was assessed in the 
reservoir, conduit and contractile phase with conventional echocardiography and 2D 
strain imaging (QLAB 9 speckle tracking software). 
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5.1.4 Results 
The mean age was 44±13.6 with 83% female subject.  LA static volumes were 
higher in CRMR compared to controls (p<0.05).  LA stiffness index was greater in 
CRMR than controls (0.95±1.89 vs 0.16±0.13, p=0.009).  LA dysfunction was noted 
predominantly in the reservoir and contractile phases compared to controls (p<0.05). 
Conduit function parameters except left atrial passive emptying fraction (LA PEF) 
were still preserved when compared to controls (p<0.05).  LA ƐR, LA ƐCT and LV 
peak systolic strain (PSS) were decreased in CRMR compared to controls (p<0.05). 
Eighty-six percent of the patients had decreased LA ƐR, 58% had depressed LV 
PSS. Decreased ƐR and normal LV PSS was noted in 42%.  Thirteen percent had 
normal ƐR and LV PSS. Only one patient had normal ƐR with decreased LV PSS.  On 
multivariate linear regression analysis, the main determinants of LA ƐR were age, LV 
PSS and LAVi (p<0.001). 
 
5.1.5 Conclusion 
In CRMR there is predominant LA dysfunction in the reservoir and contractile 
phases. LA dysfunction likely precedes LV dysfunction.  Therefore, abnormalities in 
LA function may serve as an early indication for surgery.  Finally, age irrespective of 
CRMR may be an important contributor to decline in LA and LV function.  
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5.2 Introduction 
 
Chronic mitral regurgitation (MR) results in volume overload of the left ventricle 
(LV) and the left atrium (LA) (Aksakal et al. 2012).  The LA compensates by 
increasing compliance through neuro-hormonal modulation and undergoing 
structural changes such as cellular hypertrophy and interstitial fibrosis to meet the 
needs of the new haemodynamic load (Aksakal et al. 2012, Enriquez-Sarano et al. 
2005).  The LV also undergoes similar adaptation to the increased preload (Gaasch 
et al. 2008).  After a period of compensation, LA and LV dysfunction supervenes, 
culminating in atrial fibrillation, HF and death if left untreated (Borg et al. 2009).  Until 
now the LV and the LA in MR have been studied in isolation, despite the fact that 
their interaction is crucial for optimal cardiovascular haemodynamics in both health 
and disease states (Nishimura et al.1997).  Both the LA and the LV undergo phases 
of compensation before reaching the lower limb of the Frank-Starling curve and 
irreversible remodelling (Mehrzad et al. 2014, Bonow et al. 2012, Gaasch and Meyer 
2008).  We suspected that the temporal sequence may differ in an individual patient, 
where in some LA may transition from a phase of compensation to decompensation 
prior to LV and the reverse may occur in others, depending on a variable 
combination of preload, afterload and intrinsic characteristics of the two chambers. 
Therefore, the alteration in some patients’ LA functional indices may serve as an 
early sign heralding the onset of a decompensated state.  This may occur even in 
the presence of normal LV functional indices and absence of symptoms (Enriquez-
Sarano et al. 2005).  Further, in RHD, we suspect that the LA haemodynamics will 
differ, compared to the LA in MR due to other aetiologies, secondary to  involvement 
of the of the LA by the rheumatic process (Edwards and Chisholm 2006, Shriki et al. 
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2011, Roberts and Vermani 1978, Plaschkes et al. 1971).  Additionally, the impact of 
preoperative dual chamber dysfunction may confer greater postoperative morbidity 
and mortality than isolated LV or LA dysfunction.  Thus, limiting surgical indications 
to predominantly LV parameters may miss the opportunity to intervene early.  Thus, 
we sought to study the LA and LV function in moderate or severe chronic rheumatic 
mitral regurgitation (CRMR) with the aid of traditional volumetric parameters and 
newer echocardiographic techniques of 2D strain.  Further, it was hypothesized that 
in CRMR, LA dysfunction may precede LV dysfunction. 
 
5.3 Methods  
 
This study was part of a prospective cross-sectional study at the Chris Hani 
Baragwanath Academic Hospital (CHBAH).  Patients were enrolled from January 
2014 and October 2014.  All patients were screened and patients deemed to have 
moderate or severe CRMR, were referred for possible inclusion in the study.  Ninety-
one patients with presumed chronic, rheumatic MR underwent clinical evaluation, 
resting electrocardiogram and detailed echocardiographic assessment according to 
a pre-determined protocol.  
The inclusion criteria were patients aged 18 years or older with 
echocardiographic features of moderate or severe chronic rheumatic MR.  Patients 
were excluded if:  
1) they had significant aortic valve disease; 
2) concurrent MS with a valve area of less than 2.0 cm2;  
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3) documented ischaemic heart disease;  
4) preexisting non-valvular cardiomyopathy;  
5) prior cardiac surgery;  
6) congenital or pericardial disease; 
7) pregnancy; 
8) severe systemic disorders such as renal failure;  
9) uncontrolled hypertension (systolic blood pressure>140mmHg and diastolic blood 
pressure>90mmHg) on medication;   
9) severe anaemia (haemoglobin <10g/dL). 
Fourteen patients were excluded due to the following: AF, anemia, renal 
dysfunction, mild MR, MR of non-rheumatic etiology and inadequate image quality.  
The final sample included 77 patients.  Forty age and gender-matched controls were 
also included in the study.  A tolerance of 5 years was allowed for age matching. 
The study was approved by the University of the Witwatersrand Ethics 
Committee (M140114). 
 
5.3.1 Echocardiographic evaluation 
Transthoracic echocardiography was performed on all patients in the left lateral 
position by experienced sonographers using a S5-1 transducer on a Philips iE33 
system (Amsterdam, The Netherlands).  The images were obtained according to a 
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standardised protocol.  The data was transferred and analysed off-line using the 
Xcelera workstation (Philips). 
 
5.3.2 Two dimensional and Doppler quantification 
All linear chamber measurements were performed according to the ASE 
chamber guidelines (Lang et al. 2005). Maximum LA volume (LAmax) was obtained at 
left ventricular end-systole, from the 2D frame, just before MV opening (Kowallick et 
al.2014, Vianna-Pinton et al. 2009).  Pre-atrial volume (Vpre-A) was obtained from the 
diastolic frame, just before MV reopening as the result of atrial contraction (Vianna-
Pinton et al. 2009). LA minimum volume (LAmin) was assessed at left ventricular end-
diastole, from the smallest volume seen after LA contraction (Kowallick et al. 2014, 
Vianna-Pinton et al. 2009). 
Left atrial (LA) phasic function assessment was done by using the following 
formulae:  
1) Reservoir function: LA emptying fraction (LAEF) total = (LAmax - LAmin)/LAmax) × 
100%; Expansion index = (LAmax - LAmin)/ LAmin) × 100%;  
2) Conduit function: Passive emptying volume (PEV) = (LAmax - Vpre-A); Passive LA 
emptying fraction (LAPEF) = LAmax - Vpre-A/LAmax x100%; and conduit volume = LV 
stroke volume - (LAmax - LAmin)   
3) Booster pump function: LA active emptying fraction (LAAEF) = (LApre-A – LAmin)/ 
LApre-A) × 100%; LA active emptying volume (LA active EV) = (Vpre-A - LAmin) (Vianna-
Pinton et al. 2009, Kowallick et al. 2014).  
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All the LA volumetric parameters were indexed to body surface area (BSA) 
(Vianna-Pinton et al. 2009). 
Left ventricular (LV) end-diastolic- volume (EDV), end-systolic-volume (ESV) 
and ejection fraction (EF) were assessed using the Simpsons method and indexed to 
BSA (Lang et al. 2015).  Measurements relating to LV diastolic function were 
performed in accordance with the ASE guidelines on diastolic function and included 
pulse wave Doppler at the mitral tips and tissue Doppler of both medial and lateral 
mitral annuli (Nagueh et al. 2009).  Measurements relating to the RV were based on 
the ASE guidelines on the RV (Rudski et al. 2010). 
MR was considered rheumatic in aetiology when the morphology of the valve 
satisfied the World Heart Federation (WHF) criteria for the diagnosis of chronic 
rheumatic heart disease (RHD) (Reményi et al. 2012), MR severity was assessed 
using qualitative, semi-quantitative and quantitative methods as per the ASE and 
ESC valvular regurgitation guidelines (Lancelloti et al. 2013, Zoghbi et al. 2003).  In 
equivocal cases the echocardiographic data was integrated with the clinical 
evaluation by an experienced cardiologist to distinguish moderate from severe MR. 
 
5.3.3 Speckle tracking echocardiography 
5.3.3.1 Left atrial strain 
Apical four and two-chamber (4C and 2C) views were obtained using two 
dimensional grey-scale echocardiography for speckle tracking analysis (Vieira et al. 
2014, Vianna- Pinton et al. 2009).  This was performed during end-expiratory breath- 
hold and stable ECG recording (Kowallick et al. 2014, Vieira et al. 2014, Vianna-
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Pinton et al. 2009).  An adequate grey-scale image that allowed separation of 
myocardial tissue and surrounding structures was obtained (Vianna-Pinton et al. 
2009).  Three consecutive cardiac cycles were recorded and averaged (Vianna-
Pinton et al. 2009).  The frame rate was set between 60 and 80 frames per second 
(Vianna-Pinton et al. 2009).  Philips QLAB version 9.0 software allowed off-line semi-
automated analysis of speckle-based strain.  The endocardial surface of the LA was 
traced manually in both 4C and 2C views by a three point and click approach 
(Vianna-Pinton et al. 2009).  The system then automatically generated an epicardial 
surface tracing (Vianna-Pinton et al. 2009).  The region of interest (ROI) was thus 
created and manually adjusted as needed, to allow for adequate speckle tracking. 
The software divides the ROI into seven segments in the 2C and 4C views.  It 
then generates the longitudinal Ɛ curves for each segment and a mean curve of all 
segments (Vianna-Pinton et al. 2009).  The onset of the QRS was used as a 
reference point for calculation of LA strain. 
 
5.3.3.2 Left ventricular strain 
Two dimensional echocardiography images were obtained at end-expiration 
from LV apical long-axis, 4C, 3C and 2C views with frame rates of 60 and 80 frames 
per second (Younan 2015).  Three consecutive cardiac cycles were recorded and 
averaged (Marciniak et al. 2007).  LV endocardial surface was traced manually in the 
three views by a point and click approach (Younan 2015, Kocabay et al. 2014).  The 
speckle tracking points were modified to allow for adequate speckle tracking of the 
LV wall (Younan 2015, Kocabay et al. 2014).  The LV was divided into 17 segments. 
Peak LV longitudinal systolic strain was calculated for apical long-axis 4C, 3C and 
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2C views, and global LV systolic strain was calculated by averaging the three apical 
views (Younan 2015, Kocabay et al 2014).  The onset of the QRS was used as a 
reference point for calculation of LV strain. 
The LA stiffness index was calculated non-invasively as the ratio of E/E´ lateral 
and ƐR (Boyd et al. 2011, Kurt et al. 2009). 
 
5.3.4 Statistical analysis 
Statistical analysis was performed with Statistica, version 12.5, series 0414 for 
Windows.  Continuous variables are expressed as means ± SDs or medians (IQRs). 
Student’s t test or Mann-Whitney U test were used to compare continuous variables. 
Categorical variables were evaluated by the chi-square and Fisher’s exact test when 
necessary.  Univariate and multivariate linear regression analyses were used to 
identify possible independent determinants of peak positive LA ƐR.  Six separate 
models to predict peak positive LA ƐR were selected in a multiple linear regression 
analysis. Univariate variables with Pearson’s correlation coefficient ≥0.8 were not 
included in the multivariate models.  Additionally, only clinically and statistically 
significant variables (P <0.05) were selected for inclusion in multivariate linear 
regression analysis.  The aforementioned models were further analysed using the 
forward and backward multiple linear regression methods.  The assumptions were 
verified by performing residual analysis and advanced Durbin-Watson statistics.  
The intra-observer and inter-observer variabilities were assessed for peak 
positive LA ԐR, peak negative LA ƐCT, and LV global longitudinal strain. 
Measurements were done in 20 randomly selected subjects.  To assess inter-
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observer variability two independent observers measured the LA volumetric and 
strain parameters (LA and LV), whilst intra-observer variability was calculated from 
the analysis by the same observer after one month of the first measurement. Inter-
observer and intra-observer reproducibility was assessed by calculating coefficients 
of variation (CV).  The CV was calculated as the standard deviation of the 
differences divided by the mean.  The T- test for dependent variables was used to 
compare the mean and SD of the values derived for strain and volumes and to 
calculate the significance value.  A p value <0.05 was considered statistically 
significant. 
 
5.4 Results 
 
Baseline characteristics of the study and the control population are shown in 
Table 5.1.  The control and MR groups showed no significant difference with regards 
to age, gender, BMI, blood pressure and heart rate.  Moderate MR was present in 
51(66%) and severe MR was present in 26 (34%).  The LA and LV diameters and 
volumes were increased in the study patients compared to controls (p<0.05). 
Surrogates of LV systolic function were worse in CRMR compared to controls (S´ 
medial: 6.3±1.3 cm/s vs 7.1±1.6 cm/s, p=0.004; ESVi: 40.0±22.2 mL/m2 vs17.8±6.4 
mL/m2, p<0.0001).  Patients with CRMR had higher E/Eˈ ratio compared to controls 
(E/E´ medial ratio: 20.1±10.7 vs 9.4±3.0, p<0.0001) as a result of higher E wave 
velocity (133.8±48.1 vs 77.0±17.6, p<0.0001).  However, there was no difference in 
the ejection fraction between the group with MR and controls (p=0.07).   
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LA phasic volumes and functional analysis are summarised in Table 5.2.  The 
LA maximum, minimum, and pre-atrial contraction volumes were higher in the study 
patients compared to controls (p<0.0001).  However, the indices of reservoir, conduit 
and contractile function were all depressed in the study patients compared to 
controls (p<0.001).  Left atrial stiffness index was greater in MR patients compared 
to controls (0.95±1.89 vs 0.16±0.13, p=0.009).  
Maximum-LAVi, minimum LAVi and pre-A LAVi showed no statistical difference 
between moderate MR and severe MR, despite a trend toward larger volumes in 
severe MR. There was no difference in the reservoir function parameters between 
the moderate and severe MR groups (p>0.05). Amongst the conduit phase 
parameters LA PEV was lower in moderate MR (12.0±9.8ml/m2vs20.4±17.2ml/m2, 
p<0.001) and is consistent with the greater E wave velocity (114.7±40.4cm/s 
vs170.5±39.9cm/s, p<0.001) in severe MR compared to moderate MR. The active 
emptying fraction (booster function) was greater in moderate MR compared to 
severe MR (27.6±13.1%vs17.6±10.7%, p<0.001).  The LA stiffness index was less in 
moderate MR compared to severe MR (0.6±1.83vs1.65±1.8, p=0.01). 
As expected the LV dimensions were less in moderate MR compared to severe 
MR (LVEDD 52.6±8.4 vs 59.1±9.9, p<0.001; 39.1±9.4 vs 45.9±8.2, p<0.001). The 
volumes were greater in severe MR compared to moderate MR (EDVi-
113.3±29.1ml/m2 vs 82.8±25.1ml/m2, p<0.001; ESVi- 48.1±24.5ml/m2 vs 
35.7±20ml/m2, p<0.001) but there was no difference in the ejection fraction 
(58.3±17.0%vs 58.5±10.3%, p=0.19). There was no difference in systolic function 
(lateral Sˈvelocity - 7.3±2.1cm/s vs7.3±3.2cm/s, p=0.2) between the moderate and 
severe MR groups. Analysis of diastolic function parameters revealed that there was 
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no difference in E’ but the E wave was higher and consequently E/E’ higher in 
severe MR (13.8±7.4 vs18.4±10.6, p<0.001). 
LA peak systolic and contractile strain were decreased in both moderate and 
severe MR compared to controls (LA peak systolic strain 21.3±9.5 vs 19.5±11.1 vs 
39.0±7.3; p<0.001 and Contractile strain -0.48±1.79 vs -0.67±1.46 vs -2.28±2.05; 
p<0.001) but no difference was noted between moderate and severe MR groups 
(P>0.05). LV peak global strain was preserved in moderate and severe MR when 
compared to controls (-15.3±5.0 % versus -16.5±5.5% versus -17.9±2.1%, p=0.06). 
Thus, there was no difference in LA and LV strain in between moderate and severe 
MR groups (p>0.05). 
LA and LV strain parameters are indicated in Table 5.2 and Figure 5.1. LA peak 
systolic reservoir strain (ƐR), peak contractile strain (ƐCT) and LV peak global systolic 
strain (LV PSS) were decreased in the MR group compared to the controls (p=0.04) 
(Table 5.2). Eighty-six percent of MR patients had decreased LA ƐR (Figure 5.1). 
Fifty-eight percent had depressed LV PSS. Thirteen percent had normal ƐR and LV 
PSS (category 1). One patient had normal LA ƐR, with decreased LV PSS (category 
2). Decreased LA ƐR and LV PSS was present in 44% (category 3). Decreased LA 
ƐR and normal LV PSS was noted in 42% (category 4).  
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Table 5.1 Baseline clinical and echocardiographic characteristics of study 
patients.* 
Variable Study patients 
(n=77) 
Controls 
(n=40) 
p value 
Clinical 
Age (years) 44±13.6 42±13.4 0.4 
Gender (M:F) 13:64 8:32 0.6 
BSA (m2) 1.7±0.2 1.8±0.2 0.01 
BMI (kg/m2) 27.1±5.9 28.4±6.2 0.3 
SBP (mmHg) 124.2±11.4 124±12.5 0.93 
DBP (mmHg) 77±9.1 75.7±12.6 0.52 
Heart rate (beats/min) 77.1±12.6 76.3±14.1 0.75 
NYHA (I/II / III) ( %) 42%/ 49%/9% -  
Hypertension (%) 40 -  
HIV (%) 13 -  
Hypertension and HIV (%) 15 -  
Echocardiographic 
LV EDD (mm) 54.8±9.4 42.5±4.8 <0.0001 
LV ESD (mm) 41.4±9.4 27.1±4.2 <0.0001 
IVSD (mm) 8.6±2.1 9.5±1.9 0.02 
LV PWD (mm) 8.5±1.5 9.2±1.9 0.03 
EDVi (mL/m2) † 93.2±30.1 47.9±13.5 <0.0001 
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ESVi (mL/m2) † 40.0±22.2 17.8±6.4 <0.0001 
LAVi (mL/m2) † 64.1±39.9 21.9±4.9 <0.0001 
LVEF (%) 58.5±12.9 62.8±11.2 0.07 
LVMi (kg/m2) † 102.7±36.3 65.6±20.3 <0.0001 
E wave (cm/s) 133.8±48.1 77.0±17.6 <0.0001 
A wave (cm/s) 98.4±33.5 59.6±13.0 <0.0001 
Deceleration time (ms) 214.5±62.2 135.4±42.3 <0.0001 
E/A ratio 1.5±0.6 1.3±0.4 0.06 
E´medial (cm/s) 7.3±2.3 8.8±2.8 0.002 
E´ lateral (cm/s) 10.1±4.0 13.4±3.6 <0.0001 
E/E´ medial (cm/s) 20.1±10.7 9.4±3.0 <0.0001 
E/E´ lateral (cm/s) 15.4±8.8 5.9±1.6 <0.0001 
S´ medial (cm/s) 6.3±1.3 7.1±1.6 0.004 
S´ lateral (cm/s) 7.3±2.5 8.2±2.6 0.07 
PASP (mmHg) 35.1±16.9 21.5±6.4 <0.0001 
* Data are presented as mean± SD or %. † Values are indexed to BSA. BSA - Body 
surface area; BMI - Body mass index; DBP - Diastolic blood pressure; EDVi,- End-
diastolic volume indexed; ESVi - End-systolic volume indexed; HIV - Human 
Immuno-deficiency Virus; IVSD - Interventricular septal diameter; LAVi - Left atrium 
volume indexed;  LV - Left ventricle; LV EDD - Left ventricular end-diastolic diameter; 
LVEF - Left ventricular ejection fraction; LVESD - Left ventricular end-systolic 
diameter; LVMi - Left ventricular mass indexed; NYHA  - New York Heart 
Association; PASP - Pulmonary artery systolic pressure; PWD - Posterior wall 
diameter; SBP - Systolic blood pressure. 
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Table 5.2 Left atrial and ventricular peak systolic strain and left atrial 
volumetric and phasic functional parameters in chronic rheumatic mitral 
regurgitation.* 
Variable CRMR  
(n=77) 
Control  
(n=40) 
p value 
Volumes    
Maximum LAVi (mL/m2) † 64.1±39.9 21.9±4.9 <0.0001 
Minimum LAVi (mL/m2) † 39.6±35.5 8.1±3.1 <0.0001 
Pre A-LAVi (mL/m2) † 49.4±39.0 13.6±4.6 <0.0001 
Reservoir function    
LA total emptying volume indexed 
(mL/m2) † 
24.6±13.7 15.6±12 <0.001 
LAEF total (%) 45.4±16.5 61.2±12.0 <0.0001 
LA exp index (%) 98.6±62.6 194.4±131.8 <0.0001 
Conduit function    
LAPEVi (mL/m2) † 14.9±13.4 8.2±4.4 0.003 
LAPEF (%) 26.7±19.4 38.3±14.9 0.001 
Conduit volume (mL/m2) † 28.8±21.6 16.7±9.8 <0.001 
Booster function    
LA AEF (%) 24.1±13.1 38.6±13.4 <0.0001 
LA AEVi (mL/m2) † 9.7±6.3 4.9±2.8 <0.0001 
Strain parameters    
 ƐR (%) 20.7±10.0 39.0±7.3 <0.0001 
 ƐCT (%) -0.5±1.6 -2.28±2.05 <0.0001 
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LV global peak systolic strain (%) -16.1±5.3 -17.9±2.1 0.04 
Left atrial stiffness index 0.95±1.89 0.16±0.13 0.009 
* Data are presented as mean± SD. † Values are indexed to BSA. LA AEVi - left 
atrial active emptying volume index; LAEF - left atrial emptying fraction; LA exp index 
- left atrial expansion index; Max-LAVi - maximum left atrial volume index; Min- LAVi 
- minimum left atrial volume index; PEF - passive emptying fraction; LA PEVi - Left 
atrial passive emptying volume index; Pre-A LAVi, - pre- atrial contraction left atrial 
volume index; ƐR - peak left atrial strain in the reservoir phase; ƐCT - peak left atrial 
strain in the contractile phase. 
 
  
 
Figure 5.1 Depicting decreased LA peak systolic strain (top right) and 
preserved LV peak systolic strain (top left) in a patient with severe rheumatic 
mitral regurgitation (bottom). 
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5.4.1 Predictors of LA peak systolic strain 
On univariate analysis age, gender, LVESD, LVEF, ESVi, Sˈvelocity at medial 
and lateral mitral annuli, LV PSS, maximum LAVi and hypertension emerged as 
predictors of peak LA systolic strain in CRMR (Table 5.3).  
On multivariate linear regression analysis, the main determinants of LA peak systolic 
strain were age, LV PSS and maximum LAVi (Table 5.4). 
 
5.4.2 Reproducibility of LA peak systolic strain, LA peak negative strain and LV 
peak systolic strain 
The intra-observer coefficient of variation for LA ƐR was 4.8% with a mean 
difference of 3.2±0.67 (p=0.3) and for LA ƐCT was 4.6% with mean difference of 
1.43±0.31 (p=0.3).  The inter-observer variability coefficient was 9% for both LA ƐR 
(p=0.6) and ƐCT (p=0.6) with a mean difference of 3.2±0.35 and 1.2±0.13, 
respectively. 
The intra-observer coefficient of variation for LV PSS was 2.4% with mean 
difference of 1.1±2.7 (p=0.09).  The inter-observer variability coefficient for LV PSS 
was 9.8% with a mean difference of 0.25±2.4 (p=0.6) respectively. 
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Table 5.3 Univariate analysis for determinants of peak systolic LA strain in 
chronic rheumatic mitral regurgitation. 
Variable β±SE R p value 
Age(years) -0.38±0.07 0.52 <0.001 
Gender(M) 6.9±2.9 0.25 0.02 
LVESD(mm) -0.41±0.11 0.39 0.0003 
LV ESVi (mL/m2) -0.14±0.04 0.32 0.003 
LV PSS (%) -0.89±0.19 0.47 <0.001 
LVEF(%) 0.21±0.08 0.27 0.014 
Lateral Sˈ(cm/s) 1.49±0.43 0.37 0.0009 
Medial Sˈ(cm/s) 3.57±0.76 0.47 <0.001 
LAVi (cm/s) -0.12±0.02 0.48 <0.001 
LA stiffness index -1.2±0.60 0.23 0.04 
LAVi - Left atrial volume indexed; LVEF - Left ventriclular ejection fraction; LVESD - 
Left ventricle end-systolic diameter; LVESVi-Left ventricular end-systolic volume 
index; LV PSS - Left ventricular peak systolic strain. 
 
Table 5.4 Multivariate analysis for determinants of peak systolic LA strain in 
chronic rheumatic mitral regurgitation. 
Model 1  R=0.82 p<0.001   
Variable β±SE p value 
Age(years) -0.31±0.05 <0.001 
Gender(M) 2.8±1.96 0.15 
Medial Sˈ(cm/s) 1.30±0.63 0.04 
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LAVi(mL/m2) -0.11±0.01 <0.001 
LV PSS (%) -0.48±0.15 0.001 
Model 2 R=0.81 p<0.001   
Variable β±SE p value 
Age(years) -0.33±0.05 <0.001 
Gender(M) 3.85±1.9 0.05 
LV PSS(%) -0.57±0.15 <0.001 
LV ESVi (mL/m2) -0.03±0.03 0.37 
LAVi (mL/m2) -0.10±0.01 <0.001 
Model 3 R=0.81 p<0.001   
Variable β±SE p value 
Age (years) -0.33±0.05 <0.001 
Gender(M) 3.7±1.9 0.06 
LV PSS (%) -0.60±0.16 0.0003 
LVEF(%) 0.02±0.06 0.67 
LAVi (mL/m2) -0.11±0.01 <0.001 
Model 4 R=0.69 p<0.001   
Variable β±SE p value 
Age(years) -0.30±0.06 <0.001 
Gender(M) 3.7±2.3 0.11 
LV PSS(%) -0.47±0.21 0.03 
LVEF(%) 0.03±0.08 0.62 
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Medial Sˈ(cm/s) 1.47±0.78 0.06 
Model 5 R=0.81 p<0.001   
Variable β±SE p value 
Age (years) -0.33±0.05 <0.001 
Gender(M) 3.79±1.97 0.05 
LVESD (mm) -0.01±0.10 0.85 
LV PSS (%) -0.62±0.17 <0.001 
LAVi (mL/m2) -0.10±0.001 <0.001 
Model 6 R=0.81 p<0.001   
Variable β±SE p value 
Age(years) -0.33±0.05 <0.001 
Gender(M) 3.8±1.9 0.05 
LAVi (mL/m2) -0.10±0.01 <0.001 
LV PSS (%) -0.59±0.13 <0.001 
LA stiffness index -0.33±0.38 0.39 
LA - Left atrium; LAVi - Left atrial volume indexed; LVEF -  Left ventriclular ejection 
fraction; LVESD - Left ventricle end-systolic diameter; LVESVi -  Left ventricular end-
systolic volume index; LV PSS - Left ventricular peak systolic strain. 
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5.5 Discussion 
 
The main findings of this study are:  
1) Absolute volumes of the LA increase during the three phases compared to normal 
whereas the relative percentage change in volume is diminished in all phases.  
2) Both reservoir and booster LA strain was decreased in the study group compared 
to normal individuals.  
3) LA reservoir strain was abnormal in the majority of patients (86 %) while 
concomitant diminished LV strain was found in only half of these patients (44%).  
4) Age, maximum LAVi and LV PSS were the most important determinants of peak 
left atrial reservoir strain. 
The LA has three main functions namely: reservoir, conduit and contractile 
function (Todaro et al. 2012).  During the reservoir phase the LA receives blood from 
pulmonary veins during LV systole; in the conduit phase there is passive emptying of 
blood into the LV during early diastole; and in the contractile phase the LA actively 
ejects blood into the LV in late diastole (Todaro et al. 2012).  MR is characterised by 
systolic volume overload of the LA (Moustafa et al. 2011, Borg et al. 2009).  In this 
study volumetric measures of global LA function were increased namely LA 
maximum, minimum and pre-atrial contraction volume.  The increased LA maximum 
volume would be expected secondary to systolic volume overload as a result of MR 
which occurs in addition to the normal venous return from the pulmonary veins.  An 
increased pre-A LA and minimum LA volumes similar to prior studies was also noted 
in the present study (Ren et al. 2014, Aksakal et al. 2012, Moustafa et al. 2011, Borg 
et al. 2009).  However, there appears to be discrepancies in the literature with regard 
to whether the three phasic LA volumes are increased (Ren et al. 2014, Aksakal et 
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al. 2012, Moustafa et al. 2011, Borg et al. 2009).  Borg et al. and Ren et al. found an 
increment in the percentage change of reservoir LA volumes with preserved booster 
function based on volumetric indices (Ren et al. 2014, Yurdakul et al. 2014, Borg et 
al. 2009).  In contrast, both in our study and in those of Aksakal et al. and Moustafa 
et al.,  a relative decrement in reservoir and booster function was observed (Aksakal 
et al. 2012, Moustafa et al. 2011).  Of the three phases, the conduit function, was 
preserved or increased in all the studies (Ren et al. 2014, Yurdakul S et al. 2014, 
Aksakal et al. 2012, Moustafa et al. 2011, Borg et al. 2009).  The possible reasons 
for similarities and differences in the phasic LA functional parameters in these 
studies may be attributed to a variable combination of duration and severity of MR, 
LV compliance, LA compliance and the intrinsic characteristics of the LA and the LV 
(Gasparovic et al.2014, Ren et al. 2014, Yurdakul S et al. 2014, Cameli et al. 2013, 
Aksakal et al. 2012, Moustafa et al. 2011, Borg et al. 2009).  
It is likely that findings from the present study may relate to altered LA and LV 
pathophysiology in MR.  In the patient exhibiting compensation with significant MR, 
the LV diastolic function would be expected to be normal or increased to 
accommodate the increased blood volume that would be required to enter the LV. 
This ultimately causes an increase in LVEDV, the essential step in the path to LV 
diastolic overload.  Thus, atrial volumetric markers of conduit and booster function 
would be normal or even potentially relatively increased.  Conversely, in the 
decompensated state, impaired LV systolic function will result in significant diastolic 
dysfunction and a high LV end-diastolic pressure which would then impair LV 
diastolic filling and result in higher LA volumes during these phases.  The increased 
pre-A LA and minimum LA volumes observed in this study, implies that atrial filling of 
the LV during diastole is impaired.  This implies that pan-diastolic LV diastolic 
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dysfunction can occur in patients with normal LVEF and in the absence of overt 
clinical LV HF.  Thus, the atrial volumetric markers in diastole may serve as 
surrogates for impaired LV diastolic dysfunction of the LV in compensated MR 
patients.  Prior studies and the recent ASE guideline on LV diastolic dysfunction, 
accentuate the difficulties of utilising conventional mitral inflow Doppler and annular 
tissue Doppler parameters in MR (Zaid et al. 2013).  Identifying this 
pathophysiological phase may be important as it implies that despite the eccentric 
remodelling of the LV in MR, the diastolic compliance of the LV may become 
affected, resulting in suboptimal early filling as reflected by the impairment during the 
conduit phase.  However, with an impairment in LV diastolic early relaxation, atrial 
booster function would increase resulting in a greater proportion of filling in late 
diastole as is observed in patients with LV diastolic dysfunction due to other causes 
e.g. hypertension.  This expected increment in booster function does not occur and 
this must imply the coexistence of intrinsic LA contractile dysfunction. Fibrosis of the 
LA maybe a key abnormality contributing to this dysfunction which may be attributed 
to three potential factors: aging, chronic volume overload and the rheumatic process 
itself (Gasparovic et al. 2014, Cameli et al. 2013, Asakal et al. 2012, Casaclang-
Verzosa et al. 2008, Edwards et al.2006, Shriki et al. 2011, Roberts and Vermani 
1978, Thiedemann and Ferrans 1977, Plaschkes et al. 1971).  
We noted a decrease in LA ƐR and ƐCT in the majority of the patients. Similarly, 
some studies report that strain during the reservoir phase increases with preserved 
booster strain in MR compared to a normal heart (Borg et al. 2009).  These 
differences relate to all the reasons we proposed above for my volumetric findings.  
In this study, the decrease in ƐR can be explained by:  
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1) An increase in initial length maybe expected in this cohort due to increased LA 
minimum volume.  
2) A decrease in the final length maybe due to the decrease in mitral annular systolic 
descent which we observed.  
The latter may reflect LV longitudinal systolic impairment in MR (Zaky et al. 1967, 
Simonson et al. 1989, Pai et al. 1991, Elnoamany and Abdelhameed 2006).   
A second hypothesis is that intrinsic LA compliance is impaired as evidenced 
by the increased LA stiffness index.  Therefore despite an increase in the LA 
maximum and LA minimum volumes and thus the reservoir volume, the peak ƐR 
does not increase as expected, due to a limitation in the ability of the atrial wall to 
stretch in response to volume overload as in the study by Borg et al. (Yurdakul et al. 
2014, Borg et al. 2009).  This implies that the same pathophysiological process 
impairing relaxation of the atria (for example fibrosis) may be responsible for intrinsic 
abnormal atrial contractile function as supported by histopathology and MRI studies 
(Cameli et al.2013, Gasparovic et al. 2014). 
In chronic moderate or severe MR, the two main patterns noted were 
depressed LA reservoir strain with either normal or depressed LV peak systolic 
strain. This implies that LA function may decline in some patients before LV 
longitudinal function.  This must relate to different clinical profiles for the same 
degree of MR e.g. age or intrinsic abnormality of the LA compared to the LV such as 
degree of fibrosis, abnormal energetics and neuro-hormonal factors.  LA contractile 
performance improves after surgery, suggesting a state of decreased atrial function 
prior to surgery, even in patients with apparently normal LV function (Dardas et al. 
2004).  
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Based on the aforementioned data from prior studies and the data from this 
study, I postulate that in chronic MR, five major groups of patients can be identified:  
Group 1 - This group comprises patients with normal LA and LV function (category 
one in this study);  
Group 2 - is characterised by increased early LV filling (preserved conduit and 
reservoir function) while atrial contraction is decreased (decreased Aˈ) with normal 
LV function (similar to the findings of Borg et al. 2009);  
Group 3 - is characterised by decrement in the reservoir, contractile and conduit 
function of the LA; pan-diastolic decrement of ventricular filling, LV diastolic 
dysfunction with normal systolic LV function (category 4 in our study and Askakal et 
al. 2012);  
Group 4 - decreased LA conduit, contractile and reservoir function; pan-diastolic 
filling impairment with impairment of LV longitudinal function with normal EF 
(category 3 in our study, Yurdakul et al. 2014).  This correlates to the transitional LV 
phase of MR and phase where the LA is enlarged with normal or elevated left atrial 
pressure (Gaasch and Meyer 2008, Braunwald and Awe 1963); 
Group 5 – decompensated phase with irreversible abnormalities of the LA and LV 
structure and function in all phases (Braunwald and Awe 1963, Gaasch and Meyer 
2008).  
However, from the discussion above and variable findings in different studies it 
is clear that not all patients with chronic MR can be neatly categorised into these five 
groups and that numerous grey-zones exist between them.  Thus, these five groups 
may serve as a mere guide to help in risk stratification of patients with MR, who may 
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or may not benefit from surgical intervention but the decision still needs to be 
individualised. 
In contrast to what we expected, the functional indices of reservoir and conduit 
function were deranged to a similar extent, in both moderate and severe MR. This 
may be explained by a combination of factors such as direct involvement of the LA 
by rheumatic process, volume overload secondary to MR, and age related fibrosis in 
this cohort of rheumatic MR. Furthermore, it can be speculated that volume overload 
is not the sole cause of LA dysfunction in rheumatic MR, and that the 
aforementioned factors contribute to a variable extent, in LA remodelling and 
impaired function. Additionally, the relatively more compliant LA in moderate MR 
resulted in a greater booster function and thus active emptying fraction in this group. 
The greater passive emptying volume in severe MR despite greater LV filling 
pressures can be explained on the basis of proportionately higher volumes in severe 
MR compared to moderate MR. As expected there was no difference in the LV 
ejection fraction between the two groups as this is “preserved” until late stage in the 
natural history of MR (Bonow et al 2012). LA strain was depressed to a similar 
degree in both groups, implying abnormalities of strain manifesting even in moderate 
rheumatic MR, likely due to intrinsic abnormalities of the LA, rather than simply a 
result of changes induced by volume overload. However, LV strain was preserved in 
both groups, and this further argues for using LA functional and strain parameters as 
a guide for clinical follow up and perhaps referral for surgery, rather than LV 
parameters. 
 
 128 
 
Age, coupled with LV PSS and maximum LAVi were by far the most important 
predictors of peak LA strain in our study.  As the maximum LAVi increased (atrial 
wall stretch), LV PSS decreased.  This was unexpected and can be explained on the 
basis of decreased LA compliance in the study. Aging was associated with 
decreased LA peak systolic strain. The decrease in LA reservoir strain can be 
attributed to a decrease descent of the mitral annulus with age and possibly to 
intrinsic abnormalities of the LA such as altered energetics and increasing fibrosis as 
a result of the aging process (Burstein and Nattel 2008, Casaclang –Verzosa et al. 
2008, Lakatta and Levy 2003).  Thus, identifying abnormal LA strain is important but 
its causes are likely multifactorial. 
 
5.5.1 Study Limitations 
Our study had several limitations:  
1) Diagnostic coronary angiogram and right and left heart catheterisation were not 
performed on all patients unless there was an indication for surgery.  
2) MR severity was not confirmed by another modality such as Cardiac MRI or 3D 
echocardiography.  
3) Patients with mild MR and AF were excluded. 
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5.6 Conclusion 
 
In chronic rheumatic mitral regurgitation there is functional decline of 
predominantly the reservoir and the contractile atrial phases.  Decline in LA function 
likely precedes the decline in LV function as noted from the predominant decrease in 
LA longitudinal strain with or without preserved LV strain in this study.  Advancing 
age may be a contributing factor independent of CRMR to changes in LA and LV 
function. 
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Chapter 6 
 
 
Unmasking right ventricular dysfunction in  
chronic rheumatic mitral regurgitation 
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6.1 Abstract 
 
6.1.1 Background 
In chronic rheumatic mitral regurgitation (CRMR) RV function may be 
influenced by several mechanisms including interaction with LV mechanics; neuro-
hormonal abnormalities; increased afterload associated with secondary pulmonary 
hypertension; and in RHD, possible direct RV myocardial involvement following 
rheumatic carditis.  No studies have documented abnormalities of RV function by 
conventional or newer techniques of speckle tracking echocardiography (STE) in 
CRMR.  
The aims of this study were:  
1) To test the utility of RV peak systolic strain (PSS) as a tool for assessing RV 
function in patients with CRMR; and compare STE with traditional RV systolic 
function indices.  
2) To determine predictors of RV PSS. 
 
6.1.2 Methods 
We prospectively enrolled 77 patients with moderate or severe CRMR and 40 
age and gender matched controls, seen from 2014 and 2015 at the Chris Hani 
Baragwanath Academic Hospital.  All patients underwent transthoracic 
echocardiography using a Philips iE33 system.  The data was transferred and 
analysed off-line using the Xcelera workstation (Philips).  RV PSS and LV PSS were 
measured using Philips QLAB 9 speckle tracking software. 
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6.1.3 Results 
The mean age was 44±13.6years with 83% females.  No difference was noted 
in the tricuspid annular plane systolic excursion and RV S´ in patients with CRMR 
and controls (2.1±0.4 cm vs 2.2±3.2 cm, p=0.78; 13.2±11.8 cm/s vs 11.6±2.0 cm/s, 
p=0.39).  There was no difference in RV systolic function in the group with moderate 
MR compared to the one with severe MR (RV S´11.6 (9.9-14.6) cm/s vs 11.4(9.4-
13.4) cm/s, p=0.29).  The RV PSS was lower in the CRMR group compared to 
controls (-16.8±4.5% vs -19.2±3.4%, p=0.003).  Patients with severe MR had greater 
degree of reduction in RV PSS compared to moderate MR group (-14.3±4.23% vs -
18±4.18%, p<0.0001).  Patients with LV systolic dysfunction had a greater 
decrement in RV PSS and LV PSS compared to those with preserved LV systolic 
function (p=0.001).  PASP was greater in those with systolic dysfunction compared 
to those with preserved LV systolic function (p<0.02).  However, no difference in the 
conventional RV systolic function parameters was noted between those with normal 
LV systolic function and those with poor LV systolic function (p>0.05).  On 
multivariate linear regression analysis after adjusting for covariates, LV PSS was an 
independent predictor of RV PSS (p=0.01). 
 
6.1.4 Conclusion 
In CRMR, RV PSS is a sensitive marker of subclinical RV systolic dysfunction 
and in addition to LV systolic function, may play an important role with regards to 
timing of surgical intervention in this patient group. 
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6.2 Introduction 
 
Systolic function of the RV is a known predictor of mortality after acute 
myocardial infarction or CABG, in HF and primary PHT (De Groote et al. 2012, Lang 
et al. 2010, Damy et al. 2009).  The limited studies in organic degenerative MR have 
failed to conclusively define the prognostic role of the RV in MR (Le Torneau et al. 
2013).  In addition to the LV parameters, RV systolic function provides adjunctive 
information in the decision-making process regarding surgical intervention in MR 
(Hyllen et al. 2014, Le Torneau et al. 2013).  Preoperative RV function is an 
important determinant of intraoperative and postoperative outcomes in MR and thus 
has prognostic implications (Le Torneau et al. 2013, Mafessanti et al. 2012).  
Additionally, RV dysfunction may have important implications in terms of predicting 
greater haemodynamic impairment of the LV and secondary PHT due to MR (Grose 
et al.1983, Polak et al.1983).  Yet the RV remains under-studied, partly due to its 
complex geometry, which presents challenges to its accurate structural and 
functional assessment by conventional echocardiography (Fukuda et al. 2011, 
Rudski et al. 2010).  Recently, newer imaging techniques such as speckle tracking- 
derived RV strain have emerged, which offer several advantages over traditional 
echocardiographic parameters for assessing overt and subclinical RV systolic 
dysfunction (Morris et al. 2016, Hyllen et al. 2014, Kumar et al. 2014, Fine et al. 
2014, Ternacle et al. 2013, Guendouz et al. 2012).  There are no studies that have 
assessed RV function in rheumatic MR.  
  
 134 
 
We thus aimed:  
1) To study the RV systolic function using STE and compare RV PSS with 
conventional echocardiographic parameters. 
2) To determine the predictors of RV peak systolic strain in CRMR. 
 
6.3 Methods 
 
We conducted a prospective cross - sectional study at the Chris Hani 
Baragwanath Academic Hospital (CHBAH). Patients were enrolled from January 
2014 and October 2014.  All patients were screened and patients deemed to have 
moderate or severe chronic rheumatic MR were referred for possible inclusion in the 
study.  A total of 91 patients with presumed chronic, rheumatic MR underwent 
clinical evaluation, resting electrocardiogram and detailed echocardiographic 
assessment according to a pre-determined protocol.  
The inclusion and exclusion criteria were similar to those described in chapter 
5.  The study was approved by the University of the Witwatersrand Ethics Committee 
(M140114). 
 
6.3.1 Echocardiographic evaluation 
As described in chapter 5. 
6.3.2 Two dimensional and Doppler quantification 
As described in chapter 5. 
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6.3.3 Speckle tracking echocardiography 
RV free wall peak systolic strain (PSS) was derived from modified apical 4 
chamber view (A4C) RV focused view (Kumar et al. 2014).  Three consecutive 
cardiac cycles were recorded and averaged (Todaro et al. 2015).  The frame rate 
was set between 60 and 80 frames per second (Todaro et al. 2015).  Once the three 
points (RV apex, medial and lateral tricuspid annulus) were defined, the software 
automatically traced the endocardial and epicardial border (Kumar et al. 2014). 
Philips QLAB version 9.0 software allowed off-line, semi-automated analysis of 
speckle-based strain.  This results in the division of RV into six standard segments in 
the apical 4-chamber view (Mingo-Santos et al. 2015, Kumar et al. 2014, Konishi et 
al. 2013).  The region of interest (ROI) once created, can be manually adjusted as 
needed to allow for adequate speckle tracking (Hyllen et al. 2014).  The free wall RV 
PSS was obtained by averaging 3 lateral segments (the basal RV lateral wall, the 
mid-RV lateral wall, and the apical RV wall) (Todaro et al. 2015).  The interventricular 
septum was excluded from analysis (Nowell et al. 2014, Mingo - Santos et al. 2015, 
Konishi et al. 2013).  The longitudinal Ɛ curves for each segment and a mean curve 
of all segments was then generated by the software.  These curves were used to 
derive RV free wall PSS. 
 
6.3.3.1 Left ventricular peak systolic strain 
As described in chapter 5. 
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6.3.4 Statistical analysis 
Statistical analysis was performed with Statistica version 12.5, series 0414 for 
Windows.  Continuous variables are expressed as means ± SDs or medians (IQRs). 
Student’s t test or Mann-Whitney U test were used to compare continuous variables. 
Categorical variables were evaluated by the Chi-square and Fisher’s exact test when 
necessary.  A p value of<0.05 was recognised as statistically significant.  
Univariate and multivariate linear regression analysis was used to identify 
possible independent determinants of RV PSS.  Univariate variables with Pearson’s 
correlation coefficient ≥0.8 were not included in the multivariate models.  
Additionally, only clinically and statistically significant variables (P <0.05) were 
selected for inclusion in multivariate linear regression analysis.  The aforementioned 
models were further analysed using the forward and backward multiple linear 
regression methods.  The assumptions were verified by performing residual analysis 
and advanced Durbin-Watson statistics.  
The intra- and inter-observer variabilities were assessed for RV free wall and 
LV PSS. Measurements were done in 20 randomly selected subjects. To assess 
inter-observer variability two independent observers measured the strain parameters 
whilst intra-observer variability was calculated from the analysis by the same 
observer after one month of the first measurement. Inter-observer and intra-observer 
reproducibility was assessed by calculating coefficients of variation (CV). The CV 
was calculated as the standard deviation of the differences divided by the mean. The 
T- test for dependent variables was used to compare the mean and SD of the values 
derived for strain and volumes and to calculate the significance value. A p 
value<0.05 was considered statistically significant.  
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6.4 Results 
 
6.4.1 Clinical characteristics 
There was no statistical significant difference in age, gender, SBP, DBP, BMI 
and HR between the patients with MR and the controls (p>0.05) (Table 6.1). 
Hypertension, HIV and combination of the two comorbidities were identified in 
41.5%, 12.9% and 15.5%, respectively.  Forty-two percent of the patients were in 
NYHA functional class I, the remainder were in class II (49%) and III (9%), 
respectively. 
 
Table 6.1 Baseline clinical characteristics of the study population.* 
Variable CRMR 
n=77 
Controls 
n=40 
p value 
Age (years) 44±13.6 42±13.4 0.4 
Gender (M:F) 13:64 8:32 0.6 
Body surface area (m2) 1.7±0.2 1.8±0.2 0.01 
Body mass index (kg/m2) 27.1±5.9 28.4±6.2 0.3 
SBP (mmHg) 124.2±11.4 124±12.5 0.93 
DBP (mmHg) 77±9.1 75.7±12.6 0.52 
Heart rate (beats/min) 77.1±12.6 76.3±14.1 0.75 
* Data are presented as mean± SD or %. DBP - Diastolic blood pressure. SBP – 
Systolic blood pressure.  
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6.4.2 Echocardiographic characteristics  
Among the CRMR patients, moderate MR was present in 51(66%) and severe 
MR in 26 (34%).  The LV end-systolic and end-diastolic volumes were higher in the 
CRMR group compared to controls (p<0.0001) (Table 6.2).  The LV systolic and 
diastolic function parameters were altered in CRMR group compared to controls 
(p<0.001) (Table 2).  Left and right atrial volumes indexed were higher in the MR 
group compared to controls (LAVi: 64.1±39.9 mL/m2 vs 21.9±4.9 mL/m2, p<0.0001; 
RAVi: 23.1±12.9 mL/m2 vs 18.6±5.4 mL/m2, p=0.03) (Table 6.2).  Greater degree of 
PHT was present in the MR group compared to controls (35.1±16.9mmHg vs 
22.1±5.6mmHg, p<0.0001).  No difference was noted between TAPSE and RV S´ 
between CRMR and control group; or when moderate and severe MR groups were 
compared (p>0.05) (Table 6.2).  
 
Table 6.2 Echocardiographic parameters of the study population.* 
Variable CRMR 
(n=77) 
Controls 
(n=40) 
p value 
LV parameters 
EDD (mm) 54.8±9.4 42.5±4.8 <0.0001 
ESD (mm) 41.4±9.4 27.1±4.2 <0.0001 
IVSD (mm) 8.6±2.1 9.5±1.9 0.02 
LV PWD (mm) 8.5±1.5 9.2±1.9 0.03 
EDVi (mL/m2) † 93.2±30.1 47.9±13.5 <0.0001 
ESVi (mL/m2) † 40.0±22.2 17.8±6.4 <0.0001 
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* Data are presented as mean± SD or %. † Values are indexed to BSA. EDVi - End-
diastolic volume indexed; ESVi - End-systolic volume indexed; IVSD - 
LAVi (mL/m2) † 64.1±39.9 21.9±4.9 <0.0001 
EF (%) 58.5±12.9 62.8±11.2 0.07 
LVMi (kg/m2) † 102.7±36.3 65.6±20.3 <0.0001 
E wave (cm/s) 133.8±48.1 77.0±17.6 <0.0001 
A wave (cm/s) 98.4±33.5 59.6±13.0 <0.0001 
Deceleration time (m/s) 214.5±62.2 135.4±42.3 <0.0001 
E/A ratio 1.5±0.6 1.3±0.4 0.06 
E´medial (cm/s) 7.3±2.3 8.8±2.8 0.002 
E´ lateral (cm/s) 10.1±4.0 13.4±3.6 <0.0001 
E/E´ medial (cm/s) 20.1±10.7 9.4±3.0 <0.0001 
E/E´ lateral (cm/s) 15.4±8.8 5.9±1.6 <0.0001 
S´ medial (cm/s) 6.3±1.3 7.1±1.6 0.004 
S´ lateral (cm/s) 7.3±2.5 8.2±2.6 0.07 
LV PSS (%) -16.1±5.3 -17.9±2.1 0.04 
RV parameters 
RV base (mm) 32.1±6.9 30.8±4.7 0.28 
RV S´ (cm/s) 13.2±11.8 11.6±2.0 0.39 
TAPSE (cm) 2.1±0.4 2.2±3.2 0.78 
RAVi (mL/m2) † 23.1±12.9 18.6±5.4 0.03 
PASP (mmHg) 35.1±16.9 22.1±5.6 <0.0001 
RV Free wall PSS (%) -16.8±4.5 -19.2±3.4 0.003 
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Interventricular septal diameter; LAVi - Left atrial volume indexed;  LV - Left ventricle; 
EDD - End-diastolic diameter; EF - Ejection fraction; ESD - End-systolic diameter; 
LVMi,- Left ventricular mass indexed; NYHA - New York Heart Association; PASP - 
Pulmonary artery systolic pressure; PWD - Posterior wall diameter; PSS - Peak 
systolic strain - RAVi,- Right atrial volume indexed; RV - Right ventricle; TAPSE - 
Tricuspid annular plane systolic excursion. 
 
6.4.3 LV PSS and RV free wall peak systolic strain (RV PSS) in CRMR 
LV PSS and RV PSS were lower in patients with CRMR compared to controls 
(LV PSS: -16.1±5.3% vs -17.9±2.1%, p=0.04; RV PSS: -16.8±4.5% vs -19.2±3.4%, 
p=0.01) (Table 6.2 and Figure 6.1).  When comparing moderate and severe MR 
groups, patients with severe MR had greater degree of reduction in RV PSS (-
15±4.7% vs -17.7±4.2%, p=0.01) (Table 6.3).  RV PSS declined as PASP increased 
(r=0.29, p=0.02) and TAPSE decreased (r=-0.36, p=0.004).  RV PSS and LV PSS 
had a positive correlation (r=0.3, p<0.001) (Figure 6.2).  There was no correlation 
between RV PSS and RV Sˈ (r=-0.16, p=0.17). 
 
Table 6.3 Right ventricular systolic function parameters according to severity 
of mitral regurgitation.* 
Variable Moderate CRMR 
(n=51) 
Severe CRMR 
(n=26) 
p value 
HIV 3(5.8%) 7(26.9%) 0.007 
Hypertension 26(50.9%) 6(23.0%) 0.02 
Hypertension and HIV 7(13.7%) 5(19.2%) 0.48 
RVH(mm) 5.9±1.6 7.2±2.3 0.006 
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PASP (mmHg) 31.0±12.3 43.9±21.3 0.001 
RV S´ (cm/s) 11.6(9.9-14.6) 11.4(9.4-13.4) 0.29 
TAPSE (cm) 2.1±0.38 2.0±0.4 0.28 
RV free wall PSS (%) -17.7±4.2 -15±4.7 0.01 
* Data are presented as median (IQR), mean± SD or %. HIV -  Human 
Immunodeficiency virus; PAS -  Pulmonary artery systolic pressure; PSS - Peak 
systolic strain; RV - Right ventricle; RVH - Right ventricular hypertrophy; TAPSE - 
Tricuspid annular plane systolic excursion. 
 
6.4.4 Comparison of RV systolic functional parameters in CRMR according to 
LV systolic function  
RV PSS was diminished in those with EF <60% compared to those with 
EF≥60% (-14.6±4.1% vs -18.2±4.2%, p=0.0003).  LV PSS was higher in those with 
EF≥60% compared to those with EF<60% (-18.2±3.9% vs -13.1±5.6, p<0.001). 
Similarly, RVPSS was diminished in those with LV EDD≥55mm compared to those 
with LV EDD<55mm (-15.1±4.3% vs -18.3±4.2 %, p=0.001).  However, no difference 
in traditional RV systolic function parameter was found between patients with 
preserved and decreased LV systolic function (p>0.05). PASP was greater in those 
with depressed systolic function compared to those with preserved LV systolic 
function (p=0.02) (Table 6.4). 
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Table 6.4 Comparison of right ventricular systolic function parameters in 
CRMR according to left ventricular systolic function.* 
Variable LVEF<60% 
(n=32) 
LVEF≥60% 
(n=45) 
p value 
RV S´ (cm/s) 11.3(9.7-13.0) 12.0(9.6-14.7) 0.27 
TAPSE (cm) 1.9±0.30 2.1±0.41 0.07 
LVPSS (%) -13.1±5.6 -18.2±3.9 <0.001 
RVPSS (%) -14.6±4.1 -18.2±4.2 0.0003 
PASP (mmHg) 39.9±21.5 31.6±11.5 0.03 
Variable LV EDD≥55mm 
N=37 
LV EDD<55mm 
N=40 
p value 
RV S´ (cm/s) 11.7(9.6-13.4) 11.5(9.8-13.9) 0.32 
TAPSE (cm) 2.1±0.34 2.1±0.41 0.9 
RVPSS (%) -15.1±4.3 -18.3±4.2 0.001 
PASP (mmHg) 39.5±20.4 30.8±11.4 0.02 
* Data are presented as median (IQR), mean± SD or %. EDD - End-diastolic 
diameter; LV -  Left ventricle; PASP - Pulmonary artery systolic pressure; PSS -  
peak systolic strain; RV - Right ventricle; RVH - Right ventricular hypertrophy; 
TAPSE - Tricuspid annular plane systolic excursion. 
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Figure 6.1 Reduced RV free wall peak systolic strain in CRMR. 
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Figure 6.2 Correlation between RV free wall peak systolic strain (Y-axis) and 
LV peak systolic strain (X-axis) in CRMR. 
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6.4.5 Predictors of RV PSS 
On univariate linear regression analysis severe MR (r=0.38, p<0.0001), TAPSE 
(r=-0.36, p=0.003), PASP (r=0.31, p=0.006), LVEF (r=0.3, p=0.003), LV EDD (r=0.3, 
p=0.007), Lateral S´ (r=0.24, p=0.03) and LV PSS (r=0.4, p<0.0001) were 
determinats of peak RV PSS.  
On multivariate linear regression analysis after adjusting for age and gender 
TAPSE, LV PSS and LV EDD emerged predictors of RV PSS (Table 6.5). LV PSS 
was the most important determinant of RV PSS (p=0.01) (Table 6.5). 
 
6.4.6 Feasibility and reproducibility of RV free wall PSS and LV PSS 
RV and LV PSS measurements were feasible in all 77 patients. The intra-
observer coefficient of variation for RV free wall PSS was 7% with a mean difference 
± SD of 0.4 ± 2.7 (p=0.5) and for LV PSS was 2.4% with mean difference ± SD of 
1.1± 2.7 (p=0.09).  The inter-observer variability coefficient was 7.6% for RV free wall 
PSS with a mean difference ± SD of 0.5 ± 3.8 (p=0.5) and for LV PSS was 9.8% with 
a mean difference ± SD of 0.25±2.4 (p=0.6), respectively. 
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Table 6.5 Multivariate linear regression model for RV PSS in chronic rheumatic 
mitral regurgitation. 
R=0.54, p<0.001 
Variable β±SE p value 
Age (years) 0.03±0.04 0.41 
Gender (M) -1.29±1.47 0.38 
PASP (mmHg) 0.05±0.03 0.13 
Severe MR  2.4±1.36 0.07 
TAPSE (cm) -3.7±1.39 0.01 
R=0.46, p<0.004 
Variable β±SE p value 
Age (years) -0.01±0.03 0.7 
Gender (M) -1.07±1.28 0.4 
LV PSS (%) 0.30±0.12 0.01 
Lateral S´ (cm/s) -0.03±0.24 0.87 
LV EF (%) -0.04±0.04 0.35 
R=0.5 p<0.001 
Variable β±SE p value 
Age (years) 0.03±0.03 0.36 
Gender (M) -1.5±1.2 0.22 
LV EDD (mm) 0.15±0.04 0.003 
TAPSE (cm) -3.9±1.24 0.002 
R=0.53 p<0.0001 
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Variable β±SE P value 
Age (years) 0.01±0.03 0.76 
Gender (M) -1.2±1.2 0.31 
LV EDD (mm) 0.09±0.05 0.07 
TAPSE (cm) -2.8±1.2 0.02 
LV PSS (%) 0.25±0.09 0.01 
EDD -  End-diastolic diameter; Ef -  Ejection fraction; LV - Left ventricle; MR - Mitral 
regurgitation; PASP - Pulmonary artery systolic pressure; PSS - peak systolic strain; 
RV - Right ventricle; TAPSE - Tricuspid annular plane systolic excursion. 
 
6.5 Discussion 
 
The pertinent findings of this study are:  
1) RV free wall PSS is a more sensitive marker of RV dysfunction than traditional RV 
systolic function parameters in CRMR.  
2) LV PSS was the most important determinant of RV free wall PSS. 
RV function impairment and decreased LV ejection fraction are powerful predictors 
of CVS and overall survival in degenerative MR (Hyllen et al. 2014).  The main 
determinants of RV function are RV load, myocardial function, neuro-hormonal 
abnormalities and ventricular interaction (Le Torneau et al. 2013a, b, Friedberg and 
Redington 2014).  
Only RV free wall PSS was measured in this study as the interventricular 
septum contributes minimally to RV function (Fine et al. 2014).  RV PSS is known to 
have prognostic and predictive value in various CV disease states (Lang et al. 2015, 
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Fine et al. 2014). In this study RV systolic dysfunction was more prevalent by STE 
than with commonly used conventional markers of systolic function such as TAPSE 
and RV Sˈ.  Speckle tracking echocardiography-derived RV PSS has been shown to 
be feasible and reproducible for clinical use (Morris et al. 2016, Lang et al. 2015, 
Ternacle et al. 2013).  In this study RV PSS was feasible and reproducible in 
assessing RV function in CRMR.  STE has been shown to be advantageous over 
conventional echocardiographic parameters used to measure RV systolic function in 
a variety of CV disorders such as HF, pulmonary hypertension and preoperative and 
postoperative RV function assessment prior to cardiac surgery (Morris et al. 2016, 
Hyllen et al. 2014, Ternacle et al. 2013, Guendouz et al. 2012, Fukuda et al. 2011). 
RV PSS derived by STE was superior in assessment of RV function in this study. 
The above finding can be explained by technical aspects as STE is not angle-
dependent and is less influenced by heart motion compared to TAPSE and RV Sˈ 
(Lang et al. 2015).  Additionally, TAPSE and Sˈ only measure regional RV function, 
whereas RV free wall strain is able to provide more global assessment of RV 
function (Lang et al. 2015).  Further, Focardi et al. recently showed that among all 
RV systolic function parameters, RV PSS had the best correlation with RV ejection 
fraction measured by cardiac MRI (Focardi et al. 2015).  Therefore, even though 
STE is limited by imaging quality and load dependence, unlike traditional 
echocardiographic parameters, it is able to detect subclinical longitudinal RV 
dysfunction and thus may help in risk stratification for surgery. 
TAPSE emerged as an important determinant of RV PSS in this study. This 
finding can be explained by the fact that both RV PSS and TAPSE represent 
longitudinal function of the RV (Konishi et al 2013, Rudski et al 2010). There is still a 
disprepacy in the literature as to which parameter is the best for measuring RV 
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systolic function most accurately. There are no studies in MR. Giusca et al and 
Camelli et al found RV PSS to be a better marker of RV contractility than TAPSE in 
post endarterectomy patients and for pre-operative assessment of patients for 
cardiac transplant, respectively. This contrasts with Meris et al where a close 
correlation between TAPSE and RV PSS was noted in patients with RV systolic 
dysfunction and in normal controls (Camelli et al 2012, Meris et al 2010, Giusca et al 
2009). Focardi et al noted RV PSS to have the best correlation with RV ejection 
fraction measured by cardiac MRI (Focardi 2015). Therefore, even though TAPSE 
only measures regional RV function and is subject to limitations as described in prior 
studies, it may still be utilized as a useful surrogate of RV systolic function in certain 
groups of patients with poor image quality where RV PSS may not be feasible 
(Rudski et al 2010). Current right heart function assessment guidelines and chamber 
guidelines recommend assessment of RV function based on more than one 
parameter and reserve utility of strain for research purposes only, until more data 
becomes available (Rudski et al 2010, Lang et al 2015).  
The decrease in RV PSS in this study, with preserved traditional markers of RV 
systolic function would imply presence of subclinical RV dysfunction in these 
patients.  The mechanism of decrement in RV strain may be partially explained by a 
relatively high PASP in this study - as the RV is extremely sensitive to afterload 
(Friedberg and Redington 2014, Fukuda et al. 2011).  Even small changes in 
peripheral vascular resistance can markedly decrease RV contractile function.  Prior 
studies have noted a similar relation between RV systolic performance and 
pulmonary hypertension in degenerative MR (Hyllen et al. 2014, Le Torneau et al. 
2013a, b).   
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Le Torneau et al. have shown that, even though increased RV afterload 
secondary to PHT was an important cause of RV dysfunction in MR, LV dysfunction 
also contributed significantly to RV dysfunction, due to their interdependent 
relationship (Le Torneau et al. 2013a, b).  In this study, PASP was only modestly 
elevated but the markers of LV remodelling and systolic function such as LVPSS, LV 
EDD and Sˈ velocity were markedly abnormal in CRMR.  Therefore, in agreement 
with Le Torneau et al, we think that LV remodelling and LV dysfunction, in addition to 
the modest elevation in PASP, may be an important cause of RV function 
impairment in CRMR.  This is supported by the finding of reduced RV PSS in 
patients with LV EDD≥55 mm, LVEF<60% and reduced LV PSS.  However, 
conventional RV systolic function parameters were still preserved even in presence 
of LV systolic dysfunction.  Hence, once abnormalities in LV systolic function are 
noted in MR, systematic RV function assessment must be done with not only 
traditional parameters but also STE, in order to detect subclinical RV dysfunction and 
avoid mortality associated with biventricular function impairment (Le Torneau et 
al.2013a, b).  
Severe MR was associated with worse RV function impairment, in a study by 
Le Torneau et al. (Le Torneau et al. 2013a, b).  It was found to be a determinant of 
RV PSS in this study.  Volume overload as a result of chronic MR results in LV 
remodelling as noted in our study, and this in turn, results in abnormalities of RV and 
LV interaction.  RV free wall strain was lower in patients with severe MR compared 
to moderate MR.  This association can be explained by greater chronic volume 
overload of LV, the left atrium accompanied by increased PASP as a result of 
backward transmission of increased LV pressure as well as remodelling of the 
pulmonary vasculature in severe MR compared to moderate MR (Bonow et al. 
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2012).  However, there was no difference in traditional RV systolic function 
parameters between the moderate and severe MR groups, and thus quantitative RV 
function assessment in CRMR mandates evaluation by both conventional indices 
and RV longitudinal strain.  
Finally, the decline in RV PSS may be partially attributed to primary RV 
dysfunction.  The intrinsic myocardial function abnormality may be a result of 
longstanding activation of neuro-hormonal pathways and increased afterload 
secondary to chronic mitral regurgitation (Friedberg and Redington 2014, Polak et al. 
1983).  We further speculate that there may be direct involvement of the RV 
myocardium by the rheumatic process. 
 
6.5.1 Study Limitations 
This study had several limitations:  
1) A lack of reference standard for RV functional assessment such as additional 
imaging in the form of cardiac MRI and 3D echocardiography.  
2) We did not perform right and left heart catheterisation to measure PASP, 
pulmonary vascular resistance, and coronary angiogram unless there was clinical 
indication.  
6.6 Conclusion 
In CRMR speckle tracking-derived RV PSS is feasible and reproducible. RV 
PSS is a more sensitive marker for detecting earlier RV systolic dysfunction than 
traditional RV functional parameters. LV PSS is an important determinant of RV PSS 
in this study. Therefore, presence of LV systolic dysfunction mandates careful search 
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for RV systolic dysfunction in MR using STE. These findings may have implications 
regarding decision for surgical intervention:  
1) Presence of significant RV dysfunction may help strategize the preoperative and 
postoperative management of patients with MR.   
2) Earlier referral for surgery before LV dysfunction supervenes in cases where LV 
function is preserved.  
3) Deferring surgery in patients with coexisting LV dysfunction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152 
 
 
Chapter 7 
 
 
Cardiac magnetic resonance and echocardiographic characteristics 
of chronic rheumatic mitral regurgitation and relation with 
biomarkers of collagen metabolism 
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7.1 Comparison of chronic rheumatic mitral regurgitation severity between 
cardiac magnetic resonance imaging and echocardiography 
 
7.1.1 Abstract 
 
7.1.1.2 Background 
Recently, magnetic resonance imaging (MRI) has emerged as a useful non-
invasive tool for assessing valvular lesions, especially where echocardiography is 
unable to provide complete information.  In degenerative mitral regurgitation, MRI 
has proven useful in accurate assessment of severity of MR, LV structure and 
function.  Assessment of CRMR severity, using cardiac MRI has not been explored. 
CRMR is largely characterised by eccentric jets and thus accurate quantification is 
difficult with the guideline recommended PISA method alone.  Thus, cardiac 
magnetic resonance (CMR) may be of added benefit for assessment of lesion 
severity in CRMR.  We sought to study and compare echocardiography with MRI for 
assessment of CRMR severity.  
 
7.1.1.3 Methods 
After application of appropriate inclusion criteria, 22 patients with isolated 
moderate or severe CRMR underwent cardiac MRI as part of a sub-study at CHBAH. 
All underwent echocardiography and cardiac MRI on the same day.  
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7.1.1.4 Results 
The mean age was 36.3±13.9 years with 81% females.  Overall there was no 
difference in MR severity (based on qualitative and quantitative parameters) 
assessment between the two imaging modalities (p>0.05).  However, six patients 
were reclassified after MRI to severe MR and one to moderate MR based on 
quantitative parameters of regurgitant volume (RegV) and RF.  EDVi and RegV were 
higher on MRI compared to echocardiography (98.5(81-111.1) mL/m2 vs 90.4(71.5-
103.8) mL/m2, p=0.03; 47.0±19.9 mL/m2 vs 34.3 ±15.1mL/m2, p=0.003).  There was 
no difference between ESVi and regurgitant fraction (RF) between echocardiography 
and MRI (p>0.05).  Although there was a positive correlation between LV volumes 
and RegV on the two imaging modalities, there was no agreement between 
echocardiography and MRI for assessment of MR severity parameters such as RF, 
RegV and LV volumes. 
 
7.1.1.5 Conclusion 
CMR may be a useful adjunctive tool for quantitative assessment of MR 
severity in equivocal cases where echocardiographic integrated approach of MR 
assessment is insufficient.  
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7.1.2 Introduction 
 
Quantification of severity of MR is of utmost importance when considering a 
patient for surgery, yet the best method for grading MR remains elusive (Enriquez-
Sarano et al.1993).  Accurate quantification of MR using the current guideline based 
recommendation such as PISA is appropriate for MR with central jets but poses 
several limitations in assessment of MR secondary to eccentric jets (Zoghbi et al. 
2003, Enriquez-Sarano et al.1993).  Further, PISA measurements show poor inter-
observer agreement (Biner et al. 2010).  CRMR is a disease characterised by 
predominantly Carpentier IIIa leaflet dysfunction and eccentric jets which make its 
accurate quantification difficult using the current guideline recommendation. 
Recently, the utility of CMR has been highlighted in quantification of MR severity in 
degenerative MR and its role in risk-stratification of patients with MR has been 
emphasised especially in moderate and severe MR cases where echocardiographic 
assessment alone may be insufficient (Uretsky et al. 2015, Van De Heyning et al. 
2013).  The main advantage of CMR as opposed to echocardiographic assessment 
of MR severity is its ability to quantify LV volumes and flow much more precisely, 
using semi-automated methods of volume calculation and phase contrast velocity 
mapping, respectively (Kar and Sharma 2015).  To the best of our knowledge this is 
the first study evaluating severity of CRMR by echocardiography and MRI.  We 
postulate that CMR will be valuable in quantification of CRMR where the jets are 
predominantly eccentric.  Thus, we sought to compare the assessment of MR 
severity using cardiac MRI quantitative methods of MR severity assessment (RF, 
RegV and LV volumes) and echocardiography based integrated approach 
(qualitative, semi-quantitative and quantitative methods). 
 156 
 
7.1.3 Methods 
 
This study was part of a prospective cross-sectional study at the Chris Hani 
Baragwanath Academic Hospital (CHBAH).  Patients were enrolled from January 
and October 2014.  All patients were screened, and those deemed to have moderate 
or severe CRMR were referred for possible inclusion in the study.  A final number of 
91 patients with presumed chronic, rheumatic MR underwent clinical evaluation, 
resting electrocardiogram and detailed echocardiographic assessment according to 
a pre-determined protocol.  
The inclusion criteria were patients aged 18 years or older with 
echocardiographic features of moderate or severe chronic rheumatic MR.  Patients 
were excluded if they had:  
1) comorbidities,  
2) significant aortic valve disease,  
3) concurrent MS with a valve area of less than 2.0 cm2,  
4) documented ischaemic heart disease, 
5) preexisting non-valvular cardiomyopathy, 
6) prior cardiac surgery , 
7) congenital or pericardial disease,  
8) pregnancy,  
9) severe anemia (haemoglobin <10g/dL),  
10) presence of a pacemaker or defibrillator,  
11) claustrophobia, 
 157 
 
12) renal dysfunction eGFR<60mL/min, 
13) refusal to undergo MRI. 
Of the original 91 patients with CRMR, 69 were excluded due to the following: 
1) comorbidities (HIV n=22, hypertension n=44, diabetes mellitus n=3),  
2) atrial fibrillation (n=4),  
3) anaemia (n=3),  
4) renal dysfunction (n=3), and  
5) inadequate image quality (n=5).  
The final sample comprised 22 patients. Fourteen age and gender-matched 
controls were also enrolled.  A tolerance of 5 years was allowed for age matching. 
In degenerative MR, varying haemodynamics due to alterations in systolic 
blood pressure, impact MR assessment (Zoghbi et al. 2003).  In rheumatic MR 
where the orifice tends to be fixed rather than dynamic, the impact of change in 
afterload is minimal (Uretsky et al. 2015, Zoghbi et al. 2003).  Despite this assertion, 
we performed echocardiography and cardiac MRI on the same day to negate the 
impact of varying afterload. 
The study was approved by the University of the Witwatersrand ethics 
committee (M140114) and is in accordance with the principles outlined in the 
Declaration of Helsinki.  The baseline clinical characteristics of these individuals 
were recorded and they subsequently underwent comprehensive echocardiography 
and CMR imaging. 
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7.1.3.1 Echocardiographic evaluation 
Transthoracic echocardiography was performed on all patients in the left lateral 
position by experienced sonographers using a S5-1 transducer on a Philips iE33 
system (Amsterdam, The Netherlands).  The images were obtained according to a 
standardised protocol.  The data was transferred and analysed off-line using the 
Xcelera workstation (Philips). 
 
7.1.3.2 Two dimensional and Doppler quantification 
All linear chamber measurements were performed according to the ASE 
chamber guidelines (Lang et al. 2015).  Measurements relating to LV diastolic 
function were performed in accordance with the ASE guidelines on diastolic function, 
and included pulse wave Doppler at the mitral tips and tissue Doppler of both medial 
and lateral mitral annuli (Nagueh et al. 2009).  MR was considered rheumatic in 
aetiology when the morphology of the valve satisfied the World Heart Federation 
(WHF) criteria for the diagnosis of chronic rheumatic heart disease (RHD) (Reményi 
et al. 2012).  MR severity was assessed using qualitative, semi-quantitative and 
quantitative methods as the ASE and ESC valvular regurgitation guidelines (Zoghbi 
et al. 2003, Lancelloti et al. 2013).  MR jet was classified as eccentric if there was 
contact with the leaflet of the MV posterior to the regurgitant orifice and impingement 
to the lateral or medial wall of the LA was present.  It was deemed central if the MR 
jet was directed into the centre of the LA (Biner et al. 2010).  In equivocal cases the 
echocardiographic data was integrated with the clinical evaluation by an experienced 
cardiologist to distinguish moderate from severe MR. 
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7.1.3.3 Cardiovascular magnetic resonance acquisition and analysis 
CMR studies were performed on a 1.5-Tesla whole body scanner (Siemens), 
using a six-channel phased-array body coil.  The images were obtained during 
patient breath- hold for approximately 8 seconds and were ECG gated (Kim et al. 
2000).  Left and RV volumes and mass and LA volumes were acquired in line with 
standard cardiovascular MRI (1.5T magnetom Avanto; Siemens Healthcare, 
Erlangen, Germany) protocols.  Steady-state free-precession imaging (echo times 
1.5/3.0 ms, flip angle 60°, temporal resolution 45 ms, slice thickness 7 mm, 3 mm 
gap, matrix size 256 x 256 mm, field of view 380 x 309 mm) were performed to 
obtain long axis cines and a contiguous stack of short-axis cines for assessment of 
LV dimensions, mass and ejection fraction as previously described (Hudsmith et al. 
2005).  Images were analysed by an independent experienced reader blinded to the 
echocardiographic results with Argus software version 2002B (Siemens Medical 
Solutions, Erlangen) as previously described (Karamitsos et al. 2007).  The 
assessment of cardiac function and chamber sizes were performed in standard 
views in the long-axis (horizontal and vertical) and short axis planes.  Ejection 
fractions for the LV was assessed with the following formula:  
Ejection fraction = end-diastolic volume – end-systolic volume/end-diastolic volume.  
LV volumes and EF were obtained by semi-automatic tracing of contours on the 
short-axis images in end-diastole and end-systole, with manual corrections when 
required (Schulz-Menger et al. 2013, Siemens avanto protocols).  From the short-
axis LGE images, basal, midventricular, and apical slices were selected based on 
anatomic landmarks (papillary muscles, LV outflow tract), and endocardial and 
epicardial borders were traced manually (Schulz-Menger et al. 2013, Siemens 
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protocols).  The anatomy of the MV was assessed in both, the basal short axis and 
long axis steady-state free-precession cines of the MV, using a standardised 
approach (Edwards et al. 2014).  The severity of MR was based on regurgitant 
volume (RegV) and fraction.  RegV was calculated as the difference between the LV 
stroke volume and the aortic forward stroke volume.  Regurgitant fraction was 
calculated with the aid of the following formula:  
Regurgitant fraction (%) = [mitral regurgitant volume ÷ LV stroke volume] ×100) 
(Edwards et al. 2014).  Mitral regurgitation was considered severe when RF≥42% 
(Chan et al. 2008).  
 
7.1.3.4 Statistical analysis 
Statistical analysis was performed with Statistica (version 12.5, series 0414 for 
Windows).  Continuous variables are expressed as means ± SDs or medians (IQRs). 
Categorical data was expressed as percentages.  The differences for continuous 
variables were calculated using Student’s t- test or Mann-Whitney U test when the 
distribution was non-normal.  Wilcoxon’s matched pairs test was used to compare 
two dependent samples when distribution was not normal.  Chi-square and Fisher’s 
exact test were used to calculate the difference for categorical data for independent 
samples. McNemar’s test was used to compare two dependent samples.  Pearson’s 
and Spearman’s correlation coefficient were used to calculate correlations 
depending on whether data was normally or non-normally distributed. Bland- Altman 
plots were used to display agreement between MRI and echocardiographic variables 
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used for assessment of MR severity.  A p value<0.05 was considered statistically 
significant. 
 
7.1.4 Results 
 
7.1.4.1 Baseline characteristics 
Of the 69 patients excluded, their mean age was 51.7±1.1 years, mean LVEF 
was 59±13% and LVESD was 43.4±9mm. Fifty eight of these individuals were 
females. Of the 22 patients included, the mean age was 36.3±13.9 years, 81% were 
females (Table 7.1.1). All the patients had isolated moderate, or severe chronic 
rheumatic MR and no comorbidities.  Of the 22 patients 10 were in NYHA functional 
class I, the remainder were NYHA functional class II. Four patients were on medical 
treatment with diuretics (furosemide) and anti-remodelling therapy (spironolactone, 
carvedilol, enalapril) for previous HF secondary to MR.  Eight patients were on 
diuretics alone. 
 
Table 7.1.1 Baseline characteristics of the study patients and controls.* 
Variable Study group 
n=22 
Control 
n=14 
p value 
Age (years) 36.3±13.9 40.3±14.2 0.40 
Gender (F:M) 18:4 10:4 0.36 
Systolic blood 
pressure (mmHg) 
123.2±9.5 122.9±5.1 0.91 
Diastolic blood 
pressure (mmHg) 
77.2±6.4 74.6±12.3 0.34 
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Pulse (beats/min) 74.6±13.1 75.5±13.3 0.55 
Body mass index 
(kg/m2) 
24.8±4.7 28±5.7 0.06 
Body surface area 
(m2) 
1.6±0.2 1.7±0.2 0.24 
* Data are presented as mean± SD. 
 
7.1.4.2 CMR and Echocardiographic characteristics 
The EDVi and ESVi were increased on both echocardiographic exam and on 
MRI (for normal MRI reference range-see appendix) but when the two modalities 
were compared there was no difference in ESVi between the two techniques 
(39.6±19.6 mL/m2 vs 49.1±36.7 mL/m2, p=0.1) (Table 7.1.2 and Table 7.1.3). 
However, there was a difference in EDVi [EDVi-90.4(71.5-103.8) mL/m2 vs 98.5(81-
111.1) mL/m2, p=0.03)].  On echocardiography, nine patients had LV EDD<55 mm 
and 13 patients had LV EDD >55 mm.  There was no statistically significant 
difference between EDVi and ESVi between echocardiography and MRI in those 
with LV EDD<55 mm (EDVi: 84.2±18.4 mL/m2 vs 91.0±15.7 mL/m2, p=0.21; ESVi: 
32.8±11.7 mL/m2 vs 31.2±10.3 mL/m2, p=0.5).  In those with LV EDD >55mm (EDVi: 
106.8±35.5 mL/m2 vs 130.5± 49.2 mL/m2, p=0.08, ESVi: 49.1±24.9 mL/m2 vs 
75.1±45.9 mL/m2, p=0.050) there was a tendency of volumes to be greater on MRI 
compared to echocardiography but was not statistically significant.  The mitral RegV 
was higher on MRI than on echocardiography (34.3 ±15.1mL vs 47.0±19.9 mL, p= 
0.003).  There was no difference in regurgitant fraction (RF) between the two 
modalities (MRI vs echo: 49.2% (31.7-56.2) vs 33.3% (27.4-47.6), p=0.1). The LV EF 
measurements were similar on both MRI (58.8±15.1%) and echocardiography 
(59.8±10.6%).  There was a good correlation between EDVi and ESVi 
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measurements between the two imaging modalities (r=0.69, p<0.001; r=0.7, 
p<0.001) but the agreement was poor (Figure 7.1.1 and Figure 7.1.2).  Similarly, 
RegV measurements showed modest correlation (r=0.48, p=0.02) and little 
agreement. RF measurements showed no correlation or agreement between the two 
modalities (r=0.26, p=0.2) (Figures 7.1.3 and 7.1.4).  There was no correlation 
between echocardiographic effective regurgitant orifice area (EROA), RegV, 
regurgitant fraction and LV volumes on MRI (p>0.5). 
All the MR jets were eccentric (Figure 7.1.5).  Echocardiography classified 14 
patients as moderate MR and eight as severe MR based on quantitative and 
qualitative parameters.  The EROA and RegV derived using the PISA method were 
0.2±0.12 cm2 and 34.3 ±15.1 mL, respectively. Even though no difference was 
observed between MR severity assessment in the overall group, we noted 
discrepant findings in terms of classification of valve lesion severity in seven 
patients, based on current cut- offs for RegV and fraction, between MRI and 
echocardiography. Based on RegV and RF, six patients previously classified as 
moderate MR on echocardiogram were reclassified as severe MR on CMR, and one 
patient with severe MR on echocardiography was re-categorised as moderate. 
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Table 7.1.2 Echocardiographic characteristics of the study patients compared 
to controls.* 
Variable Study group 
n=22 
Control 
n=14 
p value 
Echocardiographic parameters 
LV EDD (mm) 56.2±7.4 42.2±6.1 <0.001 
LVESD (mm) 41.5±8.6 26.7±4.0 <0.001 
LV EDVi (mL/m2) † 90.4(71.5-
103.8) 
43.2(35.2-
43.2) 
<0.001 
LV ESVi (mL/m2) † 39.6±19.6 15.3±4.6 0.001 
EF (%) 59.8±10.6 60.6±17.1 0.5 
LV mass index 
(g/m2) † 
100.1±33.8 61.4±18.7 0.004 
E wave (cm/s) 147(95.3-197) 81.2(66.6-
95.0) 
<0.001 
E/A ratio 1.7±0.68 1.4±0.38 0.1 
Lateral Eˈ(cm/s) 12.8±4.6 13.8±3.9 0.5 
Lateral E/Eˈ(cm/s) 13.6±7.5 6.0±1.6 <0.001 
Lateral Sˈ(cm/s) 7.6±2.1 7.2±2.2 0.11 
PASP (mmHg) 35.0±17.0 20.7±3.8* 0.08 
LAVi (mL/m2) † 44.8(39-62.7) 23.2(17.7-
25.4) 
<0.001 
 
* Data are presented as median (interquartile range), mean± SD or %. † Values are 
indexed to BSA. EDVi -  End-diastolic volume indexed; ESVi - End-systolic volume 
indexed; LAVi - Left atrial volume indexed; LV - Left ventricle; EDD - End- diastolic 
diameter; EF - Ejection fraction; ESD - End- systolic diameter; PASP - Pulmonary 
artery systolic pressure. 
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Table 7.1.3: Comparison between Echocardiographic and CMR characteristics 
of study patients 
Variable Echocardiographic 
characteristics  
n=22 
CMR 
characteristics 
n=22 
p value Correlation 
coefficient 
and p value 
Regurgitant 
volume (mL) 
34.3 ±15.1 47.0±19.9 0.003 r=0.48, p=0.02 
Regurgitant 
fraction (%) 
33.3(27.4-60.1) 49.2(31.7-56.2) 0.1 r=0.26, p=0.2 
Vena contracta 
(cm) 
0.6±0.2 - - - 
Moderate MR 14(63.6%) 9(41%) 0.14 - 
Severe MR 8(36.3%) 13 (55%) 0.3 - 
Eccentric jet 22(100%) 22(100%) - - 
LV EDVi 
(mL/m2) 
90.4(71.5-103.8) 98.5(81-111.1) 0.03 r=0.69, 
p<0.001 
LV ESVi 
(mL/m2) 
39.6±19.6 49.1±36.7 0.1 r=0.7, p<0.001 
Ejection 
fraction (%) 
59.8±10.6 58.8±15.1 0.7 r=0.3, p=0.08 
* Data are presented as median (interquartile range), mean± SD or %. † Values are 
indexed to BSA. EDVi -  End-diastolic volume indexed; ESVi - End-systolic volume 
indexed; LV - Left ventricle; MR -  Mitral regurgitation. 
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Figure 7.1.1 Bland-Altman plot for measuring end-diastolic volume 
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Figure 7.1.5 Two dimensional echocardiographic views depicting: a) Restricted 
leaflet motion of anterior and posterior mitral leaflet secondary to rheumatic 
heart disease b) Eccentric mitral regurgitation jet c) Incomplete continuous 
wave Doppler envelope generated by poor continuous wave Doppler alignment 
of the jet. 
 
7.1.5 Discussion 
 
The main finding of this study was that echocardiographic and CMR techniques 
differ with regard to assessment of MR severity based on quantitative parameters in 
a minority of patients. However, the majority of echocardiography- based integrated 
approach of severity of MR assessment was concordant with that of MRI quantitative 
assessment.  
There were discrepancies on assessment of MR severity by CMR and 
echocardiography in seven patients in our study based on quantitative parameters. 
Various studies have shown superiority or equivalence of MRI over 
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echocardiography when assessing severity of mitral regurgitation, mostly in the 
context of degenerative MR (Van De Heyning et al. 2013, Sukpraphute 2012, 
Uretsky et al. 2010, Cawley and Otto 2009, Hellgren et al. 2008, Gelfand et al.  
2006). Our findings concur with a recent study by Uretsky et al. where similar 
discrepancies in MR quantification, between the two imaging modalities was noted 
(Uretsky et al. 2015).  
The discordance in MR severity assessment between MRI and 
echocardiography in this study may be as a result of eccentric jets in rheumatic MR 
due to distorted leaflet morphology. This resulted in errors in quantification of MR 
severity on echocardiography due to:  
1) assumption of sphere when calculating PISA radius,  
2) generation of an incomplete continuous Doppler envelope,  
3) inaccurate radius measurement and 4) imprecise identification of regurgitant 
orifice; thus rendering the PISA method suboptimal for MR quantification. (Biner et 
al. 2010, Cawley and Otto 2009).  
The volumes obtained on echocardiography by the biplane Simpson’s method 
tend to be underestimated, especially in large ventricles due to foreshortening of the 
apex (Uretsky et al. 2015, Van De Heyning et al. 2013, Hellgren et al. 2008). This 
results in underestimation of the volumes and thus regurgitant fraction. We tried to 
minimise the aforementioned error by selecting only patients with the best imaging 
quality for this sub-study and, even then we found overall LV EDVi to be higher on 
MRI compared to echocardiography. The volumes obtained on MRI may be more 
reliable, as most post-processing software uses semi-automated algorithms to trace 
the endocardial border (Kar and Sharma 2015, Hellgren et al. 2008).  
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RegV measurement was higher on CMR compared to PISA-derived RegV in 
this study. Studies comparing RegV measurements on MRI and echocardiography in 
MR have shown variable results with some overestimating RegV on 
echocardiography, and others underestimating RegV (Van De Heyning et al. 2013). 
In all studies, these two imaging modalities could not be used interchangeably for 
measurement of this MR severity parameter. CMR, however, probably allows more 
accurate quantification of MR based on calculation of RegV using the formulae 
stated previously (based on phase contrast imaging and planimetry of LV contours at 
end-systole and diastole) than the PISA method, especially in eccentric jets 
secondary to rheumatic MR. Additionally, the current cut-offs for RF pertaining to 
classification of MR severity differ between echocardiography and MRI, with the 
threshold for  severity being lower on MRI compared to echocardiography (Zoghbi et 
al. 2003, Myerson 2012). Thus, more patients were classified as severe MR on MRI 
than echocardiography. In this study, CMR added incremental value in accurate 
quantification of MR, in the moderate and severe MR categories in a minority of 
patients. In these patients, quantitative and qualitative parameters were not useful in 
categorising MR severity on echocardiography and thus MRI proved to be a useful 
adjunctive tool.  
The main limitation of this study was the small sample size. None of the 
controls underwent MRI due to logistical reasons. Patients with mild MR and AF 
were excluded.  
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7.1.6 Conclusion 
 
CMR derived quantitative parameters may be useful for accurate classification 
of moderate or severe rheumatic MR characterised by eccentric jets, especially in 
equivocal cases, where integrated MR quantification by echocardiographic alone is 
insufficient.  
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7.2 Assessment of fibrosis by late gadolinium enhancement imaging and 
biomarkers of collagen metabolism in chronic rheumatic mitral regurgitation  
 
7.2.1 Abstract 
 
7.2.1.2 Background 
Presence of fibrosis by late gadolinium enhancement (LGE) on cardiac MRI 
has been shown to be of prognostic value in various disease states such as 
hypertrophic cardiomyopathy, ischaemic heart disease as well as in degenerative 
MR. In rheumatic mitral regurgitation, the involvement of the myocardium by the 
rheumatic process has been controversial. Older studies have postulated affliction of 
predominantly the posterobasal region of the LV by the rheumatic process. 
Additionally, there are limited studies in humans and animals which have explored 
the role of biomarkers of collagen metabolism in degenerative MR and rheumatic 
MR. There are no studies which have explored the prevalence of myocardial fibrosis 
using LGE and biomarkers in rheumatic MR. Therefore, we sought to study the 
presence of fibrosis by LGE and biomarkers of collagen turnover in CRMR.  
 
7.2.1.3 Methods 
Twenty-two patients with isolated moderate or severe CRMR underwent 
cardiac MRI as part of a sub-study at CHBAH. All underwent echocardiography and 
cardiac MRI the same day. Blood tests for biomarkers were drawn at the time of 
echocardiography.  
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7.2.1.4 Results 
The mean age was 36.3±13.9years with 81% females. Four patients had 
fibrosis on LGE.  PICP and PIIINP were similar to controls except for MMP-1 which 
was increased compared to controls (log MMP-1 3.5±0.68 vs 2.7±0.9, p=0.02). 
There was increased MMP-1 activity as the MMP-1 to TIMP-1 ratio was higher in 
CRMR compared to controls (-1.2±0.6 vs -2.1±0.89, p=0.002). No correlation was 
noted between biomarkers and CMR parameters (p>0.05).  
 
7.1.2.5 Conclusion 
 LV myocardial fibrosis in CRMR is rare. CRMR is a state characterised by 
predominance of collagen degradation rather than synthesis.  
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7.2.2 Introduction 
 
Myocardial fibrosis can be reliably detected non-invasively using late 
gadolinium enhancement (LGE) CMR (Doltra et al. 2013). LGE by CMR is a useful 
non-invasive correlate of myocardial fibrosis on histology (Barone-Rochette et al. 
2013). Fibrosis represents an end-stage process in various cardiac conditions, 
irrespective of aetiology and denotes adverse outcomes (Khan and Sheppard 2006). 
Limited recent studies have shown the value of cardiac MRI in valvular heart disease 
such as degenerative MR and aortic stenosis, in predicting prognosis based on 
presence of fibrosis (Edwards et al. 2014, Hoffman et al. 2014, Barone-Rochette et 
al. 2013). In CRMR there may be involvement of the LV by the rheumatic process 
especially in the posterobasal region of the LV (Barlow 1987, Stollerman et al.1975, 
Choi et al. 2006). Sepulveda et al. reported diffuse, mesocardial and heterogenous 
enhancement of myocardium by LGE in ARF (Sepulveda et al. 2013). Thus, the 
possible resultant fibrosis may be studied by LGE and have prognostic value similar 
to degenerative MR. Further, data concerning biomarkers of collagen degradation 
and formation in MR are limited and mostly comprise animal studies in degenerative 
MR (Hezzell et al. 2014, Verheule et al. 2003). In a recent study in rheumatic MR, an 
increase in biomarkers of collagen synthesis and degradation was reported 
(Banerjee et al. 2014). Biomarkers of collagen turnover may serve as non-invasive 
tools for identification of myocardial remodelling and add an incremental value in risk 
stratification for surgery or institution of aggressive medical treatment at an early 
stage (Lopez et al. 2010, Braunwald 2008, Spinale et al. 1999).  
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Thus, we sought to assess:  
1) the presence of LV fibrosis in CRMR using cardiac MRI  
2) the relation of biomarkers of collagen degradation and synthesis with CMR 
parameters in CRMR  
 
7.2.3 Methods 
 
This study was part of a prospective cross-sectional study at the Chris Hani 
Baragwanath Academic Hospital (CHBAH).  Patients were enrolled from January 
2014 to October 2014.  All patients were screened, and patients deemed to have 
moderate or severe CRMR were referred for possible inclusion in the study.  A final 
number of 91 patients with presumed chronic, rheumatic MR underwent clinical 
evaluation, resting electrocardiogram and detailed echocardiographic assessments 
according to a pre-determined protocol. After applying appropriate inclusion and 
exclusion criteria (detailed in section 7.1), 22 patients were enrolled in this sub-study. 
Additionally, 14 age and gender-matched controls were enrolled. The study was 
approved by the University of the Witwatersrand ethics committee (M140114) and 
was conducted in accordance with the principles outlined in the Declaration of 
Helsinki. The baseline clinical characteristics of these individuals were recorded and 
they subsequently underwent comprehensive echocardiography and CMR imaging. 
 
7.2.3.1 Echocardiographic evaluation 
Detailed in section 7.1  
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7.2.3.2 Biomarker analysis / Procollagen III N-terminal propeptide (PIIINP) 
and procollagen I C-peptide (PIP) analysis 
Peripheral venous blood samples were drawn from 14 controls and 22 chronic 
RHD subjects at the time of echocardiographic examination. Samples were collected 
in a serum separator tube, and allowed a clotting time of 30 min before centrifuging 
for 15 min at 1,000 g. The plasma was then separated into aliquots and stored at -
80°C before analysis. 
 
7.2.3.3 Procollagen III N-terminal propeptide analysis 
Serum concentrations of the procollagen III N-terminal propeptide (PIIINP) was 
determined by enzyme-linked immunosorbent assay (ELISA) using the USCN Life 
Science Inc./Cloud-Clone Corp (Wuhan, China) kit according to the manufacturer’s 
instructions. The minimum detectable dose of PIIINP is typically less than 25.9pg/ml. 
Briefly, the serum was diluted 1:100 in phosphate buffered saline (PBS-137 mM 
NaCl-2.7 mM, KCl-8 mM Na2HPO4, and 2 mM KH2PO4). The standards were 
prepared immediately before use and were diluted two-fold from 4000pg/mL to 
62.5pg/mL. Standards or samples were incubated at 37˚C for 2 hours, aspirated and 
incubated with anti-PIIINP-streptavidin-conjugated antibody for 1 hour at 37˚C. The 
wells were washed 3 times, followed by incubation at 37˚C for 30 minutes with biotin-
conjugated horse radish peroxidase (HRP). The wells were washed 5 times, followed 
by the addition of 3,3ˈ,5,5ˈ-Tetramethylbenzidine (TMBZ) substrate solution. The 
colorimetric reaction between HRP and TMB was stopped by the addition of acid. 
Absorbance at 450 nm was measured on an ELx800 microplate reader (BioTek(TM) 
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Instruments, Winooski, VT, USA). Concentrations were determined using a 5PL 
algorithm (Swart, A). 
 
7.2.3.4 Procollagen Type-I C-peptide (PIP) analysis 
Serum concentrations of the procollagen III N-terminal propeptide (PIIINP) was 
determined by enzyme-linked immunosorbent assay (ELISA) using the TAKARA BIO 
INC. (Japan) kit according to the manufacturer’s instructions. The minimum 
detectable dose of PIP is typically less than 10ng/ml. 
The serum was diluted in a ratio of 1:5, 80mL of PBS (sample diluent) with 
20mL of serum. We then transferred 100µl of antibody-POD conjugate solution into 
the first well and this was followed by addition of 20µl of standard solution prepared 
beforehand (lyophilised procollagen type-I in one mL distilled water -  a dilution 
series was prepared by mixing the standard solution and the sample diluent with a 
final concentration of 640ng PIP/mL). The microtitre plate was then allowed to 
incubate for 3 hours at 37°C. The well contents were discarded and the well was 
washed 4 times with 400µl of wash buffer [prepared beforehand by diluting 50mL of 
10X PBS in wash and stop solution (sulfuric acid) with 450mL of distilled water], 
carefully emptying the microplate after each wash. This was followed by the addition 
of 100µl of substrate solution (TMBZ) into each well and incubated at room 
temperature (20-30°C) for 15 minutes. We then added 100µl of stop solution (1 
NH2SO4) into each well in the same order as TMBZ. Absorbance at 450nm was 
measured on an ELx800 microplate reader (BioTek(TM) Instruments, Winooski, VT, 
USA). Concentrations were determined using a 5PL algorithm (Swart, A). 
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7.2.3.5 MMP-1 and TIMP-1 analysis 
Magnetic luminex screening assay (RnD systems, Minneapolis, USA) was used 
for the analysis. All the reagents, standards and samples were prepared in 
accordance to the instructor’s manual just prior to the procedure. The minimum 
detectable dose of MMP-1 is typically less than 2.7pg/ml and for TIMP-1 less than 
3.42pg/ml. 
The standard cocktails were reconstituted with calibrator diluent RD6-52. The 
serum was diluted in a 1:10 dilution. The microparticle cocktail was prepared as 
instructed and were further re-suspended by vortexing. Fifty microlitres of this 
cocktail was added to each well. After which, 50µL of standard was added. The 
microplate was sealed and incubated for 2 hours at room temperature on a 
horizontal microplate shaker set at 800±50 rpm. Prior to the washing, a magnet was 
applied to the bottom of the microplate. The microplate was washed three times after 
filling each well with 100µL of wash buffer (PBS). Subsequently 50µL of diluted 
antibody cocktail was added and the plate resealed and incubated for a further 1 
hour at room temperature on the microplate shaker set at 800±50 rpm. This was 
followed by further washing as mentioned previously. We then added 50µL of 
Streptavidin-PE into each well followed by incubation on the microplate shaker for 30 
minutes. The wells were washed three times before the addition of further 100µl of 
wash buffer and incubation for 2 minutes on the shaker. Results were obtained using 
Bioplex manager 5.0 software and checked using a straight line graph and 4Pl 
method from A Swart. 
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7.2.3.6 Cardiovascular magnetic resonance acquisition and analysis 
CMR studies were performed on a 1.5-Tesla whole body scanner (Siemens), 
using a six-channel phased-array body coil. The images were obtained during 
patient breath- hold for approximately eight seconds and were ECG gated (Kim et al. 
2000). Left and RV volumes and mass and LA volumes were acquired in line with 
standard cardiovascular MRI (1.5T magnetom Avanto; Siemens Healthcare, 
Erlangen, Germany) protocols. Steady-state free-precession imaging (echo times 
1.5/3.0 ms, flip angle 60°, temporal resolution 45 ms, slice thickness 7 mm, 3 mm 
gap, matrix size 256 x 256 mm, field of view 380 x 309 mm) were performed to 
obtain long axis cines and a contiguous stack of short axis cinesˈ for assessment of 
LV dimensions, mass and ejection fraction as previously described (Hudsmith et al. 
2005).  
Ten to fifteen minutes after the injection of 0.2 mmol/kg gadolinium-based 
contrast agent (Magnevist; Schering, Berlin, Germany), 2- or 3-dimensional LGE 
CMR images were acquired in the same axis and slice thickness used in the cine 
imaging (Hoffman et al. 2014). Inversion recovery times varying from 200-250 ms 
were used to null the signal from the intact myocardium (Hoffman et al. 2014).  
Images were analysed by an independent experienced reader, blinded to the 
echocardiographic results, with Argus software version 2002B (Siemens Medical 
Solutions, Erlangen) as previously described (Karamitsos et al. 2007). The 
assessment of cardiac function and chamber sizes were performed in standard 
views in the long-axis (horizontal and vertical) and short axis planes. Ejection 
fractions for the LV was assessed with the following formula:  
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Ejection fraction = end-diastolic volume – end-systolic volume/end-diastolic volume 
LV volumes and EF were obtained by semi-automatic tracing of contours on the 
short-axis images in end-diastole and end-systole, with manual corrections when 
required (Schulz-Menger et al. 2013, Siemens avanto protocols). From the short-axis 
LGE images, basal, midventricular, and apical slices were selected based on 
anatomic landmarks (papillary muscles, LV outflow tract), and endocardial and 
epicardial borders were traced manually (Schulz-Menger et al. 2013, Siemens 
protocols). Myocardial fibrosis was defined as a region of LGE with signal 
enhancement greater than the signal intensity of non-enhanced myocardium (as 
defined by a manually placed region of interest) (Doltra et al. 2013).  
 
7.2.3.7 Statistical analysis 
Statistical analysis was performed with Statistica version 12.5, series 0414 for 
Windows. Continuous variables are expressed as means ± SDs or medians (IQRs). 
Categorical data are expressed as a percentage. The differences for continuous 
variables were calculated using Student’s t-test or Mann-Whitney U test when the 
distribution was non-normal. Chi-square and Fisher’s exact test were used to 
calculate the difference for categorical data for independent samples. Pearson’s and 
Spearman’s correlation coefficient were used to calculate correlations depending on 
whether data was normally or non-normally distributed. Biomarker levels (TIMP1, 
MMP1, and MMP1/TIMP1 ratio) were log transformed before analysis when 
distribution was not normal. A p value<0.05 was considered statistically significant. 
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7.2.4 Results 
 
7.2.4.1 Baseline characteristics 
The mean age was 36.3±13.9 years, with 81% females (Table 7.2.1). All the 
patients had isolated moderate or severe chronic rheumatic MR and no 
comorbidities. Ten patients were in NYHA functional class I, the remainder were 
NYHA functional class II. Four patients were on medical treatment with diuretics 
(furosemide) and anti-remodelling therapy (aldactone, carvedilol, enalapril) for 
previous HF secondary to MR. Eight patients were on diuretics alone. 
 
7.2.4.2 CMR characteristics 
In this study LGE was present in four (18%) of patients with CRMR (Table 
7.2.2). A varied pattern of LGE of the LV myocardium was noted. These included:  
1) transmural LGE in the lateral wall,  
2) patchy areas of LGE in the basal septum ,mid-septum and basal inferior wall,  
3) transmural fibrosis of the inferior wall and,  
4) sub-epicardial LGE in one patient.  
The two patients with transmural involvement had normal coronary angiogram (done 
as part of their surgical workup). 
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Table 7.2.1 Baseline and echocardiographic characteristics of the study 
patients and controls.* 
Variable Study group 
n=22 
Control 
n=14 
p value 
Clinical parameters    
Age (years) 36.3±13.9 40.3±14.2 0.40 
Gender (F:M) 18:4 10:4 0.36 
SBP (mmHg) 123.2±9.5 122.9±5.1 0.91 
DBP (mmHg) 77.2±6.4 74.6±12.3 0.34 
Pulse (beats/min) 74.6±13.1 75.5±13.3 0.55 
Body mass index (kg/m2) 24.8±4.7 28±5.7 0.06 
Body surface area (m2) 1.6±0.2 1.7±0.2 0.24 
Echocardiographic parameters 
LV EDD(mm) 56.2±7.4 42.2±6.1 <0.001 
LVESD(mm) 41.5±8.6 26.7±4.0 <0.001 
EDVi (mL/m2) † 90.4(71.5-103.8) 43.2(35.2-43.2) <0.001 
ESVi (mL/m2) † 39.6±19.6 15.3±4.6 0.001 
EF (%) 59.8±10.6 60.6±17.1 0.5 
LV mass index(g/m2) † 100.1±33.8 61.4±18.7 0.004 
* Data are presented as median (interquartile range), mean± SD or %. † Values are 
indexed to BSA. DBP - Diastolic blood pressure. EDVi - End-diastolic volume 
indexed; ESVi - End-systolic volume indexed; LAVi - Left atrial volume indexed; EDD 
- End- diastolic diameter; EF - Ejection fraction; ESD - End- systolic diameter; LV - 
Left ventricle; NYHA - New York Heart Association functional class. SBP – Systolic 
blood pressure. 
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Table 7.2.2 CMR characteristics of the study patients.* 
Regurgitant volume(mL) 47.0±19.9 
Regurgitant fraction (%) 49.2(31.7-56.2) 
EDVi (mL/m2) † 98.5(81-111.1) 
ESVi (mL/m2) † 49.1±36.7 
EF (%) 58.8±15.1 
Moderate MR 9 (41%) 
Severe MR 13 (55%) 
LV mass(g/m2) † 67 (63-85.8) 
* Data are presented as median (interquartile range), mean± SD or %. † Values are 
indexed to BSA. EDVi - End-diastolic volume indexed; ESVi - End-systolic volume 
indexed; EF- Ejection fraction, LV - Left ventricle; MR - Mitral regurgitation. 
 
7.2.4.3 Biomarkers 
PIP and PIIINP were not elevated when compared to controls (11.8(6.9-21.6) 
ng/mL vs 15.7(13.6-18.5) ng/mL, p=0.09; 780.4(727.3-1263.7) vs 1065.1(589.2-
1252.0) µg/mL, p=0.13) (Table 7.2.3). Log MMP-1 was elevated in patients with 
CRMR compared to controls (3.5±0.68 vs 2.7±0.9, p=0.02). There was no difference 
in Log TIMP-1 between CRMR and controls (4.6±0.39 vs 4.8±0.30, p=0.15). The 
ratio of Log MMP-1 to TIMP-1 was increased (-1.2±0.6 vs -2.1±0.89, p=0.002). 
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Table 7.2.3 Biomarkers in the study patients compared to controls.*  
Variable Study group (n=22) Control (n=14) p value 
Procollagen III NP 
(ng/mL 
11.8(6.9-21.6) 15.7(13.6-18.5) 0.09 
Log PIIINP 2.5±0.7 2.7±2.6 0.18 
Procollagen I peptide 
(µg/mL) 
780.4(727.3-1263.7) 1065.1(589.2-1252.5) 0.13 
Log PIP 6.79±0.57 6.8±0.47 0.29 
MMP-1(ng/mL) 37.5(19.9-59.7) 16.2(6.53-37.9) 0.3 
Log MMP-1 3.52±0.7 2.7±0.9 0.02 
TIMP-1(ng/mL) 95.4(90.4-140.1) 139.2(110.3-155.5) 0.1 
Log TIMP-1 4.6±0.4 4.8±0.30 0.15 
MMP-1/TIMP-1 ratio 0.26(0.21-0.43) 0.11(0.07-0.26) 0.08 
Log MMP-1/TIMP-1 
ratio 
-1.2±0.6 -2.05±0.89 0.002 
*Data are presented as median (interquartile range), mean± SD or %. MMP - Matrix 
metalloproteinase; TIMP - Tissue inhibitor of matrix metalloproteinase; PIP - 
Procollagen Type IC-Peptide; PIIINP - Procollagen III N-Terminal propeptide. 
 
7.2.4.4 Relationship of biomarkers and MRI parameters 
No correlation was noted between biomarkers and CMR parameters of LV 
volumes, regurgitant fraction and regurgitant volumes (p>0.05).  
 
  
 185 
 
7.2.5 Discussion 
 
The main findings of this study are:  
1) Fibrosis, as assessed by LGE is uncommon in CRMR. 
2) Biomarkers suggestive of collagen degradation (MMP-1, MMP1/TIMP-1 ratio) are 
increased in CRMR, but no change in biomarkers of collagen synthesis (PIP and 
PIIINP) was noted. 
In this study the majority of patients with CRMR did not have fibrosis of LV 
myocardium on LGE. There are no studies on chronic rheumatic MR to draw 
comparisons from, but the limited studies done in degenerative MR have shown the 
presence of fibrosis on LGE in about 30% of patients compared to only 18% in the 
current study (Edwards et al. 2014, Van De Heyning et al. 2014). In contrast to our 
study, biological factors such as advanced age, comorbidities such as hypertension 
and diabetes may have contributed to higher prevalence of fibrosis in these studies 
(Edwards et al.  2014, Van De Heyning et al. 2014). Further, one study used T1 
mapping in addition to LGE, and was able to report on microvascular fibrosis, 
increasing the detection rate of fibrosis in their study (Edwards et al. 2014). An 
alternative explanation for a lack of fibrosis in the majority of patients in this study, 
may be the presence of diffuse fibrosis, which is missed by this technique, as it 
compares regions of normal myocardium to abnormal myocardium (Doltra et al. 
2013). Conversely, fibrosis may indeed be absent, and this is supported by the 
normal markers of collagen synthesis in this study. The aforementioned hypothesis 
is further supported on the basis of a study done by Ho et al. in hypertrophic 
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cardiomyopathy patients, where it was noted that a pro-fibrotic state (as assessed by 
increased biomarkers of synthesis) preceded the development of fibrosis visible on 
MRI (Ho et al. 2010). The sample size in our study was too small to draw 
comparisons based on the presence or absence of LGE, or comment on patterns of 
enhancement in detail. Interestingly though, LV fibrosis in the four patients was not 
confined to the posterobasal region, area noted to be affected more commonly by 
rheumatic fever (Barlow 1987).   
A higher prevalence of fibrosis is observed commonly in pressure overload 
states such as aortic stenosis (Barone-Rochette et al. 2013). The exact mechanism 
of greater fibrosis in pressure overload states compared to volume overload states 
remains speculative (Chemaly et al. 2013). The following reasons have been 
proposed:  
1) a greater supply/demand mismatch in pressure overload states resulting in 
ischaemia and fibrosis.  
2) data from animal studies have shown that pro-fibrotic pathways are activated to a 
larger extent in pressure overload states compared to volume overload states.   
3) the predominant pathology in mitral regurgitation may be extracellular volume 
loss, rather than excessive collagen deposition secondary to activation of Kallikrin-
Kinin system, and thereby, of bradykinin which increases MMP activity causing loss 
of collagen, and LV dysfunction as shown in an animal model (Wei et al. 2012). The 
predominance of degradation over synthesis results in loss and disruption of the 
myocardial collagen scaffold and an associated decline in matrix tensile strength, 
resulting in ventricular dilatation, systolic dysfunction and ultimately death (Lopez et 
al. 2010).  
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In our study patients with CRMR had increased collagen degradation as 
suggested by increase in MMP activity and normal levels of TIMPs and markers of 
collagen synthesis. This finding supports the lack of myocardial fibrosis observed in 
our study. These findings differ from the study by Banerjee et al. in 30 patients with 
CRMR, where they found an increased level of biomarkers of synthesis and 
degradation. The discrepancy may be explained by:  
1) younger patients than this study (mean age 29.6±2 years),  
2) possible ongoing rheumatic activity,   
3) the inclusion of patients with AF, therefore resulting in increased biomarker levels 
(Banerjee et al. 2014).  
The use of anti-remodelling therapy was similar in the current study to that of 
Banerjee et al. Thirty to forty percent of their patients were on anti-remodelling 
therapy with spironolactone and ACEI respectively, and 10% were on beta-blockers. 
In their study, only biopsies of the leaflets were performed, not the LV to assess the 
absence or presence of fibrosis. Further, they reported increased thickness of the 
leaflets and collagen deposition in eight patients that underwent surgery. It is 
unclear, however, as to whether the primary lesion was MS or MR in this subset of 
patients. Further, there was increased MMP activity in their MR patients compared to 
MS, as well as increased MMP to TIMP ratio. They acknowledge that the elevation in 
PIP was lower than anticipated in their MR cohort, and that markers of collagen 
degradation, exceeded markers of synthesis in their patients with CRMR. 
Previous studies in canine model have proposed that increase in LV mass in 
MR is not as a result of increased protein synthesis but decrease in collagen 
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degradation (Carabello 2008). However, we noted an increased LV mass despite 
increased collagen degradation and normal or decreased protein synthesis in 
CRMR. Based on our findings we support the concept that the increase in LV mass 
in MR is likely due to myocyte elongation and changes in collagen cross linkage and 
collagen weave, and not as a result of decreased collagen degradation (Lorell and 
Carabello 2000). In this study we noted a lack of relationship between biomarkers of 
collagen metabolism to LV remodelling and thus biomarker activity is likely not the 
sole cause of remodelling. Other factors such as wall stress, neuro-hormonal 
activation and perhaps cytokines such as TGFβ also play an important role (Khan 
and Sheppard 2006, Tsutsui et al. 1994,). 
The main limitation of this study was the small sample size. A larger sample size 
would have reduced the probability of chance accounting for the absence or 
presence of fibrosis. A study with a larger sample size with isolated MR, and one 
with co-morbidites and MR, may be required to account for the finding of fibrosis 
secondary to isolated MR. Patients with mild MR and AF were excluded. We did not 
use T1 mapping to exclude presence of microscopic fibrosis and did not perform LV 
biopsies.  
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7.2.6 Conclusion 
 
The prevalence of LV fibrosis by LGE imaging is low in rheumatic mitral 
regurgitation. This finding corroborates with increased level of biomarkers of collagen 
degradation and normal levels of biomarkers of collagen synthesis. 
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Chapter 8 
 
 
Is there a role for Combination anti-Remodelling therapy  
for Heart Failure secondary to Chronic Rheumatic  
Mitral Regurgitation? 
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8.1 Abstract 
 
8.1.1 Background 
Chronic mitral regurgitation (MR) is characterised by cardiac volume overload 
with resultant activation of the neuro-hormonal system.  This culminates in cardiac 
remodelling and eventually heart failure (HF).  Few non-randomised studies have 
looked at the value of beta-blockers and vasodilators in MR.  The results from these 
studies have been equivocal. No study has looked at the value of combination anti-
remodelling therapy in heart failure secondary to MR.  In developing countries lack of 
availability of cardiothoracic surgery makes the need to identify successful 
pharmacologic therapies imperative.  We thus aimed to study the effect of anti-
remodelling therapy in terms of clinical outcome, and traditional, as well as newer 
echocardiographic parameters, such as 2D strain, in patients with severe chronic 
rheumatic mitral regurgitation (CRMR) who presented in HF.  
 
8.1.2 Methods 
This sub-study formed part of an ongoing study on CRMR at Chris Hani 
Baragwanath Academic Hospital (CHBAH).  It comprised of 31 patients (29 females). 
Patients admitted and treated with combination therapy for heart failure (HF) 
secondary to CRMR with ejection fraction (EF) <60%, NYHA II-III and who refused 
surgery, were included in this prospective observational study. The patients were 
followed up at baseline, 3 months and 6 months.  They underwent clinical 
examination, blood tests (urea, creatinine and electrolytes) and their medication was 
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up-titrated to maximal tolerable doses, as part of their routine management. All 
patients underwent comprehensive clinical assessment and echocardiography at 
baseline and at 6 months, once on maximal medical therapy.  The 
echocardiographic data was acquired using the Philips iE33 system.  Two 
dimensional strain imaging was performed using QLAB 9 speckle tracking software. 
 
8.1.3 Results 
The mean age was 50.7±8.5 years.  There was no change in clinical symptoms 
and functional status, as assessed by six-minute walk test and Minnesota HF 
questionnaire at baseline and 6 months of maximal therapy [265.5±103.0 metres vs 
275.4±71 meters, p=0.6; 34 (18-61) vs 32.5 (13-48), p=0.3].  None of the patients 
died or were hospitalised for HF during the study period.  Left and right ventricular 
structural and functional indices remained static (P>0.05).  There was no difference 
in right (RA) and left atrial (LA) volumes before and after maximal therapy [RA - 26.5 
(21.7-32) mL/m2 vs 24.7 (7.4-33.8) mL/m2 (p=0.6); LA - 60.2 (47.1-89.4) mL/m2 vs 
59.5 (44.2-82.4) mL/m2 (p=0.8)]. Right (RV) and left ventricular (LV) strain did not 
show a significant change on treatment [-15.6±5.0% vs -16.4±5.9% (p=0.56); -
13.9±4.3% vs -15±4.0% (p=0.28)].  However, the peak LA systolic strain improved at 
6 months (18.7±7.7% vs 23.6±8.5%, p=0.02).  Furthermore, no difference in CRMR 
severity was noted at the end of therapy.  
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8.1.4 Conclusion 
This preliminary analysis suggests that combination anti-remodelling therapy may be 
beneficial for HF secondary to CRMR with no HF related admissions or deaths, and 
no deterioration in echocardiographic parameters of ventricular size and function. 
 
8.2 Introduction 
 
HF is an end result of various cardiovascular diseases and results from either 
pressure or volume overload (Hilfiker-Kleiner et al. 2006).  The chronic overload of 
the LV, LA and secondarily RV, results in cardiac remodelling secondary to neuro-
hormonal activation with resultant molecular, cellular and interstitial changes (Le 
Tourneau et al. 2013, Casaclang- Verzosa et al. 2008, Cohn et al. 2000).   In chronic 
MR the persistent volume overload results in myocardial dysfunction through the 
aforementioned mechanisms.  At present surgery is the mainstay of therapy for 
patients with symptomatic severe MR and markers of LV systolic dysfunction 
(Nishimura et al. 2014).  Surgery is associated with non-negligible morbidity and 
mortality even in established centres especially in patients with LV dysfunction and 
high NYHA functional class (Tribuoilloy et al. 1999, Enriquez-Sarano et al. 1995). 
Use of medical therapy for chronic MR has been largely inconclusive and 
controversial (Carabello et al. 2008).  Most of these were small studies, involving 
ACEI and beta-blockers in degenerative mitral regurgitation (Ahmed et al. 2012, 
Carabello et al. 2008, Evangelista et al. 2007).  Guidelines on valvular heart disease 
recommend medical therapy for HF (EF<50%) in chronic MR (class IIa, level of 
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evidence B) (Nishimura et al. 2014).  No study has systematically looked at the 
effects of combination therapy in HF secondary to MR.  There is proven mortality 
and morbidity benefit of combination anti-remodelling therapy in systolic HF as a 
result of ischaemia and cardiomyopathies (Yancy et al. 2013, Merlo et al. 2011, 
Cicoria et al. 2002). Therefore, we hypothesised that a similar benefit may be 
derived in HF secondary to CRMR. This would potentially offer an alternative option 
to these patients who are at high risk for surgery or are not inclined to undergo 
surgical intervention.  Further, the benefit of anti-remodelling therapy may extend to 
asymptomatic or symptomatic patients with significant MR to stabilise the disease 
process.  This might delay the time to surgery or perhaps even obviate the need for 
surgical intervention in a developing world setting, where surgical delays are 
inevitable.  
We thus aimed to study the effect of anti-remodelling therapy in terms of clinical 
outcome, and traditional as well as newer echocardiographic parameters such as 2D 
strain in patients with severe CRMR who presented in HF.  
 
8.3 Methods 
 
This prospective observational sub-study formed part of a larger study on 
CRMR at the CHBAH.  Patients were enrolled from January 2014 and December 
2014.  All patients were screened and patients deemed to have severe CRMR and 
presented in HF were referred for possible inclusion in the study. HF was diagnosed 
as per ACCF/AHA and ESC guideline definition (Yancy et al. 2013, McMurray et al. 
 195 
 
2012). The assessment of HF was made based on a combination of the patient’s 
history, clinical signs as well as available clinical records.  A total of 66 patients with 
presumed CRMR underwent clinical evaluation, resting electrocardiogram and 
detailed echocardiographic assessment according to a pre-determined protocol.  
The inclusion criteria were as follows:  
1) Patients aged 18 years or older with echocardiographic features of severe CRMR; 
2) symptomatic (NYHA II-III);   
3) LVEF ≤ 60%;  
4) declining surgery or awaiting surgery; and, 
5) receiving medical therapy for HF.  
Patients were excluded if they had significant aortic valve disease, concurrent 
MS with a valve area of less than 2.0 cm2, documented ischaemic heart disease, 
preexisting non-valvular cardiomyopathy, prior cardiac surgery, congenital or 
pericardial disease, pregnancy, severe systemic disorders such as renal failure, 
uncontrolled hypertension (systolic blood pressure >140mmHg and diastolic blood 
pressure >90mmHg) on medication or severe anemia (haemoglobin<10g/dl).   
Thirty-five patients were excluded due to the following: anemia, renal 
dysfunction, mild or moderate MR, MR of non-rheumatic etiology and inadequate 
image quality. The final sample included 31 patients. Most HF trials conducted with 
anti-remodelling agents required a minimum duration of 3 months to demonstrate 
benefit, and therefore we followed up patients in this study for a period of 6 months 
(Bangalore et al. 2012). 
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All patients included in the sub-study were receiving some form of medical 
therapy for HF.  All patients were on the minimum dose of respective HF medication 
and were up-titrated at 3 months where indicated based on symptoms, blood 
pressure, and urea and creatinine levels.  
All patients enrolled in this study were on a combination of at least one anti-
remodelling agent in addition to a diuretic for at least 1 week.  Therapy comprised of 
beta-blockers (atenolol, carvedilol), ACEI/ARBs (Enalapril, perindopril, Telmisartan), 
and an aldosterone-receptor antagonist (spironolactone), in addition to digitalis and 
diuretics.  The medication was initiated at the discretion of the treating physician.  All 
the aforementioned medication was either down titrated or withdrawn or substituted 
on follow-up visits if side effects were reported. 
The study was approved by the University of the Witwatersrand Ethics Committee 
(M140114). 
 
8.3.1Clinical follow-up 
Patients were followed up at 1 month, 3 months and at 6 months.  At 1 month 
and 6 months a full clinical assessment was done including Minnesota Heart Failure 
Questionnaire and 6-minute walk test.  The dose of the medication was titrated at 1 
month and full titration was achieved at 3 months by the treating physician. 
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8.3.2 Echocardiographic evaluation 
Transthoracic echocardiography was performed on all patients in the left lateral 
position by experienced sonographers using a S5-1 transducer on a Philips iE33 
system (Amsterdam, The Netherlands).  The images were obtained according to a 
standardised protocol at baseline and at the 6-month follow-up.  The data was 
transferred and analysed off-line using the Xcelera workstation (Philips).  The 
echocardiographic measurements were done by the researcher at baseline and the 
follow up measurements were done by an experienced sonographer who was 
blinded to the initial results.  
 
8.3.3 Two dimensional and Doppler quantification 
All linear and volumetric chamber measurements were performed according to 
the ASE chamber guidelines at baseline and at 6 months (Lang et al. 2015). 
Measurements relating to LV diastolic function were performed in accordance with 
the ASE guidelines on diastolic function and included pulse wave Doppler at the 
mitral tips and tissue Doppler of both medial and lateral mitral annuli at baseline and 
at 6 months (Nagueh et al. 2009).  Measurements relating to the RV were based on 
the ASE guidelines on the RV (Rudski et al. 2010). 
MR was considered rheumatic in aetiology when the morphology of the valve 
satisfied the World Heart Federation (WHF) criteria for the diagnosis of chronic RHD 
(Reményi et al. 2012).  MR severity was assessed using qualitative, semi-
quantitative and quantitative methods (integrated approach) as per the ASE and 
ESC valvular regurgitation guideline (Lancelloti et al 2013, Zoghbi et al. 2003).  In 
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equivocal cases the echocardiographic data was integrated with the clinical 
evaluation by an experienced cardiologist to distinguish moderate from severe MR.  
 
8.3.4 Speckle tracking echocardiography 
8.3.4.1 Left atrial strain 
Left atrial strain was performed at baseline and at 6 months. Apical four and 
two chamber (4C and 2C) views were obtained using two dimensional grey scale 
echocardiography for speckle tracking analysis (Cameli et al. 2009, Vianna-Pinton et 
al. 2009).  This was performed during end-expiratory breath-hold and stable ECG 
recording (Cameli et al. 2009, Vianna-Pinton et al. 2009).  An adequate grey-scale 
image that allowed separation of myocardial tissue and surrounding structures was 
obtained (Cameli et al. 2009).  Three consecutive cardiac cycles were recorded and 
averaged. The frame rate was set between 60 and 80 frames per second. Philips 
QLAB version 9.0 software allowed off-line semi-automated analysis of speckle-
based strain.  The endocardial surface of the LA was traced manually in both 4C and 
2C views by a three point and click approach.  The system then automatically 
generates an epicardial surface tracing.  The region of interest (ROI) was thus 
created and manually adjusted as needed to allow for adequate speckle tracking. 
The software divides the ROI into seven segments in the 2C and 4C views.  It 
then generates the longitudinal Ɛ curves for each segment and a mean curve of all 
segments.  The onset of the QRS was used as a reference point for calculation of LA 
strain (Hoit et al. 2014). 
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8.3.4.2 Left ventricular strain 
Left ventricular strain was performed at baseline and at 6 months.  Two 
dimensional echocardiography images were obtained at end-expiration from LV 
apical long axis, 4C, 3C and 2C views with frame rates of 60–80 frames per second 
(Younan 2015).  Three consecutive cardiac cycles were recorded and averaged 
(Marciniak et al. 2007).  LV endocardial surface was traced manually in the three 
views by a point and click approach (Younan 2015, Kocabay et al. 2014).  The 
speckle tracking points were modified to allow for adequate speckle tracking of the 
LV wall.  The LV was divided into 17 segments.  Peak LV longitudinal systolic strain 
was calculated for apical long axis 4C, 3C and 2C views, and global LV systolic 
strain was calculated by averaging the three apical views. 
 
8.3.4.3 Right ventricular strain 
Right ventricular strain was performed at baseline and at 6months.  RV free 
wall peak systolic strain (PSS) was derived from modified apical 4 chamber view 
(A4C) RV focused view (Kumar et al. 2014).  Three consecutive cardiac cycles were 
recorded and averaged (Todaro et al. 2015).  The frame rate was set between 60 
and 80 frames per second.  Once the three points (RV apex, medial and lateral 
tricuspid annulus) were defined the software automatically traced the endocardial 
and epicardial border (Kumar et al. 2014).  Philips QLAB version 9.0 software 
allowed off-line semi-automated analysis of speckle-based strain.  This results in the 
division of RV into six standard segments in the apical 4-chamber view (Mingo -
Santos et al. 2015, Kumar et al. 2014, Konishi et al. 2013).  The region of interest 
(ROI) once created, can be manually adjusted as needed to allow for adequate 
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speckle tracking (Hyllen et al. 2014).  The free wall RV PSS was obtained by 
averaging 3 lateral segments (the basal RV lateral wall, the mid-RV lateral wall, and 
the apical RV wall) (Todaro et al. 2015).  The interventricular septum was excluded 
from analysis (Mingo-santos et al. 2015, Nowell et al. 2014, Konishi et al. 2013).  
The longitudinal Ɛ curves for each segment and a mean curve of all segments is 
then generated by the software.  These curves were used to derive RV free wall 
PSS. 
 
8.3.5 Statistical analysis 
Statistical analysis was performed with Statistica (version 12.5, series 0414 for 
Windows).  Continuous variables are expressed as mean ± SD or median (IQR).  
Paired Student’s t test or Wilcoxon’s matched pairs test were used to compare 
continuous variables.  Categorical variables were expressed as percentage. A p 
value of < 0.05 was recognised as statistically significant. 
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8.4 Results 
 
8.4.1 Clinical parameters at baseline and 6 months of treatment  
There was no change in systolic blood pressure, diastolic blood pressure and 
heart rate from baseline to 6 months (125±12.6 mmHg vs 120.1±10.2mmHg, 
p=0.09); (76.2±12.2 mmHg vs 74.2±11.02 mmHg, p=0.5); 71.5 (70-81) beats/min vs 
71.0 (61-80) beats/min, p=0.4)) (Table 8.1).  The median Minnesota HF score was 
34 (18-61) and 32.5 (13-48) at the start and at the end of treatment at 6 months, 
respectively (p=0.3).  There was no difference in the six-minute walk test at the onset 
of treatment and at 6 months (265.5±103.0 metres vs 275.4±71 metres, p=0.6).  
None of the patients were hospitalised for HF and all were alive at 6 months. 
Baseline and maximum therapeutic doses of respective medication are summarised 
in Table 8.2. 
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Table 8.1 Baseline clinical characteristics.* 
Variable n=31 
Age (years) 50.7±8.5 
Sex (F:M) 29:2 
Systolic blood pressure (mmHg) 125±12.6 
Diastolic blood pressure (mmHg) 76.2±12.2 
Heart rate (beats/min) 71.5(70-
81) 
Body surface area (m2) 1.73±0.16 
Body mass index (kg/m2) 28.1±6.1 
NYHA II-III 31(100%) 
Hypertension (%) 29(93) 
HIV (%) 7(23) 
Atrial fibrillation (%) 2(6.4) 
* Data are presented as median (interquartile range), mean± SD or %. HIV-Human 
immunodeficiency virus; NYHA - New York heart association functional class. 
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Table 8.2 Comparison between baseline and maximum medication dose of the 
study patients.* 
Medication Number (%) Baseline dose (mg)  Dose (mg) at 6 
months 
P-value 
Furosemide  30(97) 75±25.9 78.3±34.9 0.67 
Nifedipine XL 9(29) 34.4±21.8 47.7±24.3 0.23 
Digoxin 7(23) 0.125 0.125 1.0 
Enalapril 11(35) 10(2.5-20) 20(10-20) 0.17 
Perindopril 11(35) 2.9±1 4±1.7 0.003 
Carvedilol 29(94) 12.5(3.125-12.5) 50(37.5-50) <0.001 
Spironolactone 28(90) 25(12.5-25) 50(50-75) 0.001 
Data are presented as median (interquartile range), mean± SD or %. *Two patients 
were on Telmisartan (40mg at baseline and 6 months), and one was on Atenolol 
(12.5 mg up-titrated to 25 mg at 6 months). 
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8.4.2 Echocardiographic parameters at baseline and at 6 months of treatment 
8.4.2.1 Left and right ventricular indices 
There was no change in left ventricular (LV) dimensions in systole or diastole 
between the two periods (55.5±8.4 mm vs 55.1±8.0 mm, p=0.8); 42.6±9.4 mm vs 
40.7±9.5 mm, p=0.43) (Table 8.3).  Left ventricular end- systolic indexed and end- 
diastolic volumes indexed remained unchanged (45.4±17.8 mL/m2 vs 42.8±15.8 
mL/m2, p=0.5); 81.8(68.9-98.1) mL/m2 vs 79.1(64.5-99.3) mL/m2, p=0.6.  Hence, 
there was no difference in the LV ejection fraction at baseline and at the six-month 
observational period (46.9±8.7% vs 50.9±10.3%, p=0.19).  The pulse-wave and 
tissue Doppler parameters did not show a significant difference from the start to the 
end of treatment (p>0.05). Left atrial volume indexed remained constant 60.2(47.1-
89.4) mL/m2 vs 59.5(44.2-82.4) mL/m2, p=0.8.  There was no difference noted in the 
RV dimensions at the start and end of therapy (RV base: 38.3±6.25 mm vs 35.8±8.8 
mm, p=0.2).  There was no change in RV systolic function parameters at the start 
and end of treatment (p>0.05).  Right atrial volumes indexed to BSA remained 
constant 26.5(21.7-32) mL/m2 vs 24.7(7.4-33.8) mL/m2, p=0.6. 
 
8.4.2.2 Mitral regurgitation severity  
Based on the integrated assessment (qualitative and quantitative parameters) 
MR severity did not change at the end of 6 months.  No change in quantitative 
parameters (which were likely underestimated due to predominantly eccentric MR 
jets, as previously mentioned in chapter 7.1 of the thesis) of MR assessment was 
noted at the end of 6 months (VC width: 6.5±1.9 mm vs 6.0±1.6 mm, p=0.2; RF: 
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31.7% (18.9-57.7) vs 29.2% (15.7-53.5), p=0.2; RV: 29.3±11.2 ml vs 24.3±10.1 ml, 
p=0.34).  
8.4.2.3 Strain parameters  
LA peak systolic strain increased at 6 months (18.7±7.7% vs 23.6±8.5%, 
p=0.02). However, there was no change in right and left ventricular strain at the end 
of combination therapy (-15.6±5.0% vs -16.4±5.9%, p=0.56; -13.9±4.3% vs -
15±4.0%, p=0.28).  
 
Table 8.3 Left and right ventricular echocardiographic parameters before and 
after 6 months of therapy.* 
Variable  Baseline (n=31) Six months (n=31) p value 
Left ventricular indices 
LV EDD (mm) 55.5±8.4 55.1±8.0 0.8 
LV ESD (mm) 42.6±9.4 40.7±9.5 0.43 
EDVi (mL/m2) † 81.8(68.9-98.1) 79.1(64.5-99.3) 0.6 
ESVi (mL/m2) † 45.4±17.8 42.8±15.8 0.5 
Ejection fraction (%) 46.9±8.7 50.4±10.1 0.1 
E wave (cm/s) 113.2±47.2 112.9±42.1 0.9 
A wave (cm/s) 102.0±26.5 99.4±28 0.7 
E/A wave (ratio) 1.0±0.4 1.1±0.4 0.3 
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E´ medial (cm/s) 6.6(4.5-8.2) 5.9(4.7-7.8) 0.2 
A´ medial (cm/s) 6.7(5.1-8.2) 7.1(5.9-8.3) 0.5 
Medial E/E´(ratio) 18.5±9.5 18.9±9.7 0.8 
Medial S´(cm/s) 6.1±1.4 6.1±1.2 1.0 
LAVi (mL/m2) † 60.2(47.1-89.4) 59.5(44.2-82.4) 0.8 
Right ventricular indices 
RV base (mm) 38.3±6.25 35.8±8.8 0.2 
TAPSE(mm) 20.5±2.9 20.6±2.9 0.9 
RV S´(cm/s) 11.1±2.7 11.6±2.5 0.45 
RAVi (mL/m2) † 26.5(21.7-32) 24.7(7.4-33.8) 0.6 
PASP(mmHg) 33.2±12.4 31.4±11.5 0.5 
*Data are presented as median (interquartile range), mean± SD or %. † Values are 
indexed to BSA. EDVi - End-diastolic volume indexed; ESVi  - End-systolic volume 
indexed; LAVi - Left atrial volume indexed; EDD - End- diastolic diameter; ESD - 
End- systolic diameter; LV - Left ventricle; PASP - Pulmonary artery systolic 
pressure; RAVi, - Right atrial volume index; RV - Right ventricle; TAPSE - Tricuspid 
annular plane systolic excursion. 
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8.5 Discussion 
 
The main findings of this study were:  
1) There were no HF-related hospitalisation and no deaths were observed at 6 
months of maximal medical therapy in CRMR.   
2) An improvement in LA peak systolic strain was noted, with no worsening of LV 
and RV conventional echocardiographic and strain parameters on maximal medical 
therapy. 
Limited older, pre-echocardiographic studies concerning RHD in western 
populations, demonstrated variable natural histories ranging from CRMR being a 
benign lesion (with a normal life expectancy), to a severe, progressive and ultimately 
fatal disease (Ellis et al.1969, Jhaveri et al.1960, Wilson et al.1957).  Natural history 
studies in degenerative MR (with follow-up ranging from 7 months to 10 years), have 
shown increased risk of sudden cardiac death, and increased postoperative 
morbidity and mortality in the presence of severe MR, symptoms, arrhythmias, 
LVESD ≥ 45mm and EF≤60% (Tribuoilloy et al. 2009, Rosenhek et al. 2006, 
Enriquez-Sarano et al. 2005, Grigioni et al. 1999, Enriquez-Sarano et al. 1995, 
Kligfield et al. 1987).  In a study by Wisenbaugh et al, a LVEDD >52mm in rheumatic 
MR, was associated with poor postoperative outcomes (Wisenbaugh et al. 1994).  
The aforementioned studies primarily pertaining to degenerative, significant MR 
have evaluated symptomatic and asymptomatic patients.  Most of them concluded 
that with conservative management (medical therapy), outcomes were worse 
regarding cardiac death, progression to worsening NYHA functional class, LV 
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dysfunction, HF, atrial fibrillation and pulmonary hypertension (Tribuoilloy et al. 2009, 
Rosenhek et al. 2006, Enriquez-Sarano et al. 2005, Grigioni et al. 1999, Enriquez-
Sarano et al. 1995, Kligfield et al. 1987).  Rosenhek et al. showed 55±6% survival 
free of any indication for surgery in asymptomatic MR at 8 years of follow-up 
(Rosenhek et al. 2006). Eight deaths were reported at mean follow-up of 69.2 
months.  In their study 23% of patients were on beta-blockers and 28% were on 
ACEI therapy.  Tribouilloy et al. noted that LV ESD ≥40 mm was associated with 
increased mortality and patients that were medically treated with ACEI, diuretics and 
beta-blocker therapy did not show benefit (Tribouilloy et al. 2009).  Similarly, 
Enriquez-Sarano et al. reported that, in the presence of severe asymptomatic MR at 
5 years, death resulting from cardiac causes, progression to HF and AF was 22±3%, 
14±3% and 33±3%, respectively, in the presence of medical therapy alone.  In the 
study by Kligfield et al., there was increased incidence of arrhythmia-related deaths 
in patients with MR and poor ejection fraction, but none of the patients that died were 
on beta-blocker therapy (Kligfield et al. 1987).  Muñoz et al compared 29 patients 
with CRMR on medical therapy alone to 45 patients who underwent mitral valve 
replacement (Muñoz et al. 1975).  They found at 5 year follow-up, a lower survival, 
faster progression to higher NYHA class and more complications such as HF and 
atrial fibrillation in the medical therapy group.  The main shortcomings of the 
aforementioned studies are the inclusion of mostly asymptomatic patients with 
significant MR, and the medication and dosages used, were not systematically 
documented.  
The subset of patients we followed-up, had mostly stage D HF due to organic 
valvular heart disease.  They were on varied combination anti-remodelling therapy 
as part of their management.  This provided us with the opportunity of observing this 
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subgroup.  The lack of change in LV and RV structural and functional indices may be 
explained by the possible short duration of follow up, disease stabilising effect of 
anti-remodelling therapy and/or the relatively younger age of our patients (compared 
to degenerative MR patients).  A lack of difference in MR severity even after 
controlling the SBP in our study may be explained by the small effect of alteration in 
pressure gradient on regurgitant volume; static LV volumes, and the rheumatic 
nature of the disease whereby the orifice is fixed and not dynamic as in degenerative 
MR (Gaasch and Meyer  2008). 
There was no change in LV and RV longitudinal strain parameters and this may 
be attributed to the short duration of follow up.  The reason for marked improvement 
in LA peak systolic strain may be that the LA remodels and recovers earlier than the 
ventricles, after an injury as shown by Therkelsen et al. (Therkelsen et al. 2006). 
Additionally, LA reverse remodelling has been known to occur independently of LV 
reverse remodelling, due to direct effect of drugs that inhibit RAAS (Casaclang-
Verzosa et al. 2008).  Also, LA strain may be a more sensitive marker for detecting 
reverse remodelling, than LA volumes, as noted in this study. 
There are a number of studies that have evaluated the effects of individual 
drugs in degenerative MR.  Most of these involved beta-blocker or vasodilator 
therapy (Carabello et al. 2012, Evangelista et al. 2007).  The pathophysiologic basis 
for their use was: 1) to prevent the deleterious effect of sympathetic nervous system 
in MR (Ahmed et al. 2012, Tsutsui et al.1994); 2) decreasing afterload and LV wall 
stress thus preventing deleterious remodelling (Ahmed et al. 2012, Evangelista et al. 
2007, Carabello 1995, Spinale et al.1994, Wisenbaugh et al.1994).  Nevertheless, 
the results from mostly small, nonrandomised trials were inconclusive (Bore et al. 
2013, Carabello et al. 2008).  There are no trials that have systematically explored 
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the effects of combined therapy with or without HF due to organic rheumatic MR.  
Munoz et al. compared 29 patients with mitral insufficiency on medical therapy alone 
and those who underwent surgery and found lower survival, faster progression to 
higher NYHA class and greater degree of complications such as HF and AF in the 
medical therapy group at 5 years of follow-up (Munoz et al.1975).  However, the 
aforementioned study did not mention the specific drug therapies and dosages 
involved.  
The effect of aldosterone receptor antagonists, has not been evaluated in 
organic MR in humans.  Additionally, no trial has systematically explored the effects 
of combination therapy (with or without HF), secondary to CRMR.  The possible 
reason for the non-benefit from the aforementioned individual drugs, may be that 
they block only part of the SNS and RAAS which results in activation of the other 
arm of this system or alternative pathways.  A classic example would be that of 
aldosterone escape during prolonged ACEI therapy (Opie and Gersh 2013).  Other 
possibilities include, activation of the Kallikrein-kinin system due to an increase in 
bradykinin, which in turn activates MMPs resulting in collagen loss - a process that 
may be exacerbated by the inhibition of angiotensin II by ACEI (Wei et al. 2012).  
These drugs in combination have synergistic action - for example the 
combination of an ACEI, beta blocker and aldosterone receptor antagonist, 
suppresses myocardial fibrosis in systolic heart failure (Bonow et al. 2012). 
Therefore, combination therapy with drugs that block the SNS and RAAS systems, 
may be the answer. Most of our patients were on a combination of carvedilol, 
spironolactone and an ACEI.  However, their effect on LV function and rheumatic MR 
severity remains questionable.  Thus, other molecular mechanisms may be at play in 
heart failure secondary to chronic MR (Hilfiker-Kleiner et al. 2006).  Further, no 
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fibrosis was noted on cardiac MRI in the majority of patients with isolated MR and 
there was an increase in markers of collagen degradation (Chapter 7.2).  Thus, it 
may partially explain the lack of improvement in LV echocardiographic indices on 
anti-fibrotic therapy.  
Rheumatic disease may primarily result in leaflet fibrosis and distortion, and not 
directly affect the ventricle, thus resulting in MR with secondary LV volume overload 
and remodelling (Banerjee et al. 2014, Barlow 1987).  Therefore, primary targets 
should perhaps be leaflet inflammation and abolition of the MR, rather than 
independently targeting secondary neuro-hormonal and growth-factor pathways 
(Lorell and Carabello 2000).  This hypothesis is partly supported by the regression in 
LVH observed after aortic valve replacement for aortic stenosis and aortic 
regurgitation.  Similar concepts have been noted in hypertensive heart disease, 
whereby the effect of anti-remodelling therapy was minimal on fibrosis and LV mass. 
It was stated that the problem in this disease was primarily high afterload which was 
the main driver of increased LV mass and fibrosis, and thus one should target the 
systolic blood pressure rather than downstream signalling cascade. 
However, all the patients remained stable on combined medical therapy and 
none were hospitalised for HF or died during the 6 months of follow up.  This finding 
is relevant as ≥ 50% of patients with systolic HF are re-hospitalised within 6 months 
of HF assessment (Desai et al. 2012).  Further, the lack of sudden cardiac death and 
HF-related deaths in this study may be attributed to medical treatment, or perhaps it 
may be a chance finding in a study with small sample size.  Therefore, combined 
medical therapy may serve to stabilise the disease process likely through neuro-
hormonal modulation (perhaps the most important compensatory and deleterious 
mechanism in MR - Tsutsui et al. 1994).  Thus, possibly serving as a bridge to 
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surgery or replacement for surgery in dysfunctional ventricles in a resource limited 
setting, where most patients present late or have to await surgery.   
8.5.1 Study Limitations 
There were several limitations to this observational study:  
1) The lack of a control arm. 
2) A varied combination of medication.  
3) The exact duration of therapy at baseline was not clear due to incomplete patient 
notes.  
4) The study subjects and the researcher were not blinded to the treatment.  
5) The cardiac MRI to assess MR severity was not performed due to logistical 
reasons. 
6) Not all patients underwent coronary angiogram unless indicated to exclude 
ischaemic heart disease. 
7) The small sample size.  
8) The short follow up period. 
9) Pre-existing comorbidities. 
 
8.6 Conclusion 
 
We have shown that combination anti-remodelling medical therapy in CRMR 
may be beneficial to prevent hospitalisation for HF and death. It may have a 
stabilising effect on HF secondary to chronic rheumatic MR. Further larger studies 
are needed to test the effect of combination therapy on chronic organic MR.    
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Conclusion 
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9.1 Conclusion 
 
We have observed that the clinical characteristics of contemporary patients with 
CRMR at CHBAH, is different from that of patients studied with the same disease 
thirty years ago at this institution (Marcus et al.1994).  We specifically chose to 
examine patients with CRMR, as it is a frequently encountered lesion, and compare 
my current patients with that of Marcus et al.  The relevant demographic and clinical 
characteristics were documented as part of this thesis and are elaborated in Chapter 
1. Our patients were older, suffered from comorbidities and only one patient 
presented with features suggestive of ARF. This was in stark contrast to the Marcus 
et al. cohort; where patients were younger with no comorbidities and frequently 
presented with fulminant rheumatic carditis (Marcus et al. 1994).  
Echocardiographic findings contrasted with that of Marcus’s patients.   In this 
study, the mitral leaflets were thickened, calcified with restricted leaflet motion 
secondary to extensive disease of the sub-valvular apparatus as compared to 
Marcus’s patients where the leaflets were pliable and displayed prolapse secondary 
to elongated chordae (Marcus et al. 1994).  The aforementioned change in the 
clinical profile has important implications in terms of assessment of MR severity. 
Comorbidities such as uncontrolled hypertension can cause one to overestimate the 
severity of MR.  Further, the more deformed architecture of the MV may result in 
surgical replacement of the valve rather than repair, with resultant increased 
morbidity and mortality (Zoghbi et al. 2003, Enriquez-Sarano et al.1995). 
In a subsequent chapter, we have presented the atrioventricular mechanics in 
CRMR.  In order to study the former, we first chose to study the LA volumetric and 
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functional parameters in a normal African population.  We found that maximum left 
atrial volume indexed (LAVi) in a black African population is within the reference 
range provided in the current chamber guidelines but the upper limits of normal are 
lower than guideline definitions (Lang et al. 2015).  In contrast to other studies, 
females in this study had a higher maximum LAVi compared to males and this was 
attributed to a higher BMI.  Thus, gender and anthropometric differences must be 
taken into account when interpreting LA volumetric indices. When we further 
categorised the study subjects according to age, we noted an increased booster 
pump function with age, as the conduit function and LV diastolic function declined.  
The static LA volumes did not change with age. 
We found LA strain measurements to be feasible and reproducible using Philips 
QLAB 9 speckle tracking software. Similar to other studies, LA peak systolic strain 
declined with age (Sun et al. 2013, Saraiva et al.  2010). There was, however, no 
change in LA maximum and minimum volumes with increasing age.  Therefore, LA 
peak systolic strain may serve as a more sensitive marker for LA function 
assessment than volumes.  We have thus provided normative data in an African 
population which can serve as a reference for future studies. 
Atrioventricular mechanics in CRMR are altered (Aksakal et al. 2012).  We 
noted LA dysfunction in the reservoir and contractile LA mechanical phases and 
based on strain parameters, LA dysfunction was more frequent than LV dysfunction. 
Additionally, these two chambers are dependent on each other for maintenance of 
optimal function and thus malfunction of one is eventually followed by dysfunction of 
the other, as noted in this study, where the majority of the patients had LA and LV 
dysfunction (Nishimura et al. 1997).  Further, as most of the patients had LA 
dysfunction with or without LV dysfunction, we postulate that perhaps in CRMR LA 
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dysfunction precedes LV dysfunction possibly due to a combination of volume 
overload and may be direct involvement of the LA by the rheumatic process. 
However, both chambers cannot be studied in isolation due to the aforementioned 
relationship and the decision to operate must be individualised.  Further, age was 
found to be an important determinant of LA peak longitudinal systolic strain and thus 
must be taken into account when interpreting abnormalities of LA function.  
We further assessed RV function in rheumatic mitral regurgitation.  Traditional 
RV systolic function parameters such as RV Sˈ and TAPSE were preserved 
compared to controls.  However, RV PSS was depressed in CRMR compared to 
controls.  Thus, we concluded that RV PSS is a sensitive marker of subclinical RV 
systolic dysfunction. Therefore, in addition to traditional indices of RV function 
assessment RV PSS must be used to assess RV function.  Additionally, LV PSS was 
the most important determinant of RV PSS.  Thus, due to the intimate structural and 
functional relationship of the left and right ventricles, and the impact of biventricular 
impairment on postoperative mortality, malfunction of one chamber, usually the LV, 
requires that the other chamber (RV) must be studied in detail (Le Torneau et al. 
2013a,b).  
Among the many unexplored issues in CRMR, multimodality imaging and 
biomarkers form a large gap in the existing knowledge pertaining to this commonly 
occurring disease entity.  Degenerative MR has been fairly well studied with modern 
imaging but there is still a paucity of data in the field of biomarkers of collagen 
degradation and synthesis.  Interestingly, we noted that CRMR may not be a 
problem of collagen synthesis but rather a disease, characterised by collagen 
degradation.  This was supported by the increased MMP-1 activity, normal TIMP-1 
and markers of collagen synthesis (PIP1 and PIIINP).  Further, in comparison to the 
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previous reports in degenerative MR, the prevalence of fibrosis by LGE on cardiac 
MRI was low - a finding corroborated by the biomarker results in this study (Edwards 
et al. 2014, Van De Heyning et al. 2014). Recently, Uretsky et al., reported a 
discordance in assessment of MR severity between echocardiography and MRI in 
degenerative MR (Uretsky et al. 2015).  We tested this hypothesis in our CRMR 
patients where all patients had eccentric jets and the PISA method was suboptimal 
for quantitative MR assessment.  We found that there was a difference in MR 
severity grading between the two techniques in seven patients based on quantitative 
parameters (Enriquez-Sarano et al.1993).  Six of these patients were re-categorised 
from moderate to severe MR and one from severe to moderate.  Overall, when an 
echocardiographic integrated approach was used, MR severity assessment was 
concordant with cardiac MRI quantitative assessment in 70% of the patients.  
Therefore, cardiac MRI was useful for assessment of moderate or severe MR where 
echocardiography alone was insufficient. 
Several human and animal studies, have explored the role of beta-blockers, 
afterload reducing agents and aldosterone-receptor blockade in degenerative MR, 
but results have been largely inconclusive (Ahmed et al. 2012, Bernay et al. 2010, 
Kittleson et al. 2009, Stewart et al. 2008, Evangelista 2007, Tallaj et al. 2003, Tsutsui 
et al. 1994).  Studies have not looked at the effect of combination therapy in HF 
secondary to MR, even though combination anti-remodelling therapy is used for the 
management of these patients, and is recommended by the ACC/AHA guidelines 
(Nishimura et al. 2014).  In this study, patients with severe MR on combination HF 
therapy, were not hospitalised secondary to HF nor were there deaths in this group.  
An improvement in LA peak systolic strain was noted and the conventional 
echocardiographic indices did not worsen over a 6-month follow-up period.  Thus, 
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medical therapy may benefit CRMR patients with HF, likely through neuro-hormonal 
modulation.  It may therefore, serve as bridge to surgery in a resource poor setting, 
and provide an alternative option to patients at high surgical risk and those who 
decline surgery. 
Thus, in conclusion we have shown that the demographic and clinical profile of 
patients with rheumatic MR has evolved over the last thirty years at CHBAH from 
young patients with fulminant rheumatic carditis and no comorbidities, to older 
patients with comorbidities and a low prevalence of ARF.  We further explored 
atrioventricular and RV mechanics in this group of patients after establishing 
normative data pertaining to LA in an African population.  From the former, we have 
established that, amongst other findings, ethnicity-based differences exist in LA 
parameters in terms of LAVi albeit still within the reference range provided by ASE 
chamber guidelines (Lang et al. 2015).  There is still a need for further studies on 
different vendors to standardise normal values pertaining to LA strain, in order to 
interpret abnormality in various disease states.  We have provided age-appropriate 
values as well, in this population and this would prove useful in an era of an aging 
population.   
We have provided several hypothesis generating conclusions in the context of 
CRMR which include the following:  
1) We suggest that LA dysfunction precedes LV dysfunction based on our finding of 
predominant LA dysfunction with or without LV dysfunction in CRMR identified on 
peak systolic strain. Therefore the LA and LV cannot be studied in isolation.  
2) RV peak systolic strain is reduced prior to traditional markers of RV systolic 
function in CRMR, and LV peak systolic strain is an important determinant of RV 
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PSS. These two chambers should be carefully studied preoperatively to potentially 
improve postoperative outcomes.  
3) CRMR is likely a disease of predominant collagen degradation and not synthesis.  
This is based on our low observed prevalence of fibrosis in this group of patients.  
Furthermore, cardiac MRI may serve as an adjunctive tool for assessment of MR 
severity.  
4) Finally, there may be a role for combination anti-remodelling therapy for HF 
secondary to CRMR.  
 
We hope that these hypotheses may serve as a platform for future larger 
studies in CRMR and contribute to enhanced clinical care. 
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Appendix 
 
Calculation of Body Surface Area (BSA) 
The body surface area was calculated according to DuBois and DuBois BSA = 
0.007184 * Height0.725 * Weight0.425; M, body weight (kg); H, body height (cm)] 
(Dubois and Dubois 1916). 
 
Calculation of LV mass on echocardiography 
Left ventricular mass and left ventricular mass indexed to body surface area are 
estimated by LV cavity dimension and wall thickness at end-diastole (Lang et al. 
2015). LV Mass (g) =0.8{1.04[([LVEDD + IVSd +PWd]3 - LVEDD3)]} + 0.6 
Relative wall thickness (RWT) allows further classification of LV mass increase 
as either concentric hypertrophy (RWT >0.42) or eccentric hypertrophy (RWT ≤0.42). 
RWT =2 * PWd/LVEDD.  
 
Assessment Mitral Regurgitation on echocardiography (Lancelloti et al. 2013, 
Zoghbi et al. 2003) 
The mitral valve is assessed in the parasternal long axis (PLAX) view, short 
axis view, the apical four chamber (A4C) view and the apical three chamber (A3C) 
view. The severity of mitral regurgitation can be assessed using qualitative and 
quantitative methods. The assessment of rheumatic mitral valve starts with the 
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assessment of morphology. The following features are characteristic of the 
rheumatic mitral valve: 
 Thickened mitral valve leaflets, 
 Thickening and fusion of the mitral valve commissural edges and chordae, 
 The leaflets secondary to commissural fusion open with doming motion, 
 Thickening and shortening of chordae. 
 
The qualitative parameters include:  
 The left ventricular (LV) size. 
o Mild MR - LV dimensions are within the normal range (i.e. LV end 
systolic diameter (ESD) < 40mm, LV end diastolic diameter (EDD) < 
56mm);  
o Moderate MR - The LV size is between mild and severe; 
o Severe MR - The LVESD is > 40mm and LVEDD is > 56mm. 
 The left atrial (LA) size 
o Mild MR - The LA size is normal (i.e. LA diameter < 39mm in PLAX 
view); 
o Moderate MR – Between mild and severe; 
o Severe MR - The LA diameter is > 39mm.  
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o  Accepted cut-off values for non-significant left-sided chambers 
enlargement for mitral regurgitation:  LA volume 36 mL/m2, LV end-
diastolic volume 82 mL/m2, LV end-systolic volume, 30 mL/m2. 
 MR jet (as a percentage of the left atrium)  
o Mild MR - The MR jet is less than <20% of the LA size; 
o Moderate MR –  variable jet size; 
o Severe MR - The MR jet is > 40% of the LA size or variable size wall 
impinging jet swirling in LA. 
 Spectral Doppler density- MR is mild if the density is faint/parabolic and 
severe if it is a dense/triangular jet. 
 Vena contracta (VC) (the width of the regurgitant jet at its origin  
o Mild MR – The VC is < 3mm;  
o Moderate MR – The VC is 3-7mm; 
o Severe MR – The VC is ≥ 7mm. 
 Pulmonary vein flow systolic flow reversal into the pulmonary veins  is a 
marker of severe MR. 
 
Quantitative assessment 
The PISA (proximal isovelocity surface area) method is used for assessment of 
severity for central mitral regurgitation jets.  The mitral regurgitation is visualised 
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from the A4C view.  As the blood converges towards an orifice, imaging by Doppler 
flow reveals concentric shells or hemispheres and these are a representation of 
isovelocity surfaces.  Due to the acceleration of blood in the direction of the orifice 
aliasing of the velocity occurs and this results in a distinct red blue interface at 
periphery of the shells.  The velocity at this interface is equivalent to the Nyquist limit 
which is read off the velocity colour scale. 
The Nyquist limit can be adjusted to maximise the size of the shell thus the 
surface area can be calculated using the following formulae: 
1) Surface area = 2πr2.                    
2) Flow rate = 6.28 x r2x aliasing velocity.  
3) Flow rate = ERO (effective regurgitant orifice) x velocity jet. 
The above calculation is based on the fact that the flow through any given shell will 
equal the flow rate through the orifice. 
4) Effective regurgitant orifice (ERO) = flow rate / velocity jet. 
The regurgitant volume can be calculated as the product of ERO x TVI (where TVI is 
the velocity integral of the mitral regurgitation flow as measured by continuous wave 
Doppler imaging).  
From the above calculated parameters mitral regurgitation is considered severe 
if the EROA is 40mm2 or more, the regurgitant volume (RegV) is 60ml or above. The 
mitral regurgitation is mild to moderate if the EROA  20-29mm2 or a RegV 30-44ml 
and moderate to severe if the EROA is 30-39mm2 or RegV of 45-59ml. 
 
 224 
 
Normal values for LV volumes and mass on cardiac MRI (Kawel-Boehm et al. 
2015) 
Normal LV EDV and ESV for females (20-80 years):76±10ml/m2 (range: 56-96) and 
24±5 ml/m2 (range: 14-34). 
Normal LV ejection fraction for females (20-80 years): 67±5 %( range: 57-77) 
Normal LV mass for females (20-80 years): 61±10g/m2 (range: 41-81).  
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